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5 SUMMARY 
 
 
Background: Of all forms of dementia, Alzheimer’s disease is the most prevalent and affects 
nearly half of the population above 85 years. It is histopathologically characterized by β-
amyloid-containing plaques, protein tau-containing neurofibrillary tangles, reduced synaptic 
density and neuronal loss in selected brain areas. In a related disorder termed frontotemporal 
dementia (FTD), which is characterized by tangles in the absence of β-amyloid deposition, 
mutations in tau have been identified which also lead to neurodegeneration and dementia. In 
both, AD and FTD, tau is hyperphosphorylated, detaches from the microtubules and forms 
filaments. Tau is a substrate of protein phosphatase 2A (PP2A). PP2A is a family of 
heterotrimeric enzymes with diverse functions under physiologic and pathologic conditions. In 
brains of AD patients, mRNA levels of individual subunits of PP2A have been found to be 
reduced and to affect PP2A activity, which correlated with tangle load. Since specific inhibition of 
PP2A in vivo is not possible chemically, we have designed dominant negative transgenic mouse 
models with altered PP2A composition and/or activity, by overexpression of the mutant catalytic 
subunits L199P and L309A. Leucine 199 of the catalytic subunit Cα is in the catalytic core while 
the carboxyterminal leucine 309 plays a crucial role in the recruitment of regulatory subunits 
into the complex in vitro, a process that determines substrate specificity of PP2A.  
 
Results: As PP2A is abundant in brain, we determined the distribution and expression levels 
of the four members of the regulatory subunit family PR55/B in murine brain and human cell 
lines. PR55α levels were highest in both HEK-293 and SH-SY5Y neuroblastoma cells, whereas 
PR55β levels were lowest. In contrast, differentiation of neuroblastoma cells caused the selective 
upregulation of PR55β, implying an important role of this regulatory subunit in neuronal 
differentiation. Chronic inhibition of PP2A activity by expressing Cα L199P was sufficient to 
induce tau hyperphosphorylation and relocalization to the somatodendritic compartment in 
neurons, as well as impairment in memory and learning. Cα L309A expressing mice revealed a 
reduced recruitment of the regulatory subunits PR55α and PR61ε, and an increased recruitment 
of PR61γ and PR59 into the complex, demonstrating a role for the carboxyterminal leucine of Cα 
in regulating holoenzyme assembly in vivo. This was associated with an increased 
phosphorylation of tau in brain and a reduced capability to dephosphorylate vimentin. In 
addition we observed a delayed and impaired postnatal development of the Harderian and 
lacrimal glands, causing a depression of the eyeball within the orbit (enophthalmos). In these 
glands PP2A dysfunction brought about a pronounced inactivating phosphorylation of the 
cadherin-directed glycogen synthase kinase-3β (GSK-3β) at Ser-9. Cadherin and β-catenin were 
reduced and shifted from the membrane to the cytosol, demonstrating a role for distinct PP2A 
regulatory subunits in cell adhesion. 
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Significance: Our novel transgenic mouse models, together with the consolidated findings 
from the present studies on the distribution of PR55/B subunits and their abundance in mice and 
human cell lines, provide valuable tools to study the role of PR55/B regulatory subunits in PP2A 
specificity and activity. Our results have thereby facilitated the development and analysis of in 
vivo models of PP2A function in the brain, have contributed to the understanding of PP2A 
composition and specificity as well as the development of the lacrimal system, and have further 
revealed an involvement of PP2A activity in memory retrieval of mice. 
 
 
 
 
 
 
6 ZUSAMMENFASSUNG 
 
 
Hintergrund: Die Alzheimer-Erkrankung ist die häufigste Form der Demenz und erfasst fast 
die Hälfte aller Menschen über 85 Jahren. Sie ist histopathologisch charakterisiert durch β-
Amyloid enthaltende ‘Plaques’, Tau enthaltende neurofibrilläre ‘Tangles’, verminderte 
Synapsendichte sowie den Verlust von Neuronen in bestimmten Hirnregionen. Bei einer 
verwandten Krankheit, der Frontotemperalen Demenz (FTD), welche charakterisiert ist durch 
Tangles ohne β-Amyloid Ablagerungen, wurden Mutationen in Tau gefunden, welche ebenfalls zu 
Neurodegeneration und Demenz führen. In Alzheimer und FTD ist Tau überphosphoryliert und 
bindet dadurch weniger gut an Mikrotubuli, was die Bildung von Filamenten begünstigt. Tau ist 
ein Substrat der Protein Phosphatase 2A (PP2A). PP2A ist eine Familie von heterotrimeren 
Enzymen mit verschiedensten Funktionen unter physiologischen und pathologischen 
Bedingungen. In Gehirnen von Alzheimerpatienten sind verminderte mRNA Mengen bestimmter 
PP2A Untereinheiten und eine reduzierte PP2A Aktivität gefunden worden, welche mit der Anzahl 
Tangles korrelierte. Da eine spezifische Inhibierung von PP2A in vivo chemisch nicht möglich ist, 
haben wir dominant negative transgene Mäuse mit veränderter PP2A Zusammensetzung 
und/oder Aktivität entwickelt, welche die mutierten Cα Untereinheiten L199P und L309A 
überexprimieren. Leucin 199 der katalytischen Untereinheit Cα ist wichtig für die Aktivität von 
PP2A, während Leucin 309 in vitro eine entscheidende Rolle beim Rekrutieren von 
regulatorischen Untereinheiten in den Komplex spielt, ein Prozess, der die Substratspezifität von 
PP2A bestimmt. 
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Resultate: Da PP2A reichlich im Hirn vorhanden ist, haben wir die Verteilung und Expression 
der PR55/B Familie seiner regulatorischen Untereinheiten in Mäusehirnen und menschlichen 
Zelllinien bestimmt. PR55α war sowohl in HEK-293 als auch in SH-SY5Y Neuroblastom Zellen 
stark vertreten, während PR55β kaum vorhanden war. Wurden Neuroblastom Zellen hingegen 
differenziert, kam es zu einer selektiven Hochregulation von PR55β, was auf eine wichtige Rolle 
dieser Untereinheit in der neuronalen Differenzierung hindeutet. Chronische Inhibierung der 
PP2A Aktivität durch das Exprimieren von Cα L199P war ausreichend, um eine 
Überphosphorylierung von Tau und Umverteilung ins somatodendritische Kompartiment in 
Neuronen sowie Defizite im Lernen und Erinnern zu erreichen. Cα L309A exprimierende Mäuse 
zeigen eine verstärkte Rekrutierung der regulatorischen Untereinheiten PR61γ and PR59 auf 
Kosten von PR55α und PR61ε in den PP2A Komplex, was eine Rolle für das carboxy-terminale 
Leucin von Cα beim Zusammenfügen von Holoenzymen in vivo demonstriert. Dieselben Mäuse 
zeigen eine verstärkte Phosphorylierung von Tau im Gehirn und ein vermindertes Potenzial, 
Vimentin zu dephosphorylieren. Zudem haben wir eine verzögerte und beeinträchtigte 
postnatale Entwicklung der Harder’schen und der Tränendrüse beobachtet, welche ein 
Zurücksinken des Auges in der Orbita (Enophthalmus) zur Folge hatte. Die PP2A Fehlfunktion 
bewirkte ausserdem eine starke inaktivierende Phosphorylierung der Cadherin-gerichteten 
Glycogen Synthase Kinase-3β (GSK-3β) an Ser-9. Cadherin und β-Catenin waren dadurch 
verringert und von der Membran ins Cytosol umgelagert, was eine Rolle von spezifischen 
Untereinheiten von PP2A in der Zelladhäsion erkennen lässt. 
 
Signifikanz: Unsere neuen transgenen Maus-Modelle, zusammen mit den Erkenntnissen aus 
den vorliegenden Studien über die Verteilung von PR55/B Einheiten und deren Vorkommen in 
Mäusen und humanen Zelllinien, sind wertvolle Hilfsmittel, um den Einfluss von PR55/B auf die 
Spezifität und Aktivität von PP2A zu erforschen. Unsere Resultate haben damit die Entwicklung 
und Analyse von in vivo Modellen der Funktion von PP2A im Gehirn vereinfacht, haben Beiträge 
zum Verständnis der PP2A Zusammensetzung und Aktivität sowie der Entwicklung des 
Tränendrüsensystems geleistet, und haben ausserdem eine Funktion von PP2A beim Erinnern in 
Mäusen aufgezeigt. 
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7 INTRODUCTION 
 
7.1 Alzheimer's disease 
 
Initially described in 1907 by Alois Alzheimer, this condition, which now bears his name, 
describes a fatal neurodegenerative disorder that starts with mild memory impairment and poor 
judgment but progresses to apraxia, aphasia, and agnosia (Alzheimer, 1907; Kimberly et al., 
2001). The latter stages are often characterized by complete debilitation, requiring constant 
intensive supervision. Following initial diagnosis, the course of the disease varies from a few 
years to over 20 years, with an average of 4 to 8 years. Rare cases of AD, particularly those of 
early onset in the second and third decades of life, are familial and inherited as autosomal 
dominant disorders (Price and Sisodia, 1998; Rossor et al., 1996; Squire and Zola, 1998); 
however, the vast majority of patients are over the age of 60 such that, within industrialized 
countries, 10% of the population older than 65 years and as many as 47% of those older than 
85 years are afflicted (Bierer et al., 1995; Lobo et al., 2000).  
Clinically diagnosed Alzheimer's disease is a common condition and its public health impact will 
continue to increase with increasing longevity of the population. With up to 85% of moderate or 
severe cognitive impairments due to AD, it is the leading cause of dementia in the elderly, with 
stroke and atherosclerosis being the second most common cause and dementia associated with 
Parkinson's disease being the third (Evans et al., 1989). As suggested by data from 1995 
(Ewbank, 1999) and more recent data from the World Health Organization (WHO), AD is the 
fourth leading cause of death in developed nations (after heart disease, cancer, and stroke). 
WHO estimates that by the year 2025 more than 22 million people worldwide will have 
Alzheimer disease, which will cause enormous costs as already in 2000, the annual social cost of 
AD for the United States was approaching $100 billion. Besides memory loss, Alzheimer's 
patients show dramatic personality changes, disorientation, declining physical coordination, and 
an inability to care for themselves. In the final stages, victims are bedridden, lose urinary and 
bowel control, and suffer epileptic attacks. Death is usually due to pneumonia, bedsores or 
urinary tract infection.  
7.1.1 Genetics and risk factors for AD 
 
Alzheimer disease is a genetically complex and heterogeneous disorder. Causal mutations 
leading to predominantly early onset of FAD have been characterized in three genes: APP on 
chromosome 21 (APP), presenilin 1 on chromosome 14 (PSEN1) and presenilin 2 on 
chromosome 1 (PSEN2). These mutations are inherited in an autosomal dominant manner with 
nearly 100% penetrance (Kimberly et al., 2001). However, mutations in these genes account 
for less than 5% of the total number of AD cases. The remaining 95% are mostly sporadic late-
onset cases (SAD) with no recognizable pattern of classical Mendelian inheritance. Although 
there is a strong body of evidence for alpha-2 macroglobulin (α-2M, gene A2M) and the low-
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density lipoprotein receptor related protein (LRP, gene LRP), none of the more than three dozen 
putative AD loci proposed to date have been consistently replicated (Bertram and Tanzi, 2004). 
The ε4 allele of the apolipoprotein E (ApoE) gene is the only genetic risk factor that has been 
established and verified in multiple genetic analyses of different human populations (Cherny et 
al., 2001; Rocchi et al., 2003). Studies implicating the ApoE gene as an AD susceptibility locus 
derived from several intersecting lines of investigation; Linkage analysis on late-onset AD 
families, ApoE immunoreactivity in senile plaques and neurofibrillary tangles (NFTs) of patient 
with AD, and ApoE binding to Aβ (Irizarry et al., 2004; Kang et al., 2000). Association studies 
revealed that inheritance of the ε4 allele (ApoE4, C112R) is associated with a copy-number-
dependent increase in risk of both sporadic and late onset FAD and with a decrease in the age of 
onset in late-onset AD. Conversely, the ε2 allele confers a protective effect against late-onset 
AD. However, it seems that the inheritance of the ε4 allele may be neither necessary nor 
sufficient by itself to cause AD. In Down syndrome, where the triplication leads to 
overexpression of chromosome 21 resident genes, including the APP gene, neuropathological 
changes similar to AD can be found as early as at the age of 40 years. At 20-30 years, there is 
already formation of amyloid plaques and later neurofibrillary tangles (Andersson and Porath, 
1986). Yet, as presented above, the most important risk factor for AD is age (Bierer et al., 
1995). 
 
7.1.2 Pathology 
 
The distinctive brain lesions, senile plaques and neurofibrillary tangles, used by Alois Alzheimer 
together with the clinical deficits to describe the disease, are still used today as the defining 
features for diagnosis (Figure 1) (Haass et al., 1991; Itagaki et al., 1989). In addition to these 
striking changes, there is variable cerebral cortical atrophy and associated ventricular dilation, 
both of which are consequences of the neuron loss and astrocyte proliferation in affected 
regions. The progressive neuronal loss in AD is initiated in the medial temporal lobe (i.e. 
enthorinal cortex, hippocampus and subiculum). At later stages it extends to other neocortical 
regions, particularly association areas, the basal brain cholinergic system and several brain 
stem monoaminergic nuclei (Braak et al., 1999; Price and Sisodia, 1998). This sequentially 
destructive process is macroscopically characterized by shrinkage of the gyri, a widening of the 
sulci and an enlargement of the ventricles. The microscopical changes are manifested by 
neuronal loss and marked gliosis throughout the hippocampus and cerebral cortex, as well as 
synaptic alteration (Braak and Braak, 1995; Buee and Delacourte, 1999). 
Both neurofibrillary tangles and senile plaques are found in normal aged persons, but it is their 
quantitative increase that defines the pathologic diagnosis of AD.  
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Figure 1:  
Light micrograph of AD neuropathology. Section from the 
cortex of a patient with AD. The intraneuronal tangle (arrow) is 
stained dark brown with an antibody that specifically targets 
paired helical filaments. These filaments are also seen as the 
dense brown material (dystrophic processes) embedded in the 
extracellular plaque (arrowhead). The lighter reddish staining of 
the plaque is from another antibody directed specifically against 
β-amyloid. From Dr. J. Price (Encyclopedia of life sciences). 
 
7.1.3 Neurofibrillary tangles 
 
Neurofibrillary tangles (NFT) consist of abnormal 20-nm wide helical filaments with an 80-nm 
half-periodicity, termed paired helical filaments (PHF), and 12- to 15-nm straight filaments. 
Paired helical and straight filaments occur not only in neuronal perikaryon as neurofibrillary 
tangles, but also within dendrites and axons as neuropil threads, and within synaptic terminals 
of the large dystrophic neurites surrounding the β-amyloid deposits of senile plaques (Figure 1) 
(Braak et al., 1999). A series of studies have focused on the formation and composition of the 
PHF and how they might contribute to neuronal death. PHF is shown to be a highly organized 
structure. Both immunocytochemical and chemical analysis indicate that microtubule-associated 
protein tau in hyperphosphorylated form (Goedert et al., 1992; Grundke-Iqbal et al., 1986), 
ubiquitin (Mori et al., 1987), fatty acid and carbohydrate (Goux et al., 1995) are the 
components of PHF (Figure 2). Tau protein normally consists of a family of soluble, basic 
proteins that not only bind to microtubules but also stabilize them. The binding to microtubules 
is partly determined by the number of phosphates attached to it. Highly phosphorylated forms 
of tau proteins accumulate in AD and therefore it has been suggested that there is an imbalance 
between the activities of tau-directed kinases and phosphatases in AD (Trojanowski and Lee, 
1995). Some phosphatases, enzymes that remove phosphate groups from tau, are suppressed 
in neurons of AD patients, resulting in accumulation of extra phosphates in the system (this is 
discussed in more detail in section 7.2 “Phosphorylation as a regulatory principle”). Abnormal 
phosphorylation or hyperphosphorylation of tau disturbs its binding ability to microtubules and 
tau subsequently precipitates in the somatodentritic compartment and could finally lead to the 
formation of PHF-tau (Gotz, 2001). This alteration of microtubule stability by tau modifications 
may disrupt intracellular transport, cellular geometry and neuronal viability, harming and killing 
the nerve cells (Price and Sisodia, 1998; Roush, 1995). Tau is also released into cerebrospinal 
fluid (CSF). Elevated tau in CSF of AD subjects can be measured by an enzyme-linked 
immunosorbent assay (ELISA) (Jensen et al., 1995) or by ELISA using phosphorylation-
independent and sequence-specific antibodies (Mori et al., 1995). Comparable markers may 
provide an aid for AD diagnosis (Mehta et al., 1996). Following the complete degeneration of the 
affected neurons, the highly insoluble NFTs remain in the extracellular space (Vickers et al., 
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1992). NFTs are also found in other neurodegenerative diseases such as corticobasal 
degeneration, argyrophilic grain disease, progressive nuclear palsy and frontotemporal dementia 
with Parkinsonism (Goedert et al., 1998). 
There is now a considerable effort to understand how the two identified posttranslational 
modifications of NFT, phosphorylation and glycation, mediate the transformation of soluble tau 
into insoluble PHF.  
 
7.1.4 Amyloid plaques and amyloid-β precursor protein 
 
Understanding of the pathogenesis of amyloid-β (Aβ) deposition was greatly advanced by the 
sequencing of Aβ by G. Glenner and C. Wong in 1983 (Glenner and Wong, 1984). Subsequent 
cloning showed that Aβ is a 39- to 42-amino acid fragment of a larger 695- to 770-amino-acid, 
membrane-spanning glycoprotein, termed amyloid-β precursor protein (AβPP or APP) (Kang et 
al., 1987; Masters et al., 1985). The gene for APP resides as a single copy on the long arm of 
chromosome 21 and is comprised of 18 exons spanning a genomic region of about 400 kb 
(Lamb et al., 1993; Robakis et al., 1987). 
The importance of APP in the primary etiology of AD is fairly well established, with FAD 
associated with a number of mutations in the APP gene on chromosome 21. Some of the 
mutations in APP leading to AD have been related to Aβ processing, yielding more of the longer 
form of Aβ (Aβ42), which has a greater propensity to form Aβ fibrils (Figure 2). Additional 
support for the importance of APP in the pathogenesis of AD comes from Down's syndrome, in 
which an extra copy of chromosome 21 leads at mid-life (20 - 30 years) to a similar spectrum of 
pathologic changes as found in AD, amyloid plaques and neurofibrillary tangles (Andersson and 
Porath, 1986). 
 
 
 
 
 
 
 
Figure 2:  
Structural and antigenic 
differences between paired 
helical filaments (large arrows), 
and Aβ filaments (arrowheads) 
are readily apparent in this 
negatively stained preparation. 
Heavy subunits of neuro-
filaments are localized by 
colloidal gold to paired helical 
filaments but not to Aβ 
filaments. (× 105,000), from 
Encyclopedia of Neuroscience, 
Elsevier. 
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APP is conserved across vertebrates and invertebrates and is part of a multi-gene super family 
from which sixteen amyloid precursor–like proteins (APLP) and APP species homologs have been 
isolated and characterized (Coulson et al., 2000).  
APP is trafficked through the constitutive secretory pathway where it undergoes 
posttranslational processing including a variety of proteolytic cleavage events. The signal 
peptide is cleaved after co-translational translocation to the membrane of the endoplasmic 
reticulum (ER). Both during and after its transport through the secretory pathway to the cell 
surface, a subset of APP molecules undergoes specific endoproteolytic cleavage by α-, β- and γ-
secretases (Figure 3). The degradation of APP can occur by two different pathways: Either the 
non-amyloidogenic α-secretase pathway or the amyloidogenic β-secretase pathway (Baker et 
al., 1997), whereas the preceding cleavage of APP by either α- or β-secretase is a prerequisite 
for γ-secretase cleavage (Figure 3).  
 
Figure 3:  
Proteolytic processing of APP. APP can be cleaved by α-
secretase (α-sec) in the Aβ domain (in blue and red) to 
generate soluble APPS-α and a membrane-bound CTF-α. 
Alternatively, β-APP can be cleaved by β-secretase (β -sec) 
producing APPS-β and CTF-β bearing the total Aβ domain. 
Both CTF-α and CTF-β are substrates for an intra-
membranous cut by γ-secretase (γ-sec), resulting in the 
generation of p3 (red) and of Aβ (blue-red), respectively 
(Ruediger et al., 2001).  
 
Under normal conditions, the α-secretase pathway is predominant, precluding the formation of 
Aβ (Esch et al., 1990; Kimberly et al., 2001). A smaller proportion of APP is processed by the 
amyloidogenic pathway, which takes place intracellularly in the secretory pathway or following 
internalization of cell surface bound APP into the endosomal-lysosomal compartment. β-
secretase releases a truncated form of soluble APP (APPS-β) from the cell surface (Schubert et 
al., 1989), leaving a 99 amino acid CTF-β in the membrane, which is subsequently cleaved by 
the γ-secretase at either residue 711 or 713 to create either Aβ40 or Aβ42 (Baker et al., 1997; Di 
Rosa et al., 2002). 
The so-called Swedish mutation in APP (APPswe, K595N and M596L) or the London mutation 
(V717I) located close to the β- and γ-secretase sites, respectively, cause enhanced production of 
Aβ (Cai et al., 2001; Citron et al., 1994; Goate et al., 1991; Mullan et al., 1992; Suzuki et al., 
1994), specifically the highly pathogenic Aβ42 (Di Rosa et al., 2002; Steiner et al., 1999).  
 
The Aβ of senile plaques consists of 7- to 10-nm helical filaments (Figure 2) that share with 
paired helical filaments the ability to bind the dye Congo red. In vitro, the soluble peptides 
(dimers) precipitate and adopt a β-sheet structure (Hilbich et al., 1991). This formation of 
insoluble aggregates has been considered to be a key element in the neurotoxic mode of action 
of Aβ (Pike et al., 1993; Pike et al., 1991). Although the Aβ42 isoform contributes to only 10% of 
the total Aβ secreted by cells in culture as well as in human brain, it is the most toxic species as 
it aggregates promptly and acts as a seed for subsequent aggregation of Aβ40 species (Asami-
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Odaka et al., 1995; Jarrett and Lansbury, 1993). Moreover, intracellular Aβ42 induces neuronal 
death (Kienlen-Campard et al., 2002). 
Two different types of amyloid plaques are found in the brain parenchyma of AD patients: 
Neuritic or mature plaques and diffuse deposits. Neuritic plaques have a dense fibrillar amyloid 
core consisting mainly of Aβ42, but also containing of Aβ40 (Kimberly et al., 2001). They are 
surrounded by dystrophic neurites, activated astrocytes and microglia (Cummings et al., 1998; 
De Strooper and Annaert, 2000). In contrary, diffuse plaques are amorphous and solely consist 
of Aβ42. They do not contain degenerated axons or dendrites and lack activated microglia and 
astrocytes (Kimberly et al., 2001).  
Various sources for the Aß found in senile plaques have been considered: neuronal, glial or 
vascular. Aβ40 and Aβ42 are constitutively secreted by a multitude of different cell types and can 
be detected in conditioned cell culture medium and human cerebrospinal fluid (Haass et al., 
1992; Seubert et al., 1992). Presently, a neuronal origin for Aβ is supported by the high level of 
APP mRNA and protein in neurons. The accumulation of APP in neurites surrounding Aβ in senile 
plaques suggests that neurites may be the source of Aβ for senile plaques. In normal neurons, 
most APP is associated with vesicles, outer mitochondrial membranes, and a subclass of 
microtubules, whereas in AD it additionally accumulates in secondary lysosomes, termed dense 
bodies, and PHF. Nonneuronal cells such as microglia and astrocytes are probably not important 
in APP synthesis; however, those cells, found in the vast majority of senile plaques, may play a 
role in proteolytic processing of APP to Aβ. The nature of the neuronal abnormality responsible 
for an increased level of APP in AD is unknown, although a number of physiologic perturbations, 
such as apoxia, oxidative stress, and cell injury, do increase the level of APP. Aβ deposition is 
not only observed in brains of AD patients, but diffuse plaques can also be found in brains of 
healthy aged individuals, suggesting that the formation of plaques might be inevitable to some 
degree (Davies et al., 1988).  
 
7.1.5 Relationship between plaques and tangles  
 
As outlined above, Aβ plaques and NFTs are the defining neuropathological hallmarks of AD, but 
their pathophysiological relation is still not fully elucidated. The finding that neurons are 
primarily responsible for APP production and also contain NFT highlights a key issue in AD, the 
relationship of Aβ plaques to NFT. Recent studies demonstrated a direct high-affinity interaction 
between tau and APP.  
Several mechanisms for Aβ-induced neurotoxicity have been proposed, including oxidative 
stress, free radical formation, disrupted calcium homeostasis, induction of apoptosis, neuritic 
damage, chronic inflammation and formation of amyloid pores (Di Rosa et al., 2002; Lashuel et 
al., 2002; Pratico, 2002). Based on genetic findings in FAD and observations in Down's 
syndrome, the "amyloid cascade hypothesis" has been postulated which claims that a 
dysregulation in APP processing, resulting in increased production of Aβ or failure to clear the 
peptide leads to AD primarily through amyloid deposition. The aggregated Aβ in turn is then 
supposed to induce all subsequent pathology, including tau hyperphosphorylation, tangle 
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formation, neuronal cell death and memory impairment (Haass et al., 1991; Hardy and Higgins, 
1992). This is supported by the fact that human carriers of pathogenic mutations in the APP 
gene ultimately develop both Aβ plaques and NFT.  
Nevertheless, the amyloid cascade hypothesis was challenged because several findings 
suggested that Aβ was not the sole cause for AD, for example that tau-containing neurofibrillary 
tangles were involved in several other neurodegenerative diseases in absence of Aβ deposits. 
Also mutations in the APP gene as well as in the closely related  presenilin 1 and 2 genes 
account for less than 5% (familial) of the total number of AD cases, which are mostly sporadic 
late-onset cases (SAD) (see section 7.1.1). Furthermore, the frequency of NFT correlates to 
dementia better than does that of senile plaques (Arriagada et al. 1992), with the degree of 
dementia not correlating with the number of Aβ plaques (Terry, 1996), and neurofibrillary tangle 
formation seems to predate plaque formation (Braak et al., 1996). In addition, transgenic mice 
over-expressing APP develop little if any neurodegeneration, even with extensive amyloid 
deposition (Hsiao et al., 1996). Therefore, it is not surprising that disorders leading to 
hyperphosphorylated tau accumulation are associated with dementia. 
Nevertheless, a large body of genetic and cell biological evidence from recent studies strongly 
argues for pathogenic and inductional activities of Aβ in the formation of neurofibrillary tangles 
(Ferrari et al., 2003; Gotz et al., 2001; Lewis et al., 2001; Oddo et al., 2003). It has been 
shown in triple transgenic mice (APPswe, presenilin1 (PS1M146V), and tauP301L), that anti Aβ 
antibodies administered to the hippocampus reduce not only extracellular and intracellular Aβ 
accumulations but also lead to a clearance of an early tau pathology (Oddo et al., 2004). 
Further, the amyloid cascade hypothesis has gained strength through the observation that AD-
causing mutations identified in APP and the presenilin genes alter APP metabolism causing 
increased production of Aβ42. Furthermore, stereotactic injection of Aβ42 fibrils into the brain of a 
tau transgenic mouse line caused fivefold increase in the number of NFTs in cell bodies within 
the amygdala (Gotz et al., 2001). In related experiments, it was shown that tau filament 
formation in cells expressing mutant tau can be induced by a treatment with pre-aggregated Aβ 
(Ferrari et al., 2003). 
The pathogenic relationship of the two major lesions of AD and their relative contribution to the 
clinical features of the disease are a long-standing matter of debate. This has major implications 
for the development of treatment strategies. An Aβ-directed treatment would only reduce NFT 
formation if NFT formation were downstream of Aβ, while it would have no effect on NFT 
numbers if the formation of the two lesions were caused by an upstream pathogenic signal.  
NFT develop in specific predilection sites and spread in a predictable, non-random manner 
across the brain. This sequence of the tau pathology provides a basis for distinguishing six 
stages of disease progression (Braak and Braak, 1991; Braak and Braak, 1995): the 
transentorhinal stages I-II representing clinically silent cases; the limbic stages III-IV of 
incipient AD; and the neocortical stages V-VI of fully developed AD. 
A comparative study of the Aβ-associated pathology defined five phases. These differ markedly 
from the stages which define the spreading of NFT: The neocortical phase 1 is followed by the 
allocortical phase 2. In phase 3, the diencephalic nuclei, the striatum and the cholinergic nuclei 
of the basal forebrain develop Aβ deposits, and in phase 4, several brainstem nuclei become 
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additionally involved. Finally, phase 5 is characterized by cerebellar Aβ-deposition. These 
findings suggest that Aβ-deposition expands anterogradely into regions that receive neuronal 
projections from regions already exhibiting Aβ (Everett et al., 2002). 
Numerous correlation studies failed to demonstrate a clear relationship between the severity of 
dementia and Aβ deposition in human AD brain whereas a correlation between NFT numbers 
and severity of dementia has been reported (Arriagada et al., 1992; Bierer et al., 1995; Crystal 
et al., 1988; Morrison and Hof, 1997; Nagy et al., 1996). It was shown that total NFT counts in 
specific brain areas such as the entorhinal and frontal cortex, as well as neuron numbers in the 
CA1 region of the hippocampus were the best predictors of cognitive deficits in brain aging and 
AD (Bussiere et al., 2003; Giannakopoulos et al., 2003). Delacourte and coworkers however 
proposed a synergistic interaction between the APP- and tau-related pathology, despite a 
different spatiotemporal distribution of plaques and NFT (Buee and Delacourte, 1999; 
Delacourte et al., 2002). They also found that whenever Aβ aggregates were detected, tau 
pathology was found, at least in the entorhinal cortex. The opposite was not true as cases were 
found with an advanced tau pathology and no traces of Aβ aggregates (Delacourte et al., 2002). 
7.1.5.1 Neuronal damage 
 
In AD, only around 85% of the neuronal loss can be explained by NFT formation (Bussiere et 
al., 2003; Gomez-Isla et al., 1997). This implies that non-NFT-related mechanisms of 
neurodegeneration may also compromise vulnerable subsets of neurons. A quantitative analysis 
of NFT in human brain revealed that a substantial number of pyramidal cells may persist either 
unaffected or in a transitional stage of NFT formation. Whereas it is not possible to assess 
whether such transitional neurons are fully functional, these affected neurons might respond 
positively to therapeutic strategies aimed at protecting the cells that are prone to neurofibrillary 
degeneration in AD (Bussiere et al., 2003).  
As plaques and NFT are not only the histopathological hallmarks of FAD, but also sporadic AD 
(SAD), it will be important to know what triggers their formation and how they are functionally 
related. Some insight may be gained by an analysis of adult lifestyle risk factors combined with 
the evidence of a genetic predisposition (as determined by the inheritance of risk alleles of 
susceptibility genes), which together may cause SAD (Holness et al., 2000).  
Although the etiology of FAD and SAD differ, the clinical picture and the morphological end 
stage in the brain appear to be the same. Such a constellation, which combines heterogeneity in 
origin with homogeneity in clinical appearance and morphology of disease is, although rare, not 
unknown. A good example for this pattern is diabetes mellitus: In type I diabetes, insulin 
production is deficient, whereas in type II the function of the insulin receptor is impaired. 
Analogous to diabetes, one may subdivide AD into type I AD (the inherited forms of FAD) and 
type II AD (the sporadic forms of AD, SAD) (Hoyer, 2002).  
Beyond this mere analogy, glucose levels themselves have been claimed to play a role in the 
pathogenesis of SAD. There is evidence that SAD may be caused by a reduced neuronal activity 
due to reductions in both insulin and ATP, which would lead to the formation of both Aβ plaques 
and NFT (Salehi et al., 1995; Salehi et al., 1994; Salehi et al., 1996; Swaab et al., 1998). 
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Insulin and ATP have both been shown to regulate the phosphorylation status of tau by 
influencing the activities of kinases. A reduction in ATP activates the external signal-regulated 
kinase ERK whereas reduced insulin levels lead to an increased activity of glycogen synthase 
kinase-3 (GSK-3), both of which are candidate kinases for the process of tau aggregation and 
NFT formation (Baumann et al., 1993; Chen et al., 2004; Hong et al., 1997; Roder and Ingram, 
1991). Obviously, the glucose hypothesis does not place Aβ upstream of tau, as both tau and 
APP/Aβ would be substrates of metabolic dysfunction. 
Neuronal damage in SAD could further be caused by oxidative stress and lipid peroxidation, 
which is thought to be a prominent and especially deleterious form of oxidative damage in the 
brain due to this organ's relative enrichment in polyunsaturated fatty acids. Interestingly ApoE, 
which is involved in the transport of lipids and in particular cholesterol, represents the strongest 
genetic risk factor for SAD (see section 7.1.1) (Rocchi et al., 2003). A wide range of studies 
suggest that brain cholesterol metabolism is central to the AD pathophysiology by affecting APP 
processing and Aβ formation (Bassett and Montine, 2003; Poirier, 2003). Yet in the tau 
transgenic mice, the role of cholesterol has not been addressed so far. 
A further hypothesis proposes mitotic failure as a cause of the neuronal degeneration in AD 
(Arendt, 2003; Arendt et al., 2000; Bowser and Smith, 2002). Non-neuronal cells use 
morphoregulatory cues and internal signaling pathways to control proliferation and 
differentiation in the process of tissue repair and regeneration, after development is completed. 
In neuronal cells, synaptic plasticity is controlled by the same cues and signaling pathways, 
which have been developed primarily to control proliferation. As postmitotic neurons are capable 
of using these molecular mechanisms, according to the mitotic failure theory, this puts a neuron 
at risk to erroneously convert signals which are derived from plastic synaptic changes into 
positional cues that will activate the cell cycle. This cell cycle activation potentially links synaptic 
plasticity to cell death, as signaling cascades are activated which could lead to the accumulation 
of tau and β-amyloid. This would mean that preventing cell cycle activation of neurons might be 
crucial to prevent neurodegeneration (Arendt, 2003). To be able to test this and the other 
hypotheses mentioned above, the development of sophisticated transgenic animal models 
together with a thorough histopathological analysis of early stages of human AD would be 
required. 
 
7.1.6 Interaction of β-amyloid and tau in animal models 
 
Before NFT formation had been achieved in tau transgenic mice, the relationship of plaques and 
NFT in AD was addressed in different non-transgenic species such as rats and monkeys (Geula, 
1998). Intracerebral injection of plaque-equivalent concentrations of fibrillar, but not soluble, Aβ 
resulted in profound neuronal loss, tau phosphorylation and microglial proliferation in the aged 
rhesus monkey cerebral cortex. In contrast, the same preparations were not toxic in the young 
adult rhesus brain, indicating a role for age in Aβ toxicity. This toxicity was also highly species-
specific as it was neither observed in young nor in aged rats (Geula, 1998). These results 
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suggested that Aβ neurotoxicity in vivo is a pathological response of the aging brain, which is 
most pronounced in higher order primates. 
In transgenic mice, the presence of the P301L mutation appeared to accelerate tau filament 
formation at a younger age, while transgenic mice with high expression levels of human tau 
developed NFT only at high age (DeTure et al., 2000; Gotz, 2001; Ishihara et al., 2001). P301L 
mutant mice are therefore suitable models to determine whether β-amyloid affects the tau 
pathology in these mice. Synthetic preparations of fibrillar Aβ42 were stereotaxically injected into 
the somatosensory cortex and the hippocampus (CA1 region) of P301L and wild-type human tau 
transgenic mice and non-transgenic littermate controls, causing a fivefold increase of NFT in the 
amygdala of P301L transgenic, but not wild-type tau transgenic or control mice, eighteen days 
following the injections (Gotz, 2001). In contrast, when the reversed peptide Aβ42-1 was 
injected, levels of NFT were not affected (Figure 4) (Gotz et al., 2004). NFT formation in the 
Aβ42-injected P301L mice was tightly correlated with the pathological phosphorylation of tau at 
S422 and the epitope AT100 (T212/S214), but not AT8 (S202/T205). The finding that Aβ42 was 
not capable of inducing NFT formation in non-NFT-forming wild-type tau transgenic mice may 
reflect species differences between mice and men. Alternatively, it may imply that, at least in 
mice, Aβ42 can not induce NFT formation de novo, which would be in disagreement with the 
amyloid cascade hypothesis. Interestingly, in cultured murine hippocampal neurons, toxicity of 
Aβ42 has been shown to be dependent on the presence of tau (Di Rosa et al., 2002).  
 
Figure 4: 
APP can be proteolytically cleaved by the 
membrane-associated α-secretase, which cleaves 
APP within the Aβ domain. This pathway is non-
amyloidogenic, as this cleavage precludes the 
formation of Aβ. Alternatively, cleavage may occur 
in the endosomal-lysosomal pathway, first by the β-
secretase and then by the γ-secretase generating 
the Aβ peptide. Aβ is deposited around meningeal 
and cerebral vessels, and in the gray matter as β-
amyloid plaques. To determine the relationship 
between Aβ and the NFT/tau pathology in AD, two 
alternative approaches were pursued. One involved 
the intercrossing of APP and Tau mutant mice with 
a plaque and NFT pathology (breeding approach), 
the other the stereotaxic injection of fibrillar 
preparations of Aβ42 into mutant tau transgenic 
brains (stereotaxic approach). Both resulted in 
increased NFT formation, which was associated with 
phosphorylation of tau at the phospho-epitopes 
Thr212/Ser214 and Ser422.  
 
J. Götz, A. Schild, F. Hoerndli, and L. Pennanen 
(2003), Int. J. of Devl Neuroscience, 22, 453-465. 
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An alternative approach was chosen by Lewis and coworkers who crossed Aβ-producing APP-
mutant Tg2576 mice with their PrP promoter-driven P301L tau mutant mice (Lewis et al., 
2001). Double transgenic mice showed a more than sevenfold increase in NFT numbers in the 
olfactory bulb, the entorhinal cortex and the amygdala compared to P301L single transgenic 
mice, whereas plaque formation was unaffected by the presence of the tau lesions (Figure 4).  
When both approaches are taken together, they imply that not all brain areas are similarly 
susceptible to Aβ-mediated NFT induction. In both studies, the amygdala is a hot spot of NFT 
induction. Unless tau levels are particularly high in the amygdala compared to other brain areas 
such as the hippocampus or cortical areas, a different transcriptional profile may account for the 
observed differences. A following study of amygdala-specific gene expression provided a list of 
genes, some of which may confer an increased tau-related vulnerability of amygdaloid neurons 
to Aβ42 (Zirlinger et al., 2001). Alternatively, it may be the nerve terminals which are 
susceptible to Aβ42, whereas direct exposure of the cell body or neurites may not pose a risk to 
the tau-expressing neuron. Whether Aβ is taken up by a receptor-mediated mechanisms or 
whether it forms pores is still a matter of debate (Lashuel et al., 2002; Verdier and Penke, 
2004) (Figure 4). A recent study with double transgenic mice expressing the amyloid precursor 
protein, bearing the Swedish mutations, and expressing tau protein containing three of the 
mutations present in frontotemporal dementia linked to chromosome 17 (FTDP-17), suggested 
that Aβ could facilitate the phosphorylation of tau at a site not directed by proline, such as 
serine 262, and that modification could facilitate tau aberrant aggregation (Perez et al., 2005). 
 
Together with a study showing that aggregated synthetic Aβ42 caused a decreased solubility of 
tau along with the generation of PHF-like tau containing filaments in a human tissue culture 
system (Figure 4) (Ferrari et al., 2003; Gotz et al., 2004), the above experiments demonstrate 
pathological interactions between Aβ and tau that lead to increased NFT formation. Moreover, 
the region-specific induction of Aβ-mediated NFT formation in P301L tau transgenic mice 
mirrors, to some extent, the regional vulnerability observed in AD brains. For a complete 
review, see the recent article by Götz, Schild, Hoerndli, and Pennanen (Gotz et al., 2004). 
 
 
 
 
 
 
Figure 5:  
Stably expressed human tau in neuronally differentiated 
human SH-SY5Y cells (A, in red), exposed to aggregated 
synthetic β-amyloid peptide (Aβ42) (A, in green). Electron-
micrograph of the fibrillar preparations of Aβ42 (B). Aβ42 
caused the generation of PHF-like tau containing filaments 
that were 20 nm wide and had periodicities of 130 to 140 
nm in the presence of P301L mutant tau, or 150 to 160 nm 
in the presence of wild-type tau (C). 
 
J. Götz, A. Schild, F. Hoerndli, and L. Pennanen, Int. J. of 
Devl Neuroscience, 22, 453-465. 
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7.1.7 Histopathology of tau transgenic mouse models 
 
In one of the first tau transgenic mouse models, the longest human 4R brain tau isoform was 
expressed neuronally without any pathogenic mutation (Goedert et al., 1995). Despite the lack 
of an NFT pathology, these mice modeled aspects of human AD, such as somatodendritic 
localization and hyperphosphorylation of tau and, therefore, represented an early pre-NFT 
phenotype. The use of stronger promoters to drive transgene expression caused a more 
pronounced phenotype (Gotz et al., 2000; Ishihara et al., 1999; Moechars et al., 1999). Due to 
a high expression level of the transgene in motor neurons, large numbers of pathologically 
enlarged axons with neurofilament- and tau-immunoreactive spheroids were present, a 
neuropathological characteristic of most cases of amyotrophic lateral sclerosis (ALS), where 
they are believed to impair slow axonal transport (Hirano et al., 1984; Munoz et al., 1988; 
Rouleau et al., 1996). Tau protein extracted from transgenic brain and spinal cord has been 
shown to become increasingly insoluble as the mice became older. Despite the decreased 
solubility of tau, NFT did not form, unless the mice reached a very old age (Ishihara et al., 
2001). Taken together, these findings demonstrated that overexpression of human tau can lead 
to an axonopathy resulting in nerve cell dysfunction and amyotrophy (Chen et al., 2004; Gotz, 
2001).  
With the identification of pathogenic tau mutations in FTDP-17 in 1998, several groups achieved 
NFT formation both in neurons (Allen et al., 2002; DeTure et al., 2000; Gotz, 2001; Tanemura 
et al., 2001; Tatebayashi et al., 2002) and in glial cells of transgenic mice (Gotz, 2001; Higuchi 
et al., 2002). The P301L mutation was one of the first FTDP-17 mutations that had been 
identified in human patients (Grover et al., 1999). This mutation was shown in vitro to cause 
both an accelerated aggregation of tau into filaments and a marked reduction in the ability of 
tau to promote microtubule assembly (Barghorn et al., 2000; Hasegawa et al., 1998; Ko et al., 
1999). Also, the P301L mutation is quite frequent as it has been detected in 11% of familial 
cases of frontotemporal dementia (FTD) (Sobrido et al., 2003) and therefore, made it a fitting 
choice to be expressed in transgenic mice.  
When a human tau isoform lacking the two amino-terminal inserts was expressed together with 
the P301L mutation under the control of the murine PrP promoter (DeTure et al., 2000), 90% of 
the mice developed severe motor and behavioral disturbances by 10 months of age. These were 
more pronounced than reported in the previously published wild-type tau transgenic mouse 
models (Gotz et al., 2000; Ishihara et al., 1999; Moechars et al., 1999). Importantly, NFT were 
identified by Gallyas silver stainings and thioflavin S-fluorescent microscopy both in brain and 
spinal cord, and motor neurons were reduced twofold in the spinal cord (DeTure et al., 2000). 
The same mutation was expressed using the longest human tau isoform containing both amino-
terminal inserts. The mThy1.2 promoter was chosen instead of the PrP promoter, which may 
account for different expression patterns in these mice (Gotz, 2001). Again, NFT were identified. 
In addition, tau filaments were revealed by immuno-electron microscopy of sarcosyl extracts 
using phospho-tau-specific antibodies. Due to low expression levels in motor neurons of the 
spinal cord, no motor phenotype was observed. 
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The P301S mutation is an aggressive mutation that causes clinical signs of FTDP-17 already in 
the third decade of life (Bugiani et al., 1999). When P301S mutant tau was expressed under the 
control of the mThy1.2 promoter, massive NFT formation was found (Allen et al., 2002). To 
address the role of distinct tau phospho-epitopes in tau filament formation, tau was analyzed in 
both the soluble and insoluble fraction. Perchloric-acid soluble tau was phosphorylated at many 
phospho-epitopes of tau, with the exception of the AT100 phospho-epitope S214, whereas 
sarkosyl-insoluble tau was strongly immunoreactive with all antibodies including AT100. 
Interestingly, this site has been shown, together with S422, to be linked to NFT formation in 
P301L mice (Gotz, 2001). Together, this indicates that immunoreactivity for phospho-S214 
closely mirrors the presence of tau filaments, suggesting that phosphorylation of this site occurs 
in the course of, or after, filament assembly.  
The first tau transgenic mouse models dealt with neuronal tau and its assembly into NFT. To 
address the tau pathology in glial cells, G272V mutant tau was expressed by combining a PrP-
driven expression system with an autoregulatory transactivator loop that resulted in high 
expression in a subset of neurons and oligodendrocytes. Electron microscopy established 
filament formation associated with hyperphosphorylation of tau. Thioflavin S-positive fibrillary 
inclusions were identified in oligodendrocytes and motor neurons in spinal cord (Gotz, 2001). 
The clinical phenotype of these mice was subtle. In contrast, when human wild-type tau was 
over-expressed in neurons and glial cells using the mouse Tα1 α-tubulin promoter, a glial 
pathology was found resembling the astrocytic plaques in CBD and the coiled bodies in CBD and 
PSP (Higuchi et al., 2002). 
The role of glucose and insulin levels in NFT formation has not been addressed in the tau 
transgenic models. Of the many kinases implicated in the mitotic failure hypothesis (Arendt, 
2003), the wnt signaling pathway component GSK-3, and the activator p25 of the cyclin-
dependent kinase cdk-5 have been co-expressed with tau. Unexpectedly, co-expression of GSK-
3β with wild-type human tau reduced the number of axonal dilations and alleviated the motor 
phenotype that was typical for single human tau transgenic mice, whereas co-expression of p25 
with P301L tau was accompanied by increased numbers of NFT (Chevallet et al., 2003; 
Moechars et al., 1999; Spittaels et al., 2000).  
 
7.2 Phosphorylation as a regulatory principle 
 
During a lifetime, a cell has to fulfill many tasks. In order for cellular processes to function 
properly there has to be a tight regulation of all procedures involved. Today, centuries after the 
first discovery of phosphorylated proteins and the demonstration that enzyme activity can be 
regulated through its phosphorylation, as shown for the glycogen phosphorylase (Fischer and 
Krebs, 1955; Sutherland and Wosilait, 1955), the outstanding role of reversible protein 
phosphorylation in cell regulation is undisputable. Reversible phosphorylation of Ser, Thr, and 
Tyr residues occurring through the concerted action of protein kinases and protein phosphatases 
affects about one-third of eukaryotic proteins and represents the most frequent and general 
mechanism by which nearly all biological functions are regulated. The fundamental biological 
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importance of protein phosphorylation is underlined by the existence of more than 600 protein 
kinase genes and slightly less than 100 protein phosphatase genes within the human genome. 
Much of the specificity of protein phosphorylation resides in the kinases responsible for 
transferring the phosphate group from ATP to the target proteins, as witnessed by the rich 
diversity of cellular kinases. In Drosophila melanogaster, Saccharomyces cerevisiae and 
Caenorhabditis elegans protein kinases belong to the protein families with the most members. 
In all three organisms, they represent 2% of the total proteome (Rubin et al., 2000). In 
principle, protein phosphatases play an equally important role in the regulation of protein 
phosphorylation, but there are relatively few different protein phosphatase enzymes. In 
mammalian cells, two closely related phosphoprotein phosphatases, PP1 and PP2A, account for 
>90% of the total phosphatase activity (Depaoli-Roach et al., 1994). This figure by itself, in 
conjunction with the observation that protein phosphatases operate on a minority of potential 
phosphoacceptor residues preselected by protein kinases, would indicate that the specificity of 
phosphatases needs to be less stringent than that of protein kinases. This is especially true of 
site specificity, i.e. the ability to recognize consensus sequences defined by local structural 
features surrounding the phosphoacceptor amino acid. This is a prominent feature of most 
protein kinases, with special reference of Ser/Thr specific ones, and has been exploited for the 
design of hundreds of specific peptide substrates. These proved useful for the selective 
monitoring of individual kinases or classes of kinases, whose structural features responsible for 
site specificity in many instances have been disclosed by mutational and structural analyzes. In 
contrast many attempts to define consensus sequences recognized by individual protein 
phosphatases were less rewarding consistent with the notion that residues surrounding the 
phospho-amino acid may play a marginal role in substrate recognition, which is mainly mediated 
by targeting subunits and/or structural modules outside the catalytic core of the phosphatase 
(Shibasaki et al., 1996; Song et al., 2001). 
Protein kinases catalyze the transfer of the γ-phosphoryl group of ATP to the hydroxyl group of 
Ser, Thr, and Tyr residues within specific protein substrates. Protein phosphatases are 
hydrolytic enzymes that remove the phosphoryl group from the phosphorylated residue(s). 
Unlike protein kinases, where tyrosine specific and serine/threonine specific kinases share 
substantial sequence identity, the protein phosphatase can be divided into two unrelated large 
families: protein serine/threonine phosphatases, which remove the phosphoryl group from 
serine/threonine residues, and protein tyrosine phosphatases (PTPs), which hydrolyze 
phosphotyrosine.  
In contrast to protein kinase activation, which tends to be associated with cell growth and 
proliferation, PP2A phosphatase activity is associated with growth inhibition and cell cycle 
arrest, and abnormal phosphorylation is one of the causes or consequences of frequent diseases 
like cancer, diabetes, Alzheimer’s disease and rheumatic arthritis (Cohen, 2000). Protein 
phosphatases play critical roles in the timing, extent and localization of protein phosphorylation 
and in regulating those cellular processes modulated by phosphorylation. Therefore, specificity 
also comes from protein phosphatases, whose complexity, achieved in part through 
combinatorial subunit interactions, equals that of protein kinases (Virshup, 2000). The 
phosphorylation of a protein can alter its behavior in almost every conceivable way, and 
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multisite phosphorylation can enable several such effects to operate in the same protein 
(Cohen, 2000). In many cases phosphorylation regulates the intrinsic biological activity of 
enzymes (Gabrielli et al., 1997; Sugiura et al., 1999; Davis, R. J., 2000). Also phosphorylation 
affects stability (Brondello et al., 1999; Nosworthy et al., 1998; Szilak et al., 1997), interaction 
with other proteins (Di Paolo et al., 1997; Kann et al., 1999) or DNA (Steegenga et al., 1996), 
binding of metallic ions (Taborsky, 1991), and translocation between cellular compartments 
(Jans, 1995; Petersen et al., 1999). There are several proteins and protein domains known that 
recognize their binding partners within cellular signal cascades only when phosphorylated (Yaffe 
and Cantley, 1999; Yaffe and Elia, 2001). 
Examples for such specific modules are SH2 (src homology 2) domains (Schaffhausen, 1995), 
WW domains (Lu et al., 1999), forkhead-associated (FHA) domains (Durocher et al., 2000) and 
14-3-3 proteins (Aitken, 1996; Yaffe et al., 1997). The phosphorylation sites in eukaryotes are 
most frequently found at serine/threonine or tyrosine side chains. Dephosphorylation thereof 
follows one of two distinct mechanisms (Barford et al., 1998; Denu et al., 1996). Tyrosin 
phosphatases form a covalent phospho-enzyme intermediate at the phosphor atom, after 
nucleophilic attack of a thiolat anion from a cystein side chain (Denu et al., 1996). In contrary, 
with serine/threonine-specific protein phosphatases, there is no temporary transfer of 
phosphate to the enzyme as the nucleophilic attack at the phosphor atom is caused by a water 
molecule, activated by two metallic ions (Egloff et al., 1995). Protein phosphatase 2A (PP2A), 
together with PP1, PP2B (calcineurin), PP4 and PP5, belongs to the PPP family of protein Ser/Thr 
phosphatases. Members of this family have no sequence homology to the PPM family, to which 
belongs the Mg2+ dependent PP2C (Barford, 1996; Wera and Hemmings, 1995; Zolnierowicz, 
2000). 
 
7.2.1 Protein phosphatase 2A (PP2A) 
 
PP2A is a highly abundant and ubiquitously expressed serine/threonine-specific protein 
phosphatase with important roles in embryonic development and differentiated tissues (Mayer-
Jaekel and Hemmings, 1994; Goldberg, 1999; Janssens and Goris, 2001; Millward et al., 1999; 
Sontag, 2001; Virshup, 2000). PP2A is tightly controlled by association with regulatory subunits, 
post-translational modification and the interaction with cellular proteins. 
The PP2A holoenzyme is a heterotrimer made of a scaffolding A, a regulatory B, and a catalytic 
C subunit. The catalytic C subunit with a molecular weight of 36 kDa has so far been found as 
two isoforms, α and β, which differ only in eight out of a total of 309 amino acids (Stone et al., 
1987). Both are expressed ubiquitously in all tissues, though the isoform α is found at higher 
concentrations (Khew-Goodall and Hemmings, 1988) and it has been shown to be an essential 
protein despite a high sequence homology to the isoform β. A Cα-/- knock-out can not be 
compensated by Cβ and therefore the deletion of Cα is embryonically lethal in mice (Gotz et al., 
1998), possibly due to a different subcellular localization of both C isoforms (Gotz et al., 2000). 
The catalytic subunit of PP2A belongs to the proteins that have been the most highly conserved 
during evolution, as shown in sequence comparisons with lower eukaryotes as Saccharomyces 
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cerevisiae (Sneddon et al., 1990), Schizosaccharomyces pombe (Kinoshita et al., 1990), 
Xenopus laevis (Van Hoof et al., 1995), Drosophila melanogaster (Orgad et al., 1990) or plants 
as Arabidopsis thaliana (Perez-Callejon et al., 1998) and Brassica napus (MacKintosh et al., 
1990). PP2A is a metallo-enzyme with Fe2+ and Zn2+ in the active site (Nishito et al., 1999; 
Nishito et al., 1999). 
The A subunit is a 65 kDa protein (also called PR65) that associates with the catalytic subunit to 
form a core dimer (Groves et al., 1999; Kamibayashi et al., 1992; Kremmer et al., 1997). The 
apparent dissociation constant of this interaction has been determined at approximately 85 pM 
(Turowski et al., 1997). As well as for C, there are two isoforms of the scaffolding subunit A in 
mammals, which show a sequence homology of 87% (Hemmings et al., 1990). The three 
dimensional structure of A has been studied in much detail (Groves et al., 1999). It contains an 
array of 15 HEAT motifs consisting of 39 amino acids each. HEAT (huntingtin/ elongation/ A 
subunit/ target of rapamycin) motifs have been named after the first proteins, in which they 
have been discovered (Andrade and Bork, 1995; Groves et al., 1999). Such motifs of 37-43 
amino acids length are found in proteins in repeats of 3 to 22. All 15 HEAT motifs in the A 
subunit of PP2A build an alike structure, namely two antiparallel helices forming something like 
a double layer of α-helices. The loops between both helices of a motif contain conserved amino 
acids and exposed hydrophobic surfaces, thereby providing docking sites for both catalytic and 
regulatory subunits. Yet only A subunits in the core dimer can assemble with various regulatory 
B subunits to form heterotrimers with distinct localization and substrate specificity (McCright et 
al., 1996; Moreno et al., 2000; Strack et al., 1998; Tehrani et al., 1996). 
Four B subunit families with no sequence homologies have been identified so far, termed 
B/PR55, B’/PR56/PR61, B’’/PR59/PR72/130 and B’’’/PR93/PR110 (Janssens and Goris, 2001). In 
contrast to Drosophila, where each subunit is encoded by a single gene, mammals express at 
least two A (α and β), two C (α and β), four B, at least five B’, four B’’, and two B’’’ isoforms. As 
a result, a total of more than 72 PP2A holoenzymes can be generated. Taking into account the 
different splice variants, this number may be even higher (Martens et al., 2004; Schmidt et al., 
2002). Heterotrimers with PR55 subunits are often named PP2A1, whereas trimers including 
PR61 subunits are referred to as PP2A0, not to be confounded with PP2AD for the dimeric form. 
The four isoforms of the B/PR55 family are expressed in a tissue specific manner (Mayer et al., 
1991; Schmidt et al., 2002; Strack et al., 1999; Zolnierowicz et al., 1994) and contain six WD 
repeats (Neer et al., 1994). These weakly conserved sequence motifs of approximately 40 
amino acids probably conduce to the interaction with other proteins (Smith et al., 1999). PR55α 
for example associates with the type I transforming growth factor beta (TGF-beta) receptor, 
resulting in the phosphorylation of PR55α by the receptor kinase (Griswold-Prenner et al., 
1998). 
The B’/PR61 family consists of at least five distinct gene products (Csortos et al., 1996; 
McCright and Virshup, 1995; Tehrani et al., 1996). All PR61 family members contain a highly 
conserved central region, which is very likely required for the interaction with the A and possibly 
the C subunit (Zolnierowicz et al., 1996). They are almost exclusively phosphoroteins (McCright 
et al., 1996) and the different isoforms are expressed in a tissue-specific manner (Csortos et 
al., 1996; McCright and Virshup, 1995; Tehrani et al., 1996). 
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The B“ family comprises the two related proteins, PR72 und PR130, possibly two splice variants 
of the same gene product (Hendrix et al., 1993), and the proteins PR59 and PR48 (Voorhoeve et 
al., 1999; Yan et al., 2000). PR59 shares 56% identity and 65% similarity with PR72, but its 
expression pattern differs completely form that of PR72 (Voorhoeve et al., 1999). PR48 shares 
68% homology with PR59 and was identified as an interaction partner of Cdc6, a protein 
required for the initiation of DNA replication (Yan et al., 2000). 
The members of the fourth and last family of regulatory subunits described until now, B’’’, have 
in common a conserved epitope that they share with B’ subunits. Striatin (PR110) and S/G2 
nuclear autoantigen (SG2NA; PR93) contain WD-40 repeats and interact with PP2AD and 
additional proteins, suggesting a function as scaffolding proteins in Ca2+-dependent signaling 
(Moreno et al., 2000). 
 
7.2.1.1 Post-translational modifications of the catalytic subunit 
 
PP2A not only appears to integrate signals within phosphorylation cascades but also to be the 
focal point of a distinct post-translational modification system. The C-terminal sequence of the 
catalytic subunit is extremely well conserved, and several of its amino acids within it are 
important for binding of the third subunits to the PP2A core dimer. Recruitment of regulatory 
subunits into the PP2A complex is therefore determined by post-translational modifications of 
the C subunit at its carboxy-terminus, which contains a highly conserved DYFL motif at position 
306-309 (Ogris et al., 1997). The modifications include at least three post-translational 
modifications: methyl esterification of the C-terminal leucine 309, phosphorylation of a 
conserved tyrosine located two residues from the C-terminus and phosphorylation of an as yet 
unidentified threonine (Tolstykh et al., 2000; Turowski et al., 1995; Wu et al., 2000; Yu et al., 
2001; Zukerberg et al., 2000). Leucine 309 is reversibly methylated by a new type of 
methyltransferase (LCMT, leucine carboxyl methyltransferase), and demethylated by a specific 
methylesterase (PME-1, phosphatase methylesterase). In addition to its esterase function, PME-
1 stabilizes an inactive conformation of PP2A that can be reactivated by the PP2A activator 
(PTPA) (Fellner et al., 2003; Longin et al., 2004), a PP2A-interacting protein essential for cell 
survival (Van Hoof et al., 2000).  
Despite the fact that post-translational modifications to the catalytic regulatory subunits have 
been described, the biochemical basis for such dynamic regulation is not known. The C subunit 
is the target for inactivating phosphorylations on some of its tyrosine and threonine residues so 
that phosphorylation of either the Tyr or the Thr site inhibits phosphatase activity in vitro 
(Janssens and Goris, 2001), and most of the PR61 proteins (except PR61γ) are phosphoproteins 
in vivo (McCright et al., 1996). On the other hand, carboxyl methylation of the C subunit does 
not affect phosphatase activity in vitro (Tolstykh et al., 2000). However, purified PP2A carboxyl 
methyltransferase methylates the C subunit only in the context of an AC dimer and the resulting 
dimer containing the methylated C subunit has a higher affinity for a B regulatory subunit than 
does a dimer with an unmethylated C subunit (Tolstykh et al., 2000). Consistent with this 
observation, a tagged version of a mammalian PP2A C subunit containing a mutation of the 
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conserved C-terminal leucine showed reduced participation in ABC heterotrimers in vivo but 
normal participation as an AC heterodimer (Chung et al., 1999). These observations suggest 
that carboxyl methylation could affect the association of the C subunit with regulatory subunits 
in vivo and, as a result, alter targeting of the phosphatase towards certain substrates relevant 
for its normal biological activity. When negatively charged amino acids were introduced at 
threonine 304 or tyrosine 307 to mimic phosphorylation, the A, but not the B subunits, were 
bound by mutant C in transfected NIH3T3 cells (Ogris et al., 1997). Similar findings were 
obtained with mutants Y307F and L309Q, demonstrating the importance of the carboxy-terminal 
residues for heterotrimer assembly (Chung et al., 1999). More specifically, it was shown that 
the L309A mutant was defective in binding distinct subunits, such as B/PR55α, in vitro (Bryant 
et al., 1999). 
Comparable findings were obtained in S. cerevisiae. Removal of the carboxy-terminal leucine or 
substitution by alanine did not inhibit general PP2A activity, but abolished binding of B/PR55. 
Binding of B’/PR61 was assumed to be retained as judged from a cell growth inhibition assay 
(Evans and Hemmings, 2000). These data support the notion that B/PR55 and B’/PR61 compete 
for binding to the core dimer. The kinase–phosphatase relationship is more intimate than 
previously thought on the basis of the general antagonism between both classes of enzymes. 
Indeed, signal transduction ‘cassettes’ have been discovered in which a protein kinase and PP2A 
directly interact, or in which the kinase and PP2A are linked via a common anchoring protein. 
PP2A controls the activity of at least 50 different kinases (Millward et al., 1999). Understanding 
the regulation of these kinase–phosphatase couples will be of importance to gain deeper 
insights into the signaling pathways in which they are involved. 
 
7.2.2 PP2A in human disease 
 
PP2A holoenzymes have been shown to play an important role in human disease. The structural 
subunit A, for instance, has been identified as a tumor suppressor. It is mutated in melanomas 
and carcinomas, as well as tumor-derived cell lines (Calin et al., 2000; Ruediger et al., 2001; 
Wang et al., 1998). In addition, an expanded CAG repeat was found immediately upstream of 
the B/PR55β gene in humans with spinocerebellar ataxia, indicating that deregulation of PR55 
may have functional consequences in neurodegenerative disorders (Holmes et al., 1999). 
Finally, PP2A dysfunction has been implicated in neurodegenerative disorders such as 
Alzheimer's disease (AD) and frontotemporal dementia (FTD) (Gong et al., 1995; Gotz and 
Schild, 2003). These disease entities collectively termed tauopathies are characterized by 
neurofibrillary tangles (NFT), which are composed of hyperphosphorylated isoforms of the 
microtubule-associated protein tau (Gotz et al., 2004). In vitro PP2A is the most powerful 
enzyme able to dephosphorylate tau , and ABαC, a major form of PP2A in brain, binds tightly to 
tau protein (Gong et al., 1994; Grundke-Iqbal et al., 1986; Sontag et al., 1999; Wang et al., 
1995). Intronic mutations in the tau gene cause frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17). In vitro as well as in vivo the FTDP-17 mutations G272V, 
∆K280, P301L, P301S, S305N, V337M, G389R, and R406W inhibit by 20-95% the binding of 
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recombinant three-repeat and four-repeat tau isoforms to the ABαC holoenzyme and the AC 
core enzyme of PP2A (Goedert et al., 2000). These results indicate that altered protein-protein 
interactions between PP2A and tau may contribute to FTDP-17 pathogenesis (Goedert et al., 
2000). Tau could be modified in different tauopathies by PP2A dephosphorylation, but different 
phosphatases and kinases and other agents that could induce tau phosphorylation are also 
under investigation (see section 7.2.2.2 “Other agents that could induce tau phosphorylation in 
tauopathies”). 
 
7.2.2.1 PP2A in Alzheimer’s disease 
 
In Alzheimer’s disease brain, tau can be isolated from a cytosolic fraction, from soluble 
abnormally phosphorylated tau (P-tau), and as a component of PHF (PHF-tau) (Kopke et al., 
1993). A pool of soluble non-PHF but abnormally hyperphosphorylated tau suggests that the 
aberrant phosphorylation of tau precedes its polymerization into PHF. Thus, the cellular 
mechanisms by which tau becomes abnormally hyperphosphorylated and assembles into PHF 
should provide profound insights into the pathogenesis of the disease. Therefore, any factor that 
causes the up-regulation of protein kinases or/and the down-regulation of protein phosphatases 
(PPs) is likely to position tau into an abnormally phosphorylated state.  
Since the first discovery that activities of PP2A, PP2B, and PP1 are significantly decreased in AD 
brain (Gong et al., 1993), increasing data both in vitro and in vivo have suggested the 
involvement of a decreased phosphatase activity (Gong et al., 2000; Kim et al., 1999; Merrick 
et al., 1997; Planel et al., 2001). While it is still possible that there is an involvement of PP2B 
and PP1, several studies have demonstrated that PP2A is a major tau phosphatase (Goedert et 
al., 1995; Gong et al., 1994; Sontag et al., 1996). By using okadaic acid as a selective 
suppressor of PP2A, studies on cell lines (Arendt et al., 1998; Favre et al., 1997; Merrick et al., 
1997; Tanaka et al., 1998), primary cultured hippocampal neurons (Gong et al., 2001; Kim et 
al., 1999; Malchiodi-Albedi et al., 1997), metabolically active rat brain slices (Bennecib et al., 
2000; Gong et al., 2001; Gong et al., 2000; Mudher et al., 1999), chronic intraventricular 
microinfusion (Arendt et al., 1998) and acute injection into rat hippocampus unilaterally (Lee et 
al., 2000) all came to the point that PP2A inhibition was sure to cause tau 
hyperphosphorylation. In addition to hyperphosphorylation, injection of OA causes amyloid 
deposition, neurodegeneration, and memory impairment in rat (Arendt et al., 1995; He et al., 
2001; Tapia et al., 1999). Since OA in part also inhibits PP1, it was important to see that 
specific inhibition of PP2A in cultured cells by SV40 small t protein, as well as in a transgenic 
mouse line by the dominant negative mutant L199P of PP2AC is sufficient to induce PHF-like tau 
hyperphosphorylation (Kins et al., 2001; Sontag et al., 1996; p. 28 and Fig. 2 p. 32). In the 
mouse model, tau was not only abnormally hyperphosphorylated, but compartmentalized and 
ubiquitinated as observed in AD in the presence of a decreased PP2A activity (Kins et al., 2001). 
In addition to these data from in vitro experiments and transgenic mice, there is a growing body 
of evidence demonstrating a reduced abundance and activity of PP2A in AD patients. In AD 
brains, PP2A activity was decreased by 30% compared with controls (Gong et al., 1995). One 
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explanation for this decrease could be the downregulation of one or more PP2A subunits. 
Indeed, microarray analyses have revealed that the expression of the catalytic subunit gene 
decreases in mice hippocampus as a result of aging (Jiang et al., 2001) and is downregulated in 
early AD (Loring et al., 2001). In the hippocampus of AD patients, of five subunits analyzed, Cα, 
B/PR55γ, and B’/PR61ε mRNA expression was quantitatively decreased (Vogelsberg-Ragaglia et 
al., 2001). In addition, reduced expression levels of ABαC were recently reported in frontal and 
temporal cortices in AD. These affected PP2A activity, which was correlated with NFT load, 
suggesting that PP2A dysfunction contributes to the tau pathology in AD (Sontag et al., 2004). 
Therefore PP2A is considered to be the crucial tau phosphatase in vivo. In addition, PP2A might 
be the key phosphatase of other high-molecular-weight microtubule-associated proteins such as 
MAP1 and MAP2 (Gong et al., 2000). 
 
Figure 6: Involvement of PP2A in Alzheimer’s disease. PP2A is the major phosphatase to dephosphorylate the 
microtubule (MT) binding protein tau. As indicated by the name tau normally binds to and stabilizes the MT system. 
Abnormally phosphorylated tau is released from MTs and can form filaments and neurofibrillary tangles (NFT) in the soma 
of the neuron. This process is accelerated by aggregated amyloid β in vitro and possibly in AD brain. Interestingly, Aβ 
peptides are also a cofactor to activate glycogen synthase kinase-3 (GSK-3), which in turn phosphorylates tau. NFT has 
been shown to be directly related to neuronal cell death and dementia. 
 
 
Yet another involvement of PP2A in AD has been proposed. It is known that S-
Adenosylmethionine-dependent carboxyl methylation is essential for the assembly of PP2A 
heterotrimers, and epidemiological evidence indicates that elevated plasma homocysteine is an 
independent risk factor for AD. The PP2A methylation system could therefore be the link relating 
elevated plasma homocysteine to AD since homocysteine is a key intermediate in the methyl 
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cycle and elevated plasma homocysteine results in a global decrease in cellular methylation 
(Vafai and Stock, 2002). 
 
7.2.2.2 Other agents that induce tau phosphorylation in tauopathies 
 
In contrast to PP2A, few data are available concerning pure PP1 regulation on tau 
phosphorylation, partly due to the lack of a specific suppressor because of its diffuse 
intracellular distribution and poor knowledge of its structures and functions. Calyculin (CA) and 
OA are well-documented tools used in studies focusing on PPs. As an inhibitor CA strongly yet 
incompletely inhibits activities of PP2A and PP1 simultaneously at nanomolar concentrations 
while higher concentrations of OA are required to inhibit PP1 besides PP2A (Favre et al., 1997). 
Tau links PP1 to microtubules and might therefore be dephosphorylated by PP1 (Liao et al., 
1998). Yet in vitro PP1 has a much weaker potential than PP2A to dephosphorylate AD P-tau, 
and PP1 was reported to cause tau hyperphosphorylation only when it was inhibited together 
with PP2A (Yamamoto et al., 1995). Apart from direct phosphorylation on tau when PP2A and 
PP1 are inhibited, an indirect pathway by promoting kinase activity cannot be excluded. By 
using metabolically living brain slices, it has been shown that PP1 up-regulates tau 
phosphorylation indirectly by regulating the activities of protein kinases (Bennecib et al., 2000). 
In SY5Y cells treated with OA, the activity of mitogen-activated protein kinase (MAPK) and 
cyclin-dependent kinase (Cdk) increased as PP2A and PP1 activity was inhibited (Tanaka et al., 
1998) There is much evidence that PP2A controls the activities of more than 30 kinases of 
several major protein kinase families in the cell, and that several kinases form stable complexes 
with PP2A (Millward et al., 1999) This includes the calmodulin-dependent protein kinase II 
(CaMKII) activity, which seems to be the major tau Ser 262/356 kinase in brain (Bennecib et 
al., 2001), and MAPK cascades (Anderson et al., 1990; Gomez and Cohen, 1991; Millward et al., 
1999; Silverstein et al., 2002). MAPKs include the extracellular signal-related kinases (ERKs), 
which are activated by mitogenic stimuli including growth factors, the c-Jun N-terminal kinases 
(JNKs) and p38 MAPKs. In vitro studies suggest that PP2A plays a major role in the down-
regulation of the ERK pathway at several stages (Millward et al., 1999). MAPK 
dephosphorylation has been attributed to PP2A, in addition to a unique family of dual specificity 
phosphatases called MAP kinase phosphatases (MKPs) (Alessi et al., 1995; Chung and 
Brautigan, 1999; Guan and Butch, 1995; Hirsch and Stork, 1997). Inhibition of PP2A by OA or 
by a dominant negative mutation of PP2AC has lead to the activation of ERK and JNK signaling 
pathways in vivo (Kins et al., 2003; Sonoda et al., 1997), and activation of PP2A inhibited JNK 
activity (Shanley et al., 2001), suggesting an additional indirect role of PP2A in tau 
hyperphosphorylation. 
In AD it has been suggested that Aβ could increase tau phosphorylation possibly by GSK-3 
activation (Alvarez et al., 1999; Yankner, 1996) and it has been suggested that Aβ could act as 
an antagonist for the insulin receptor (Xie et al., 2002). Thus, protein kinase B (PKB/Akt) should 
be inactivated and as a consequence of that, GSK-3 could be more active. In addition the stress 
kinase, p38, is also activated in AD (Hensley et al., 1999; Zhu et al., 2000) and in other 
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tauopathies (Ferrer et al., 2001; Hartzler et al., 2002) and can phosphorylate tau on residues 
that are modified in AD (Anderton et al., 2001; Gomez-Ramos et al., 2003). This is particularly 
interesting since p38 could be activated in stress conditions (Anderton et al., 2001) and 
oxidative stress has been implicated in AD and other tauopathies like progressive supranuclear 
palsy (PSP) (Nunomura et al., 2001; Odetti et al., 2000; Smith et al., 1996). This suggests that 
oxidative stress could facilitate tau phosphorylation through the activation of p38. Another 
consequence of stress is lipid peroxidation causing the modification of arachidonic acid and 
yielding compounds like 4-hydroxynonenal (HNE) or acrolein (Sayre et al., 1997; Uchida et al., 
1998). Both compounds are present in the brain of AD patients and colocalize with NFT (Lovell 
et al., 2001; Sayre et al., 1997). While HNE inhibits tau dephosphorylation and allows the in 
vitro formation of tau filaments (Mattson et al., 1997; Perez et al., 2000; Perez et al., 2002), 
acrolein favors tau phosphorylation by the stress kinase p38 (Gomez-Ramos et al., 2003). 
Consequently, tau could be modified by phosphorylation in different tauopathies by different 
kinases and, as a consequence of that phosphorylation, tau could change its conformation and 
increase its capacity to assemble into aberrant polymers (Takeda et al., 2000). 
 
7.2.3 PP2A modification in the mouse 
 
The following paper (Gotz and Schild, 2003) outlines the current state of transgenic and knock-
out models of PP2A. It should give an overview about different experimental approaches to 
better understand PP2A function in vivo. Limitations of these methods are discussed as well as 
their implications for the understanding of human disease. 
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7.2.4 PP2A in learning and memory 
 
Increasing data suggest a role for PP2A and PP1 in hippocampal long-term depression (Bennett 
et al., 2001; Mulkey et al., 1994; Mulkey et al., 1993; Thiels et al., 2000). Further studies have 
shown a more direct effect of PP2A on learning and memory. Chronic intraventricular infusion of 
OA induced spatial memory deficits in rats, associated with PHF-like hyperphosphorylation of tau 
(Arendt et al., 1995). Deficits in memory retention were found in chicks treated with CA or OA 
(Bennett et al., 2001), and unilateral microinjection of OA into rat hippocampus induced a 
transient impairment of spatial memory on an eight-arm radial maze task in rats (He et al., 
2001). Not surprisingly therefore, a recent study shows tau hyperphosphorylation and 
impairment of spatial memory retention after bilateral injection of CA into rat hippocampus (Sun 
et al., 2003). Yet it is still not clear whether the association of tau hyperphosphorylation and 
spatial memory loss in rats is a causal one. 
Spatial learning and memory need protein phosphorylation and special enzyme participation. It 
is well known that spatial learning and memory is hippocampus-dependent, and single cells in 
the hippocampus can encode specific spatial information. However, how each phosphatase 
functions and the exact mechanism of behavioral abnormalities when the PPs are inhibited still 
need more consideration. 
 
 
7.3 Aim of work 
 
As outlined in section 7.2.2 (“PP2A in human diseases”), PP2A could be a cofactor responsible 
for the development of human neurodegenerative diseases with tau aggregation such as AD. 
Therefore the aim of my work was to understand in more detail the function of PP2A in brain 
pathology and its regulation by regulatory B/PR55 subunits. 
Previous work in our lab aimed at understanding PP2A function by gene targeting of Cα in mice, 
which was embryonically lethal (Gotz and Kues, 1999; Gotz et al., 1998; Gotz et al., 2000; Gotz 
and Schild, 2003). To circumvent lethality and to address PP2A function in brain, we used a 
dominant negative mutant approach. We expressed the Cα mutant L199P in brain of transgenic 
mice. PP2A activity was reduced to 66%, causing endogenous tau to be abnormally 
phosphorylated at the epitopes Ser202/Thr205 and Ser422, and ERK and JNK to be activated 
(Kins et al., 2001; Kins et al., 2003; p. 28 and Fig. 2 p. 32). 
As described in section 7.2.4 (“PP2A in learning and memory”), PP2A deficits are likely to cause 
impaired LTP, learning and memory. Therefore, the CαL199P mutant mice were tested in a set 
of behavioral tasks mainly addressing memory deficits through impairment in the hippocampus 
(Morris water maze), but also the amygdala (fear conditioning). As the L199P mutation is in the 
catalytic core of Cα, it has been shown in vitro to abolish the catalytic activity without affecting 
holoenzyme assembly (Evans et al., 1999) (but see: (Ogris et al., 1999; Yu et al., 2001)). To 
elucidate the function of distinct regulatory B subunits in targeting and activating PP2A towards 
its substrates, the Cα mutant L309A was expressed in transgenic mice using the neuron specific 
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promoter Thy1.2 (p. 28 and Fig. 2 p. 32). In addition, in collaboration with Dr. B. Hemmings’ 
group at the Friedrich Miescher Institute (FMI) in Basel, gene targeting of several of the PP2A 
regulatory subunits of the B/PR55 family was initiated. We concentrated on the PR55γ subunit, 
since its high and almost exclusive expression in brain made it the most interesting PR55 
subunit in regard to tau phosphorylation in brain, with a potential involvement in AD and other 
tauopathies (Schmidt et al., 2002) (see section 8.2 p. 41). The function of B/PR55 regulatory 
subunits was also addressed by applying the very novel technology of short interfering RNA 
(siRNA) to stably and specifically knock down mRNA levels in human neuroblastoma and kidney 
cells. 
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8 RESULTS 
 
8.1 Behavioral analysis of PP2A/Cα(L199P) transgenic mice 
 
Transgenic mice expressing the dominant negative L199P mutation in the catalytic subunit Cα of 
PP2A and wild-type (WT) littermates as a control group were tested in spatial learning tasks 
using two different protocols of the Morris water maze test. Previous experiments with these 
transgenic mice revealed a 30% reduction of PP2A activity in brain homogenates, together with 
abnormally phosphorylated endogenous tau that was partly relocated to the somatodendritic 
compartment. Also these mice were the first transgenic mouse model showing that PP2A is an in 
vivo phosphatase of tau (Kins et al., 2001). 
 
To exclude motor deficits that could disturb the evaluation of learning and memory capacity, 
L199P and WT mice were tested for their ability to maintain balance on the rotarod at 
accelerating rotation speeds of up to 40 rpm. 
 
8.1.1 L199P transgenic mice show modest learning deficits  
 
In a first Morris water maze test, the acquisition phase consisted of 4 days with 6 trials each 
(Figure 7). On the 5th day, the platform was removed and the time every mouse stayed in the 
target and the opposite quadrant were measured for one minute (called probe trial; Figure 8). 
After two days of rest, the platform position was changed to the opposite quadrant and the mice 
had to relearn the new platform position in an acquisition phase consisting of 3 days with 6 
trials per day (Figure 7). On day four, the platform was again removed and memory retention 
was examined in a single 60 sec trial (Figure 8). The time required finding the platform during 
acquisition and the time spent in quadrants in the probe trial was determined as a measure of 
learning success. 
In the first and second acquisition phases, L199P mice showed a similar performance as WT 
littermates. Both groups learned to navigate using spatial cues and found the platform on 
average within 20 s in the last two trials of the first acquisition phase, and in trials 10 to 18 of 
the second acquisition phase, respectively. While there is no major difference in the learning of 
the first platform position between transgenics and wild-types, the second acquisition phase 
with a reversed platform position reveals that the transgenic mice had some difficulties to 
navigate to the platform in the first trials on the second day (trials 7-9). This effect disappeared 
in the following trials, in which mice of both groups performed very well. 
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Figure 7: Similar performance of transgenic and WT mice in the acquisition of a target in the Morris water 
maze. Escape times were measured for each trial, 6 trials per day. The graphs show mean escape latencies of 9 transgenic 
(light grey) and 18 WT littermates (black). Error bars represent standard errors (SEM).  
 
 
Two probe trials, one after the acquisition phase for each platform position, were analyzed for 
the time spent in the target and opposite quadrants. Animals were observed for one minute and 
the times spent in each quadrant were calculated as per cent (Figure 8). By spending more than 
25% of time (chance) in the target quadrant, again both groups of mice showed that they can 
navigate and have learned the platform position very well. But while WT mice search the 
platform in the correct quadrant more than 50% of the time in the first probe trial, L199P mice 
spent significantly less time in the target quadrant (P=0.01). This finding does not project 1:1 
to the opposite quadrant (P=0.12), which indicates that the time L199P mice do not search in 
the target quadrant must be equally spent in all remaining quadrants (Figure 8). The results of 
the probe trial for the second reversed platform position resemble the ones for the first position. 
Transgenic mice spent less time in the quadrant of the new platform position (Figure 8). This 
effect is somewhat less pronounced than in the first probe trial (P=0.05), but on the other hand, 
in this trial L199P mice spent significantly more time in the opposite quadrant, where the old 
target had been (P=0.04) (Figure 8). This could indicate that transgenic mice confounded the 
task of learning a new platform position with the search for the old position, an effect that could 
have caused the differences observed on day 2 of the second acquisition phase (Figure 7). 
 
To confirm these significant but rather small behavioral differences between L199P and WT 
mice, I adapted a more sophisticated learning-capacity test for the water maze described by the 
group of Richard Morris (Chen et al., 2000). The main difference was that each mouse had to 
search for five different platform positions drawn from a set of 20 possible locations whereas the 
performance criterion to get a new platform position was three trials in a row with an average 
escape latency of less than 15 s. The maximum number of trials was 40 for location 1, and 32 
trials thereafter, therefore the maximal duration of the test was 21 days. 
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Figure 8: Transgenic mice perform worse in probe trials in the Morris water maze. After acquisition, the time each 
mouse spent in target and opposite quadrants, and new and old quadrants, respectively during one minute were analyzed. 
The graphs show the average time per cent 9 transgenic (light grey) and 18 WT littermates (black) spent in quadrants. 
Error bars represent standard errors (SEM). By spending more than 25% of time (chance) in the target quadrant, both 
groups showed that they can navigate and have well learned the platform position. But while WT mice search the platform 
in the correct quadrant more than 50% of the time in the first probe trial, L199P mice spent significantly less time in the 
target quadrant (P=0.01). In the search of the second reversed platform position, transgenic mice spent less time in the 
quadrant of the new platform position (P=0.05) and spent significantly more time in the opposite quadrant, where the old 
target had been (P=0.04). 
 
 
 
 
 
 
Figure 9: Bivariate scattergram split by groups and descriptive statistics inclusion criteria. Trials to criterion [x] 
(TTC) of mice numbers 06 and 20 are 3.3 standard deviations (STD) above mean while the cumulative search error [m*s] 
(CSE) of mice 06 and 20 are 5.3 STD above mean. These two mice (numbers 06 and 20) can therefore be excluded from 
the analysis. The inclusion criteria for all mice (29, “count”) are summarized in the table. SEM, standard error of mean; 
min., max., minimum and maximum values included. The dotted lines represent the mean values. (in collaboration with Dr. 
D. Wolfer) 
 TTC CSE 
mean 10.94 133.1 
STD 2.99 45.7 
SEM 0.555 8.49 
count 29 29 
min. 5.670 56.45 
max. 16.40 234.6 
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Inclusion criteria were set such that a mouse that performed very badly, as described by the 
number of trials to criterion and the cumulative search error, was excluded from the analysis 
(Figure 9). Trials to criterion of mice numbers 06 and 20 were 3.3 standard deviations above 
mean while their cumulative search errors were 5.3 standard deviations above mean. These two 
mice were therefore excluded from the analysis. Descriptive statistics inclusion criteria and a 
bivariate scattergram split by groups for all mice are shown in Figure 9. 
The more sophisticated relearning paradigm revealed that transgenic L199P mice navigate less 
precisely than WT littermates (Figure 10). These effects were statistically significant but small 
and they were only captured by path geometry directly. They do not translate into a general 
escape performance and therefore I can say that the navigation problem does not appear to be 
linked specifically to the continuous relearning situation (Figure 10). I could as well observe that 
transgenics adapted normally to the test, that thigmotaxis, indicating that a mouse is constantly 
swimming along the wall of the pool, was not increased, and that the tendency to float was 
even smaller for L199P mice. In contrast, the average swim speed was significantly increased in 
transgenics (P=0.04) (Figure 10). 
 
 
 
 
 
 
 
 
 
 
Figure 10: L199P mice navigate less precisely as captured by path geometry. A more sophisticated relearning 
water maze protocol shows that the general escape performance as measured by the number of trials to criterion (A), the 
escape time per task (B), and the cumulative swim path (C) was not different in the two groups analyzed. In contrast, 
parameters describing path geometry as the path in 16 cm corridor (D) and the path parallel to border (E) revealed that 
transgenic L199P mice navigate less precisely than WT littermates. These effects were statistically significant but small. The 
average swim speed increased in both groups over all trials and was significantly increased in transgenics (P=0.04) (F). (in 
collaboration with Dr. D. Wolfer) 
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Finally L199P and WT mice were analyzed in a fear conditioning test. During fear conditioning, 
subjects learn to associate a neutral stimulus (CS) or training situation (context) with a 
coinciding painful stimulus (US). Subsequently, learning performance and fear-related behavior 
can be analyzed in the conditioned subject. The amygdale has been shown to be required for 
both the acquisition and expression of a learned fear response to explicit cues or a context 
(LeDoux, 2000; Repa et al., 2001). The hippocampus is not required to associate a single cue 
such as a tone with foot shock, provided that the two stimuli overlap temporally, contextual and 
cued fear conditioning however requires the intact hippocampus (Bach et al., 1995; Chen et al., 
1996).  
The L199P mice tested did not show any differences in context and emotional learning. This is 
not particularly surprising since other groups have found largely intact fear conditioning despite 
severe learning deficits in other tasks (Minichiello et al., 1999). 
 
 
8.2 PP2A in the wild-type mouse 
 
To increase our understanding of the function of PP2A in the mouse under physiological 
conditions, the following study was carried out. It was designed to obtain the necessary 
information to interpret the phenotype in PP2A transgenic and knockout mouse models.
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8.3 B/PR55 levels in undifferentiated and neuronally 
differentiated cells 
 
Microtubules and microtubule-associated proteins such as tau provide the major mechanical 
support for the shape of neurites and neurite formation has been shown to be regulated by 
protein phosphorylation (Chiou and Westhead, 1992; Rogers et al., 1994; Veeranna et al., 
1995; Wu and Bradshaw, 1993). Chemical suppression of microtubule elongation, using 
cytochalasin B and D or latrunculin A to depolymerize actin filaments or colcemid (demecolcine) 
to disassemble microtubules, as well as treatment with okadaic acid (OA), a potent inhibitor of 
PP2A, abolished process formation in an immortalized mouse podocyte cell line (Kobayashi et 
al., 2001). In addition, treatment of PC12 cells with OA revealed a requirement for PP2A in 
neurite outgrowth by nerve growth factor (NGF) and maintenance of neurites (Chiou and 
Westhead, 1992). There is evidence that PP2A is mainly responsible for the dephosphorylation 
of neurofilaments (NFs) (Strack et al., 1997; Veeranna et al., 1995). PP2A thereby produces 
and preserves filamentous forms of NFs in neurons (Sacher et al., 1992; Sacher et al., 1994; 
Saito et al., 1995). Thus, PP2A regulates phosphorylation of NFs and the interaction of 
cytoskeletal proteins during axonal outgrowth. 
In a previous study using PC12 like cells, endogenous B/PR55β, B/PR55γ, and B'/PR61β protein 
expression was shown to be induced during nerve growth factor (NGF)-mediated neuronal 
differentiation (Strack, 2002). In that study, transient expression of PR55γ, but not PR55α, 
facilitated neurite outgrowth, irrespective of the presence of NGF. PR55γ specifically promoted 
long lasting activation of the MAPK cascade (Strack, 2002). This in turn may initiate the gene 
transcription events required for neuronal differentiation by NGF, as it was suggested in the 
case of PC12 cells. (Traverse et al., 1992). 
These implications of PP2A in neuronal differentiation and neurite stability, together with high 
expression levels of PP2A subunits in brain compared to peripheral tissues, imply that PP2A may 
have unique functions in the brain. 
Significant insight into PP2A function in vivo is expected to be obtained by genetic approaches in 
mice (Gotz and Schild, 2003; Janssens and Goris, 2001). To provide a framework for the 
interpretation of phenotypes of mice that either lack PP2A subunits (Gotz et al., 1998; Gotz et 
al., 2000) or display an altered PP2A composition or activity (Kins et al., 2001; Kins et al., 
2003; Planel et al., 2001), we previously determined the genomic organization, identified novel 
splice variants and analyzed the mRNA and protein expression of the PR55/B regulatory 
subunits of PP2A in different tissues, in particular the brain (Schmidt et al., 2002). Here, we 
determined mRNA levels of the four members of the PR55 subunit family in human embryonic 
kidney (HEK-293) and in undifferentiated and neuronally differentiated human neuroblastoma 
cells (SH-SY5Y). 
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8.3.1 High levels of PR55α mRNA compared to PR55β, γ and δ in HEK-
293 and undifferentiated SH-SY5Y cells 
 
By multiple tissue Northern blot analysis using isoform-specific probes we have previously 
shown that PR55α and δ mRNA transcripts were present in all tissues examined in the mouse. 
PR55β was mainly confined to brain and testis, and at low levels to lung and spleen, whereas 
PR55γ was restricted to brain. Northern blot analysis of different embryonic stages has revealed 
transcription of PR55β, whereas transcripts of the remaining three subunits were not detectable 
(Schmidt et al., 2002). Here, PR55 transcription was addressed in human tissue culture systems 
with a special emphasis on neuronal differentiation by using two cell-lines, SH-SY5Y 
neuroblastoma cells (Figure 11A) and HEK-293 embryonic kidney cells (Figure 11B). The former 
can be neuronally differentiated in a step-wise manner (Figure 11C,D). SH-SY5Y cells were 
initially derived from the parental SK-N-SH line, which comprises a major neuroblastic (N-type) 
(Figure 11A, arrowhead) and a minor substrate adherent (S-type) species (Figure 11A, arrow) 
(Ross et al., 1983).  
 
Figure 11: Step-wise neuronal 
differentiation of human SH-SY5Y 
neuroblastoma cells. (A) SH-SY5Y 
cells comprise a major neuroblastic (N-
type; arrowhead) and a minor substrate 
adherent (S-type; arrow) species (Ross 
et al., 1983). (B) Non-neuronal HEK-
293 are shown for comparison. (C) 
Upon neuronal differentiation of SH-
SY5Y cells with RA for 5 days, a 
considerable proportion of the 
neuroblastic cells differentiate into a 
more neuronal phenotype by extending 
neuritic processes (N-R-type). (D) By 
incubating the cells for additional 5 
days with BDNF, S-type cells disappear 
and basically all cells display a fully 
mature neuronal phenotype, with a 
robust network of neuritic processes (N-
R/B-type). Scale bar: 30 µm. 
 
 
Steady-state mRNA levels of the four B/PR55 subunits were determined by qRT-PCR for both 
cell lines. The primers used for this study discriminate the four isoforms, but if PR55β was 
spliced similar in humans as in mice, they would not detect the two splice variants (Schmidt et 
al., 2002). I found comparable mRNA levels of the four members of the PR55 family in both 
HEK-293 and undifferentiated SH-SY5Y cells (Figure 12). PR55α was the major species in both 
cell-types, with four- to seven-fold higher mRNA levels compared to PR55δ. Amounts of PR55γ 
mRNA were slightly lower than those of PR55δ. Compared with PR55α, PR55β concentrations 
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were 62-fold lower in SH-SY5Y cells and barely detectable in HEK-293 cells. This suggests that 
the PR55β subunit, despite its low relative levels compared to the other three subunits, may 
perform a distinct function in cells that are capable of neuronal differentiation.  
 
 
 
 
 
 
 
 
 
Figure 12: PR55α, β, γ and δ mRNA levels in 
undifferentiated SH-SY5Y cells and HEK-
293 cells as determined by qRT-PCR. 
mRNA levels of the four members of the PR55 
family are comparable in both cell-types. 
PR55α is the major species, with four- to 
sevenfold higher levels compared to PR55δ. 
Levels of PR55γ are slightly lower than those of 
PR55δ. PR55β levels are very low in SH-SY5Y 
cells and barely detectable in HEK293 cells. 
Compared with PR55α, PR55β levels were 62-
fold lower in SH-SY5Y cells.   
 
 
 
8.3.2 Neuronal differentiation of SH-SY5Y cells causes an increase in 
PR55β mRNA levels, followed by a rise in PR55γ and PR55δ 
mRNA, but not PR55α  
 
To determine whether neuronal differentiation would affect PR55 subunit mRNA levels, I 
sequentially differentiated SH-SY5Y neuroblastoma cells into neuron-like cells. In a first step, 
cells were incubated with retinoic acid (RA) for 5 days (N-R-type, Figure 11C), followed by BDNF 
treatment for additional 5 days (N-R/B-type, Figure 11D). RA treatment causes both an 
inhibited growth rate and an extension of neuritic processes. BDNF enhances the differentiating 
effects of RA, resulting in a homogeneous population of cells (i.e. lacking S-type cells) with 
rounded cell bodies and lengthened neuritic processes. The cultures are characterized by 
neuritic arborization, forming extensive networks and displaying growth cones. When SH-SY5Y 
cells were differentiated for 5 or 10 days, mRNA levels of PR55β, γ and δ subunit mRNA 
increased 2.7-, 2.3-, and 1.9-fold, respectively (p=0.013, 0.007, 0.024) (Figure 13A). On the 
contrary, the amount of PR55α mRNA did not change significantly during differentiation (p=0.1) 
(Figure 13A). As there were major differences in absolute mRNA levels for the four subunits 
under non-differentiated conditions, I set these values at 100% (Figure 13B). Moreover, the two 
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differentiation stages were looked at separately. Upon differentiation into N-R-type cells, the 
quantity of PR55β mRNA increases 2.8-fold (p=0.048), while PR55α, PR55γ, and PR55δ 
displayed only non significant increases in mRNA levels (p=0.5, 0.2, and 0.5). When SH-SY5Y 
cells were further differentiated into N-R/B-type cells, amounts of PR55γ and PR55δ increase 
2.9- and 2.6-fold compared to undifferentiated SH-SY5Y cells (p=0.004 for both isoforms). The 
2.7-fold increases of PR55β mRNA levels are comparable to those obtained for N-R-type cells. 
The quantity of PR55α mRNA increased in a linear time dependent manner, but this rise was 
statistically not significant (p=0.1).  
 
Together, these data show that PR55α is likely to perform more general functions in the cell, 
which are not associated with neuronal functions, while PR55β seems to be specifically induced 
during neuronal differentiation. 
 
 
 
 
Figure 13: Relative PR55α, β, γ and δ mRNA levels in undifferentiated (n=12) compared to neuronally 
differentiated (n=6) SH-SY5Y cells as determined by qRT-PCR. (A) While the amount of PR55α mRNA does not 
change significantly during differentiation (p=0.1), levels of PR55β, γ and δ subunit mRNA increase 2.7-, 2.3-, and 1.9-fold, 
respectively, when differentiated for 5 to 10 days (*, p=0.013, **, 0.007, *, 0.024). (B) Levels of the four PR55 subunits in 
undifferentiated SH-SY5Y cells are set to 100%, while the numbers for N-R-type cells and N-R/B-type cells correspond to 
the quotients of differentiated normalized to undifferentiated. Error bars therefore show the sum of squared relative errors 
of the means. Upon differentiation into N-R-type cells, levels of PR55β increase 2.8-fold (*, p=0.048), while PR55α, PR55γ, 
and PR55δ increase to some extent, although not significantly (p=0.5, 0.2, 0.5). When SH-SY5Y cells are further 
differentiated into N-R/B-type cells, levels of PR55γ and PR55δ increase 2.9- and 2.6-fold compared to amounts in 
undifferentiated SH-SY5Y cells (**, p=0.004 for both). The PR55β mRNA levels at 2.7-fold concentrations are comparable to 
the ones obtained from N-R-type cells. The abundance of PR55α increases in a linear time dependent manner, but this rise 
is statistically not significant (p=0.1).  
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8.4 Generation and analysis of transgenic mice expressing the 
dominant negative mutant form of PP2A Cα, L309A 
 
Recruitment of regulatory subunits into the PP2A complex is determined by post-translational 
modifications of the C subunit at its highly conserved carboxy-terminus, which contains a DYFL 
motif at position 306-309 (Ogris et al., 1997). The modifications include tyrosine 
phosphorylation and methylation of leucine 309 (Tolstykh et al., 2000; Turowski et al., 1995; Yu 
et al., 2001; Zukerberg et al., 2000). When negatively charged amino acids were introduced at 
threonine 304 or tyrosine 307 to mimic phosphorylation, the A, but not the B subunits, were 
bound by mutant C in transfected NIH3T3 cells (Ogris et al., 1997). Similar findings were 
obtained with mutants Y307F and L309Q, demonstrating the importance of the carboxy-terminal 
residues for heterotrimer assembly (Chung et al., 1999). More specifically, it was shown that 
the L309A mutant was defective in binding distinct subunits, such as B/PR55α, in vitro (Bryant 
et al., 1999). Comparable findings were obtained in S. cerevisiae. Removal of the carboxy-
terminal leucine or substitution by alanine did not inhibit general PP2A activity, but abolished 
binding of B/PR55. Binding of B’/PR61 was assumed to be retained as judged from a cell growth 
inhibition assay (Evans and Hemmings, 2000). These data support the notion that B/PR55 and 
B’/PR61 compete for binding to the core dimer. In the present study, I focused on the role of 
leucine 309 in PP2A heterotrimer assembly in transgenic mice. 
A second aspect addressed is the role of PP2A holoenzymes in the phosphorylation of proteins 
implicated in human disease. Subunit A, for instance, has been identified as a tumor 
suppressor. It is mutated in melanomas and in tumor-derived cell lines (Calin et al., 2000; 
Ruediger et al., 2001; Wang et al., 1998). Further, an expanded CAG repeat was found 
immediately upstream of the B/PR55β gene in humans with spinocerebellar ataxia (Holmes et 
al., 1999). Finally, PP2A dysfunction has been implicated in Alzheimer's disease (AD) and 
frontotemporal dementia, both of which are characterized by neurofibrillary tangles (Gong et al., 
1995). These are composed of hyperphosphorylated forms of the microtubule-associated protein 
tau (Gotz et al., 2004). Tau is a substrate of PP2A, and frontotemporal dementia mutant tau 
shows reduced binding to PP2A (Goedert et al., 2000; Sontag et al., 1999). In AD brains, PP2A 
activity was decreased by 30% compared with controls (Gong et al., 1995), and in the 
hippocampus of AD patients, of five subunits analyzed, Cα, B/PR55γ, and B’/PR61ε mRNA levels 
were decreased (Vogelsberg-Ragaglia et al., 2001). In addition, reduced amounts of ABαC were 
found in AD cortex, and PP2A activity was correlated with neurofibrillary tangle load (Sontag et 
al., 2004). Since hyperphosphorylated tau shows a reduced affinity to microtubules and thereby 
alters their stability, abnormally phosphorylated tau may affect neuronal viability, intracellular 
transport and cell adhesion (Gotz et al., 2004). 
As the L199P mutation is in the catalytic core of Cα, it abolishes the catalytic activity, possibly 
without affecting holoenzyme assembly (Evans et al., 1999) (but see: (Ogris et al., 1999; Yu et 
al., 2001)). 
I expressed the Cα mutant L309A under the neuronal promoter Thy1.2 with strong expression in 
brain, but also the Harderian (lacrimal) gland of transgenic mice. I found an altered recruitment 
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of regulatory subunits into the PP2A complex, demonstrating the importance of residue L309 in 
PP2A heterotrimer assembly in vivo. The PP2A substrate tau was abnormally phosphorylated in 
brain. In addition, incubation of vimentin with brain extracts demonstrated a role for distinct 
PP2A heterotrimers in vimentin dephosphorylation. Moreover, L309A expression in the 
Harderian gland caused a delayed and degenerative development of the gland. I provide 
evidence that cadherin/β-catenin-mediated cell adhesion requires a normal PP2A heterotrimer 
composition.  
 
8.4.1 Expression of the dominant negative mutant form of PP2A Cα, 
L309A, in brain and Harderian gland 
 
An expression vector with the neuron-specific elements of the mThy1.2 promoter was used to 
express the human PP2A Cα mutant L309A in mice, which can not be carboxymethylated 
anymore. Although the expression of transgenes under this promoter is mainly restricted to 
postmitotic neurons, expression has also been reported in immature neuroblast layers of the 
CNS, and in several organs and tissues outside the nervous system (Campsall et al., 2002). To 
facilitate detection of the mutant protein, a haemagglutinin (HA) epitope was fused to the 
amino-terminus (Evans et al., 1999; Kins et al., 2001). Seven founders transmitted the 
transgene in a Mendelian fashion, of which three expressed the transgene at high levels (data 
not shown). Line Dom5/III was chosen for further analysis as expression was strong in the 
hippocampus and cortex, formations which are degenerating in AD, but also in the thalamus and 
the Purkinje cells of the cerebellum (Figure 14A-F). Moreover, Cα L309A was expressed in the 
Harderian gland, the major portion of the lacrimal system.  
The transgenic mice showed a normal fertility. Gross examination did not reveal any behavioral 
or neurological impairment, nor was there any evidence for neurodegeneration. Motor functions 
were unaffected as tested on the rotarod with mice at different ages (data not shown). To 
determine the expression pattern of the transgene, an HA-specific antibody was used on 
Western blots. Cα L309A was expressed in brain and Harderian gland (Figure 14G). No 
expression was found in lung, liver, heart, spleen and skeletal muscle of transgenic mice or in 
any tissue of WT littermate controls (Figure 14G). Western blot analysis of brain extracts with 
antibodies directed against epitopes conserved between human and murine PP2A C revealed 
that total levels of C were not increased upon expression of the mutant protein (data not 
shown). This finding is consistent with previous observations in mice (Gotz et al., 1998; Kins et 
al., 2001), and with tissue culture experiments, which demonstrated that protein levels of C are 
subject to an effective autoregulatory mechanism keeping total levels constant (Baharians and 
Schonthal, 1998; Wera et al., 1995). 
Staining of L309A brain sections with an HA-specific antibody revealed cytosolic expression in 
neurons within most brain areas. These included cortical layers III-VI (Figure 14A), the CA1 and 
CA3 fields of the hippocampal formation (Figure 14C,E), the thalamus, and the Purkinje cells of 
the cerebellum (data not shown), whereas no staining was detected in WT brain (Figure 
14B,D,F).  
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Together, our data show that the transgene is expressed in brain areas affected by tau 
pathology and neurodegeneration in AD. 
 
 
 
 
 
 
 
 
 
Figure 14:  
Expression pattern of Cα L309A in transgenic mice. 
Immunohistochemical staining of L309A brain sections 
using an HA-specific antibody reveals neuronal expression 
within most brain areas. Strong expression is found in 
cortical layers III-VI (A), and the CA1 (C) and CA3 (E) 
fields of the hippocampal formation. No staining is 
detected in corresponding brain areas of WT mice (B,D,F). 
Scale bar: 100 µm. (G) Western blotting of tissue 
homogenates using an HA-specific antibody shows that 
the transgene is strongly expressed in the brain but also 
in the Harderian gland of L309A mice (TG). The zygomatic 
(cheek) muscle was included because of its proximity to 
the gland and brain. Expression is not detectable in 
skeletal muscle, lung, liver, heart, and spleen. Similarly, 
no expression is found in brain and gland of WT controls. 
An antibody directed against PP2A C (endogenous and 
mutant) reveals that total levels of C are not increased 
upon expression of Cα L309A. 
 
 
8.4.2 Altered recruitment of PP2A regulatory subunits into the PP2A 
complex in L309A mice 
 
Based on in vitro findings that residue L309 regulates the recruitment of regulatory subunits 
into the PP2A complex, I assessed the heterotrimer composition in L309A mutant brain and 
Harderian gland. PP2A regulatory subunits were quantified by Western blotting using crude 
brain homogenates. This serves as an indirect measure for the recruitment of regulatory 
subunits into the PP2A complex, where they are more stable than in the monomeric unbound 
form. In L309A mice, our study revealed an altered recruitment of regulatory subunits into the 
complex (Figure 15A). In brain, PR55α and PR61ε were reduced to 49% (n=8 transgenics (TG), 
10 WT) and 48% (n=3 TG, 5 WT) (Figure 15B). Relative levels of A and C were unaffected in 
L309A mice, based on normalization with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
hence, levels of regulatory subunits were normalized to A (Figure 15B). In the Harderian gland 
PR55α was reduced to 46% (5 glands pooled) and PR61ε to 38% (2 x 5 glands pooled), whereas 
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PR61γ and PR59 were increased 2.5- and 3-fold, respectively, compared to WT (2 x 5 glands 
pooled) (Figure 15C). For comparison, B subunit levels were not altered in tissues other than 
brain and Harderian gland. Even extracts derived from the zygomatic muscle adjacent to the 
Harderian gland did not reveal altered levels of B subunits (Figure 15A). Additional regulatory 
subunits have not been examined, as for most of them specific antibodies are not available. 
Together, our data demonstrate that leucine 309 of Cα controls PP2A regulatory subunit 
composition in vivo and that regulatory subunits are stabilized upon recruitment into the PP2A 
heterotrimer complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: 
Altered levels of distinct regulatory 
subunits in L309A mice. (A) Immuno-
blotting and subsequent quantification of 
density values. In total brain extracts of L309A 
(TG) versus WT mice, PR55α and PR61ε are 
reduced to 49% (8 TG, 10 WT) and 48% (3 
TG, 5 WT), respectively, together with a non-
significant increase in levels of PR61γ and 
PR59 (B, and data not shown). Relative levels 
of subunits C and A are unaffected in L309A 
mice, based on comparison with GAPDH, and 
therefore, levels of regulatory subunits were 
normalized to A (B). Mean values and 
standard errors are shown. In total extracts of 
the Harderian gland (C), PR55α is reduced to 
46% (5 glands pooled) and PR61ε to 38% (2 x 
5 glands), and PR61γ and PR59 levels are 
increased 2.5- and 3-fold, respectively, when 
compared with WT controls for which levels 
were set to 100% (2 x 5 glands). The relative 
abundance of regulatory subunits is a measure 
of the degree of recruitment into the PP2A 
complex, as momomers are stabilized when 
bound to the core dimer. 
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8.4.3 Increased phosphorylation of the PP2A substrates tau and 
vimentin 
 
Altered PP2A subunit composition was expected to affect substrate specificity in vivo. Therefore, 
I stained L309A and WT brain sections with the phosphorylation-dependent anti-tau antibodies 
S199P, CP13, AT100, AT180, 12E8, AD2, and pS422, directed against tau phosphorylated at 
S199, S202/T205, T212/S214, T231/S235, S262/S356, S396/S404, and S422, respectively 
(Buee-Scherrer et al., 1996; Bussiere et al., 1999; Delacourte et al., 1998; Goedert et al., 
1994; Hoffmann et al., 1997; Saito et al., 1995; Sergeant et al., 1999; Seubert et al., 1995). 
These epitopes were previously used to assess tau phosphorylation in human WT and 
frontotemporal dementia mutant tau transgenic mice (Gotz et al., 2001; Gotz et al., 2001; Gotz 
et al., 1995; Probst et al., 2000). Antibody CP13 revealed phosphorylated tau in L309A mice 
throughout the brain, but predominantly in cerebellar Purkinje cells, and in axonal and 
somatodendritic compartments of cortical and thalamic neurons (Figure 16A,C,E). Other 
epitopes of tau were not phosphorylated at detectable levels. No phospho-tau immunoreactivity 
was detected in non-transgenic controls (Figure 16B,D,F). 
 
 
 
Figure 16:  
Tau phosphorylation in the brain of 
L309A mice. The CP13 antibody 
directed against tau phosphorylated at 
Ser-202/Thr-205 reveals immuno-
reactive tau throughout the brain of 
L309A transgenic mice. Staining is 
prevalent in axonal and somatodendritic 
compartments of cerebellar Purkinje 
cells (A), and neurons of the frontal 
cortex (B) and thalamus (C). 
Corresponding areas of non-transgenic 
controls are not stained (D-F). Scale 
bar: 20 µm. 
 
 
As the cytoskeletal protein vimentin is an in vitro substrate of B/PR55 containing PP2A 
heterotrimers (Turowski et al., 1999), recombinant vimentin was pre-labeled with protein kinase 
A and [γ-32P]-ATP, and subsequently dephosphorylated with L309A and WT brain extracts. I 
found that both extracts dephosphorylated vimentin within minutes, however, 
dephosphorylation of vimentin was more pronounced with WT than with L309A homogenates 
(Figure 17). Dephosphorylation by WT could be partially inhibited with 30 nM OA, a potent PP2A 
inhibitor, providing evidence for a PP2A-mediated dephosphorylation of vimentin (Figure 17).  
Finally, to assess overall PP2A activity, I analyzed total brain and hippocampal extracts using a 
commercial assay with the small artificial phosphopeptide RRA(pT)VA as substrate. I found that 
general PP2A activity was not decreased in L309A mice (data not shown). 
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Together, our data indicate that vimentin is a substrate of PP2A, and that, as shown for tau, 
distinct PP2A regulatory subunits regulate vimentin dephosphorylation. 
 
 
Figure 17: Increased vimentin 
dephosphorylation with L309A brain 
homogenates. 
Recombinant vimentin was pre-labeled with [γ-32P]-
ATP by protein kinase A, followed by 
dephosphorylation with brain extracts. 
Dephosphorylation of vimentin is more pronounced 
with WT than with L309A (TG) brain homogenates. 
This can be inhibited with 30 nM OA. The extent of 
vimentin phosphorylation is indicated by relative 
signal density values which are normalized to the 
corresponding samples at time 0 (= 100%). Shown 
are mean values and standard errors (n=3 x 3). 
 
 
 
8.4.4 Slit-eye phenotype in L309A mice caused by delayed and 
impaired development of the Harderian and lacrimal gland 
 
The L309A mice demonstrated a 100% penetrant slit-eye phenotype reminiscent of 
enophthalmos in man, which became evident at two weeks of age (Figure 18). This phenotype 
might be caused by small eyes (microphthalmia) due to impaired development or atrophy, by 
changes of the retroocular structures including lacrimal glands, fatty tissue and muscles, or by 
defects of the bony orbit itself. Microphthalmia and defects of the bony structures could be 
excluded as a possible cause implying that altered retroocular structures caused the depression 
of the eyeball within the orbit (enophthalmos). 
 
 
 
 
 
 
 
 
Figure 18:  
Slit-eye phenotype of L309A transgenic mice.  
In WT mice two weeks postnatally, the eyes bulge and 
appear large and wide open (B,D), whereas in L309A mice 
(A,C), delayed and impaired development of the Harderian 
and lacrimal glands causes the eyes to sink deeply into the 
orbits (enophthalmos).  
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Sagittal sections through the eyes of two and eleven month-old L309A mice revealed a normal 
structure of the anterior uvea with an intact iris, stroma and pigment epithelium. There was 
evidence for a slight age-related atrophy of the ciliary body and age-related degeneration of the 
outer retinal layer (Figure 19). The lens, retinal organization, photoreceptors and Bruch’s 
membrane appeared normal, except for a few old transgenic mice, where cataract was 
observed. On the contrary, haematoxylin/eosin (HE) stainings of decalcified and paraffin 
embedded mouse heads showed marked changes in the transgenic Harderian and lacrimal 
gland, implying that altered retroocular structures caused the enophthalmos. 
 
 
Figure 19: Morphology in L309A mutant eyes. Sagittal sections through the eyes of two and eleven month-old L309A 
(A) and WT (B) mice revealed a normal structure of the anterior uvea with an intact iris, stroma and pigment epithelium. 
There was evidence for a slight age-related atrophy of the ciliary body and age-related degeneration of the outer retinal 
layer; however the lens, retinal organization, photoreceptors and Bruch’s membrane appeared normal, except for a few old 
transgenic mice, where cataract was observed. Original magnification x 400. (in collaboration with Dr. Ch. Remé) 
 
The Harderian gland was first described in 1694 by the Swiss physician Johann Jacob Harder 
(1656-1711). It occurs in most terrestrial vertebrates and is located within the orbit where, in 
some species, especially ungulates and rodents, it is the largest structure. Humans only possess 
a rudimentary one. The Harderian gland is a large tubular alveolar tissue located within the 
orbit, on the posterior aspect of the eyeball. It indents the extraorbital lacrimal gland, which is 
comparably small and located in the anterior orbit. The tubules of the gland are formed of a 
single layer of columnar epithelial cells surrounded by myoepithelial cells (Payne, 1994). The 
chief product(s) of the gland varies between different groups of vertebrates, and epithelial cells 
possess granules or vacuoles whose contents may be mucous, serous or lipid. In rodents, the 
gland synthesises lipids, porphyrins and indoles. In the case of lipid vacuoles, the gland is 
unusual in releasing these by an exocytotic mechanism. It is unclear whether the gland can act 
both as an exocrine and endocrine organ. There is control of gland structure and synthesis 
through a variety of humoral agents, including gonadal, thyroid and pituitary hormones; in 
addition there is a rich autonomic innervation and many neuropeptides have been identified. 
The proposed functions of the gland are remarkably diverse. The lipids are thought to lubricate 
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the eye and the nictitating membrane (Buzzell, 1996). Secretions coat the eye, and drain down 
into the nose. Moreover, the Harderian gland has been proposed to play a role in 
osmoregulation, the immune response, photoprotection and retinal-pineal axis establishment 
and include the gland being a source of thermoregulatory lipids and growth factors. (Payne, 
1994). However, despite more than three centuries of investigation, many features of this 
gland, including its development and function, are not yet well established (Buzzell, 1996).  
Several transgenic approaches have been applied either to gain insight into Harderian gland 
function or they happened to cause a Harderian phenotype, due to choice of promoter and 
transgene. Expression of oncogenes such as v-ras caused proliferative alterations ranging from 
hyperplasia to wide tissue destruction (Sinn et al., 1987; White et al., 1990). In the most 
advanced situations, these changes were accompanied by a glandular hypertrophy (Coto-
Montes et al., 1997). These and related studies demonstrated that the Harderian gland is 
susceptible to hyperplasia and tumor formation, without providing insight into organogenesis 
and function. In int-3 transgenic mice incomplete differentiation and the presence of 
proliferating immature ductule cells were reported demonstrating that expression of the 
activated Notch-related int-3 gene causes deregulation of normal developmental controls in vivo 
(Jhappan et al., 1992). To address functional aspects, prolactin transgenic mice were compared 
with prolactin knockout mice. It was found that prolactin is required for porphyrin secretion by 
the Harderian gland but that it is not playing an essential role in the secretory immune function 
of the lacrimal gland (McClellan et al., 2001). Furthermore, FGF-10, a member of the fibroblast 
growth factor family, was shown to be required for both lacrimal and Harderian gland formation 
(Govindarajan et al., 2000).  
 
Figure 20: 
Delayed and impaired development of 
L309A Harderian and lacrimal glands. At 
postnatal day 3 (P3), a Harderian gland (A, 
asterisk) can not be detected on 
haematoxylin/eosin-stained frontal L309A 
sections. In contrast, on WT sections acini of 
the developing gland are visible in the posterior 
aspect of the eyeball (B, arrows). At P10, 
sagittal sections present a tiny gland in L309A 
(C) compared to WT mice (D). While in WT 
mice, the gland spans more than the total of 
the posterior aspect of the eyeball (D, 
arrowheads), this extension is much shorter in 
L309A mice (C, arrowheads). Insets show the 
gland at higher magnification. At P18, in L309A 
mice, most portions of the posterior aspect of 
the eyeball are devoid of glandular tissue (E, 
indicated by an asterisk). An age-matched WT 
mouse displays a lacrimal system with both the 
Harderian (arrow) and lacrimal gland 
(arrowhead) (F). Scale bar: A,B,E,F (0.10 
mm); C,D (0.25 mm); insets (46 µm).  
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While in WT mice the gland starts to develop perinatally, its development was delayed in L309A 
mice, as shown for postnatal day 3 (P3) (Figure 20A,B). WT mice start to develop an intact 
gland around birth, with secretory tubules and alveoli that grow considerably as the mice 
become older. The mThy1.2 promoter used for transgene expression is turned on at around 
embryonic day E16, shortly before the gland becomes visible in WT mice, and reaches maximal 
levels at P28 (Kollias et al., 1987; Luthi et al., 1997). At P10, the L309A Harderian gland was 
tiny compared to WT (Figure 20C,D). While the two Harderian glands grew rapidly in WT mice at 
P12, causing the eyes to bulge, the transgene-induced destruction of the Harderian gland in the 
L309A mice became visible upon external inspection as it caused the eyes to sink deeply into 
the orbits (Figure 18). A vast deterioration of the Harderian gland was evident in all L309A mice 
at P18, leaving extra space in the orbit (Figure 20E,F). Yet, cell types and the general glandular 
organization of the tissue were not affected. When 11- to 15-month-old L309A mice were 
examined, the Harderian gland was almost completely missing, with the average weight of the 
lacrimal system being reduced from 180 mg to less than a fourth (data not shown).  
Nevertheless, when 1, 3, 10 and 18 days old L309A and WT mice were analyzed with a TUNEL 
(terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling) assay, similar 
numbers of apoptotic cells were found (Figure 21). This indicates that Harderian and lacrimal 
glands are not subject to degeneration but rather to an impaired development. 
 
 
 
Figure 21: Tiny Harderian and lacrimal glands are not due to apoptosis. Sagittal sections from 10-days-old L309A 
(A) and WT (B) mice stained with TUNEL (terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-dUTP nick-
end labeling) demonstrated that the tiny glands found in L309A mice are not due to atrophy through apoptosis and 
degeneration, but rather the result of an aberrant development. Scale bar: 0.2 mm. (in collaboration with Dr. L. Ittner) 
 
 
To determine whether defective innervation may have contributed to small Harderian glands in 
L309A mice, sections from 18 days old glands were stained with the neuron-specific antibodies 
NSE and PGP9.5. These revealed comparable numbers of nerve fibers with similar diameters in 
both WT and L309A glands (Figure 22). 
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Figure 22: 
Intact innervation of the L309A Harderian gland. 
Parasagittal sections from 18-days-old L309A (A,C) 
and WT (B) mice, stained with the neuron-specific 
antibodies NSE (A,B) and PGP9.5 (C) reveal 
comparable numbers of nerve fibers with similar 
diameters in the Harderian glands at all ages analyzed. 
As a control, the primary antibody was omitted (D). 
Scale bar: A,B (28 µm); C,D (20 µm). 
 
 
Together, these data show that the carboxy-terminal leucine L309 of the catalytic subunit of 
PP2A determines PP2A heterotrimer composition in vivo. Moreover, our findings indicate that 
PP2A plays a crucial role in regulating cell adhesion in vivo, as demonstrated for the Harderian 
gland, where L309A expression causes a delayed and impaired postnatal development resulting 
in enophthalmos. Our findings imply that PP2A executes similar functions in other glandular 
tissues. 
 
 
8.4.5 Function of L309A mutant eyes 
 
To test whether enophthalmos in L309A mice altered eye function, Ganzfeld electroretinography 
(ERG) analyses of 10 month-old L309A mice (n=4) and WT littermate controls (n=4) was 
performed in collaboration with Dr. M. Seeliger and coworkers. This revealed normal retinal 
function in L309A mice lacking a proper Harderian gland (Figure 23). Moreover, scanning laser 
ophthalmoscopy after contrast dye injection showed normal blood flow in the eye although a 
pulsation of larger veins occurred in L309A mice (Figure 24). This venous pulsations in all L309A 
transgenic mice that underwent SLO imaging (n=4) may indicate altered hemodynamic 
characteristics due to the different eye position in the orbit. 
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Figure 23: Electrophysiological evaluation of L309A transgenic mice aged 10 months. Left: Scotopic (dark 
adapted) intensity series. Center: Photopic (light adapted) intensity series. Right: Dark-adapted and light-adapted b-wave 
amplitudes as a function of the logarithm of the flash intensity. In both graphs, data from the transgenic mice are given as 
box-and-whisker-plots showing 5% and 95% quantiles (whiskers), 25% and 75% quartiles (box), and the median (marked 
by a cross). The black lines delimit the range given by the 5 and 95 % quantile of the wt controls. (in collaboration with Dr. 
M. Seeliger and coworkers) 
 
Figure 24: Scanning laser ophthalmoscopy (SLO). In vivo imaging of L309 transgenic mouse eyes (bottom row) in 
comparison to WT (top row). From left to right: Native imaging in infrared (IR, 830 nm), red-free (RF, 514 nm), and 
autofluorescence mode (AF, 488 nm & barrier at 500 nm). Angiography with indocyanine green (ICG, 795 nm & barrier at 
810), and fluorescein (FLA, 488 nm & barrier at 500 nm). There is no apparent difference between the transgenic and the 
WT mice. (in collaboration with Dr. M. Seeliger and coworkers) 
 
8.4.6 Defective cell adhesion in the L309A Harderian gland 
 
Our group has previously shown defective cell adhesion in PP2A Cα-/- embryos, with reduced 
levels of β-catenin and E-cadherin. Moreover, both proteins were translocated to the cytoplasm, 
suggesting a role for PP2A in stabilizing the β-catenin/E-cadherin complex at the plasma 
membrane (Gotz et al., 2000). When I addressed cell adhesion in the L309A mice, cadherins 
and β-catenin were not significantly affected in brain. However, while both proteins showed 
prominent membrane localization in WT Harderian glands, they were significantly reduced and 
more broadly distributed throughout the cytoplasm in the L309A gland (Figure 25 and 26).  
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Figure 25: 
 Cell adhesion in the L309A Harderian gland. 
Immunohistochemical staining of Harderian glands 
reveals altered cellular localization and reduced levels of 
cadherins (A-D) and β-catenin (E,F). Frontal sections of 
L309A mice (A,C,E) and corresponding WT sections 
(B,D,F) are shown at three magnifications. Both proteins 
show prominent membrane localization in the WT gland, 
but are significantly reduced and more broadly 
distributed throughout the cytosol in the mutant gland 
(inset in D shows control without a primary antibody). 
Scale bar: A,B (11 µm); C,D (14 µm); E,F (20 µm).  
 
 
I next performed a Western blot analysis of membrane and cytosolic fractions from brain and 
gland. To confirm the purity of the fractions, antibodies specific for GAPDH and the carboxy-
terminal fragment of the amyloid precursor protein, APP, were used. Cadherins and β-catenin 
were found almost exclusively in the membrane fraction of both L309A and WT brains (Figure 
26). In the WT Harderian gland, both cadherin and β-catenin were found in the cytosolic fraction 
with levels that were approximately three times lower than in the membrane fraction. In L309A 
glands, this ratio was preserved for cadherin, however, in both fractions levels were four times 
lower than in WT. In contrast, levels of β-catenin were reduced threefold in the cytosol of the 
L309A gland, but ninefold in the membrane fraction. Together this indicates a major reduction 
of membrane-associated β-catenin in the L309A gland, resulting in similar levels of β-catenin 
both in the cytosolic and the membrane fraction (Figure 26). β-actin, which is associated with 
the cadherin-β-catenin complex through α-catenin, was equally abundant in L309A and WT 
brains, but in contrast to GAPDH, hardly detectable in the cytosolic fraction of the L309A gland 
(Figure 26). Cα L309A was found at higher levels in the cytosolic than in the membrane fraction 
in brain and almost exclusively in the cytosolic fraction of the L309A gland (Figure 25). 
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Figure 26:  
Major reduction of membrane-associated 
β-catenin in the L309A (TG) gland.  
L309A glands show similar levels of β-catenin in 
both membrane (me) and cytosolic (cy) 
fractions, whereas in WT, β-catenin is three 
times more abundant in the membrane fraction. 
Levels of cadherins are reduced fourfold in both 
fractions in the L309A compared to the WT 
gland. β-Actin is hardly detectable in the 
cytosolic fraction of the L309A gland, while it is 
equally abundant in brains of L309A and WT 
mice. Cα L309A is found at higher levels in the 
membrane compared to the cytosolic brain 
fraction, but almost exclusively in the cytosolic 
fraction of the gland. Purity of the fractions was 
confirmed with GAPDH- and amyloid precursor 
protein-specific antibodies. 
 
 
For cadherin, adhesion has previously been shown to depend on casein kinase 2 (CK2) and 
glycogen synthase kinase-3β (GSK-3β) mediated phosphorylation (Lickert et al., 2000). Since 
there are activity-dependent antibodies available for GSK-3β, but not for CK2, I concentrated 
my analysis on GSK-3β, which is negatively regulated by phosphorylation at Ser-9 (Lau et al., 
1999). By immuno-blotting, an increased phosphorylation at Ser-9 of GSK-3β was found in the 
L309A gland, but not in brain or zygomatic (cheek) muscle (Figure 27). As total levels of GSK-
3β were reduced in the L309A gland compared to WT, but not in brain or the zygomatic muscle, 
relative levels of Ser-9 phosphorylated GSK-3β in the L309A gland are even higher. 
 
 
Figure 27: In the TG gland GSK-3β is phosphorylated at Ser-9, which negatively regulates kinase activity. Total 
levels of GSK-3α and GSK-3β are reduced in the L309A gland, whereas phosphorylation at Ser-9 is increased.  
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9 DISCUSSION 
 
9.1 Modest learning deficits in L199P transgenic mice 
 
Transgenic mice expressing the dominant negative L199P mutation in the catalytic subunit Cα of 
PP2A have revealed a 30% reduction of PP2A activity in brain homogenates, together with 
abnormally phosphorylated endogenous tau that was partly relocated to the somatodendritic 
compartment. These mice were the first transgenic mouse model showing that PP2A is an in 
vivo phosphatase of tau (Kins et al., 2001). 
In two different Morris water maze tests, the “standard” and a more sophisticated protocol, 
L199P mutant mice showed similar performance as WT littermates in regard to escape latency 
and the number of trials to criterion. In contrast, in two independent probe trials, one after the 
acquisition phase and one after the reversal phase (new platform position), L199P mice spent 
significantly less time in the target quadrant. I speculate that transgenic mice confounded the 
task of learning a new platform position with the search for the old position, an effect that could 
have caused the bad performance by L199P mice on day 2 of the reversal phase. The more 
sophisticated second relearning test revealed that transgenic L199P mice navigate less 
precisely. The observed effects were statistically significant but small and were only captured by 
path geometry directly and did not translate into a general escape performance. Since this 
second test was especially focusing on the relearning, I conclude that the navigation problem 
does not appear to be linked specifically to the continuous relearning situation. Transgenic mice 
adapted normally to the test, thigmotaxis was not increased, and the tendency to float was 
even smaller for L199P mice. Analysis of the same mice on a rotarod revealed no motor deficits 
in L199P mice. Nevertheless, the average swim speed was significantly increased in transgenics. 
There is no plausible explanation for this phenomenon except for the widely accepted fact that 
the overexpression of any transgene causes many transgenic mice to be hyperactive and 
therefore more active in open field and Y-Maze tests (Holcomb et al., 1999; Moechars et al., 
1999; Wong et al., 1997), which could also make them swim faster in a water maze test. 
Weight differences and size could be another explanation, although this would probably 
translate into the ability to maintain balance on the rotarod at accelerating rotation speeds, and 
such differences in performance have never been observed.  
Although the behavioral tests using the Morris water maze revealed only modest learning 
deficits for the L199P mice, these were found several times for different parameters. It is 
expected that learning deficits would be more pronounced if the PP2A activity in the brain of 
transgenic mice would be further reduced. This could be achieved by overexpressing the 
dominant negative mutant form of PP2A/Cα, L199P, by breading our mice to homozygosity. 
Another approach would be to reduce levels of endogenous PP2A/Cα to increase the dominant 
negative effect by crossing the L199P mice to the heterozygous Cα knock-out mice. Also 
interbreeding with AD-transgenic models including tau filament-forming mice, and by a 
complete knock-out of the brain specific regulatory subunit of PP2A, PR55γ would possibly cause 
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an increased behavioral phenotype. Finally PP2A activity could be further reduced by using PP2A 
inhibitors such as OA. This has been done in chicken and rat in the course of our study. Deficits 
in memory retention were found in chicken treated with calyculin (CA) or OA (Bennett et al., 
2001), and unilateral injection of OA into rat hippocampus induced a transient impairment of 
spatial memory on an eight-arm radial maze task in rats (He et al., 2001). Recently, another 
group showed tau hyperphosphorylation and impairment of spatial memory retention after 
bilateral injection of CA into rat hippocampus (Sun et al., 2003). However, by using OA and in 
particular CA instead of transgenic approaches, these studies do not reveal whether the 
behavioral findings are due to PP2A inhibition alone and/or to PP1 inhibition. As discussed in 
section 9.3 (page 69), OA is only specific for PP2A within a specific concentration range, and CA 
is inhibiting both, PP2A and PP1. Our approach, which for obvious reasons is 100% PP2A 
specific, revealed an effect of PP2A. Yet, it remains to be established whether the association of 
tau hyperphosphorylation and spatial memory loss is a causal one. Spatial learning and memory 
need regulated protein phosphorylation executed by a specific set of enzymes. It is well 
accepted that spatial learning and memory is hippocampus-dependent, and single cells in the 
hippocampus can encode specific spatial information. However, how each phosphatase functions 
and the exact mechanism of behavioral abnormalities caused by PP inhibition are barely 
understood. 
 
 
9.2 B/PR55 levels in undifferentiated and neuronally 
differentiated cells 
 
Steady-state mRNA levels of the four B/PR55 regulatory PP2A subunits were determined by 
qRT-PCR in both HEK-293 and SH-SY5Y cells. I found comparable mRNA levels of the four 
members of the PR55 family in both HEK-293 and undifferentiated SH-SY5Y cells. PR55α was 
the major species in both cell-types, and amounts of PR55γ mRNA were slightly lower than 
those of PR55δ. PR55β concentrations were very low in SH-SY5Y cells and barely detectable in 
HEK-293 cells. This suggests that the PR55β subunit, despite its low relative levels compared to 
the other three subunits, may perform a distinct function in cells that are capable of neuronal 
differentiation. The finding that PR55γ was transcribed by non-neuronal HEK-293 cells as well, 
whereas in adult tissue it is restricted to brain, may be related to the relative ease with which 
HEK-293 cells can acquire neuronal properties upon transfection with genes encoding channel 
subunits and the like (Abraha et al., 2000). 
When SH-SY5Y cells were differentiated, mRNA levels of PR55β, γ and δ subunit mRNA increased 
significantly. On the contrary, the amount of PR55α mRNA did not change during differentiation.  
Our data show that PR55α is likely to perform more general functions in the cell, which are not 
associated with neuronal functions. In contrast, PR55β seems to be specifically induced during 
neuronal differentiation. Increased PR55β levels may both be caused by transition from an 
impure population composed of S- and N-type cells to a pure neuroblastic N-type population 
(transition of SH-SY5Y cells to N-R-type cells), and by an increased arborization during the 
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transition from N-R-type to N-R/B-type SH-SY5Y cells. Consistent with my findings, we have 
preliminary data of an impaired differentiation and a reduced viability in a partial knock-down 
cell line expressing a siRNA construct targeting PR55β (Dr. K. Schmidt, unpublished data). 
Our data, together with the fact that PP2A plays an active role in neurite outgrowth and the 
maintenance of neurites (see section 8.3), point at specific roles for distinct regulatory B 
subunits in neuron-like cells. 
To gain further insight into PR55 subunit function, short interfering RNA (siRNA)-mediated 
approaches may be envisaged to down-regulate individual PR55 subunits. However, this 
approach may be complicated by the fact that the four subunits are highly homologous 
(Schmidt et al., 2002). In addition, HEK-293 and SH-SY5Y cells are dividing at a pace that 
causes the immediate dilution of an in vitro produced and transfected siRNA construct. Also, 
down-regulation of one PR55 subunit may cause the compensatory upregulation of other 
members of the PR55 family or regulatory subunits belonging to other regulatory subunit 
families. This notion is supported by our finding in L309A mutant PP2A Cα transgenic mice 
demonstrating that recruitment of distinct regulatory subunits into the PP2A holoenzyme 
complex occurs at the expense of other subunits (Schild et al., submitted).  
 
 
9.3 Transgenic mice expressing PP2A Cα, L309A 
 
In WT mice, protein PP2A core dimers, composed of the catalytic subunit C and the structural 
subunit A, exhibit a low activity and only acquire full activity when the heterotrimer is 
assembled. The mutation L199P lies within the catalytic core of Cα and our mice therefore 
represent a transgenic mouse model in which the catalytic activity of PP2A is reduced without 
affecting holoenzyme assembly. To study PP2A heterotrimer composition in a transgenic mouse 
model, the dominant negative carboxy-terminal mutation L309A of Cα was expressed, which 
eliminates or reduces the binding of distinct regulatory subunits of PP2A. In the present study I 
showed firstly a role for L309 in regulating PP2A subunit composition in vivo, secondly a 
function for PP2A in tau and vimentin phosphorylation in brain, and thirdly a role for PP2A in cell 
adhesion in the Harderian gland. 
This was achieved by expressing the PP2A Cα mutant L309A using an expression vector with the 
neuron-specific elements of the mThy1.2 promoter. Expression of transgenes using this 
promoter is mainly limited to postmitotic neurons. Nevertheless, in immature neuroblast layers 
of the CNS, and in several organs and tissues outside the nervous system, expression under the 
mThy1.2 promoter has also been reported (Campsall et al., 2002). The mouse line chosen for 
further analysis showed a strong expression in formations affected by AD, namely hippocampus 
and cortex, but also in other brain areas and in the Harderian gland, the major portion of the 
lacrimal system. 
That total levels of C were not increased in the brain upon expression of the mutant protein was 
shown with the antibody PP2A/C and the antiserum 45, both directed against epitopes 
conserved between human and murine C. This result is consistent with tissue culture 
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experiments demonstrating that protein levels of C are subject to an effective autoregulatory 
mechanism keeping total levels constant (Baharians and Schonthal, 1998; Wera et al., 1995), 
and has also been observed in mutant L199P transgenic and heterozygous Cα knock-out mice 
(Gotz et al., 1998; Kins et al., 2001). 
In vitro data suggest that L309A can alter the binding capacity of individual regulatory subunits 
to the PP2A dimer. Therefore, I assessed the PP2A heterotrimer composition in L309A mutant 
brain and Harderian gland by Western blotting using crude brain homogenates. PP2A 
heterotrimers were also purified by immunoprecipitation using A-specific antibodies, and in 
addition, microcystin sepharose affinity chromatography was used to enrich for protein 
phosphatases (Kloeker and Wadzinski, 1999; Meek et al., 1999). Enrichment for heterotrimers 
by immunoprecipitation revealed the same altered levels of regulatory subunits as for crude 
extracts and after MC purification (data not shown). This outcome indicates that regulatory 
subunits, which are not recruited by the AC core dimer, are degraded more rapidly and are 
therefore less abundant in vivo. This result is consistent with a model proposed earlier in which 
in Drosophila Schneider cells, not only was the AC core dimer unstable when not associated with 
regulatory subunits, but more importantly, knocking out A destabilized B and C, and knocking 
out C destabilized A and B (Li et al., 2002; Silverstein et al., 2002). The notion that the various 
regulatory subunits may be produced in abundance and compete for binding to the core dimer is 
supported by our finding that PR55α and PR61ε were decreased, whereas in the same tissue 
PR61γ and PR59 were increased. Additional regulatory subunits have not been examined, as for 
most of them specific antibodies are not available. Interestingly, of five PP2A subunits analyzed, 
PR61ε mRNA levels have been reported to be reduced in AD brain (Vogelsberg-Ragaglia et al., 
2001).  
 
In L309A mice, tau is abnormally phosphorylated at S202/T205, a typical AD phospho-epitope. 
Other epitopes of tau were not phosphorylated at detectable levels, which could either indicate 
specificity of regulatory subunits for S202/T205 or limitations in the detection method. Even 
though hyperphosphorylation of tau was found in brain, there was no sign of 
neurodegeneration, consistent with findings in WT and mutant tau transgenic mice with an even 
more pronounced hyperphosphorylation of tau (Goedert et al., 1995). 
The cytoskeletal protein vimentin has been shown to be an in vitro substrate of B/PR55 
containing PP2A heterotrimers (Turowski et al., 1999). I found that dephosphorylation of 
vimentin was more pronounced with WT than with L309A brain homogenates in an in vitro 
assay, and dephosphorylation by WT homogenates could be partially inhibited with 30 nM OA. 
Our data indicate that vimentin is a substrate of PP2A, and that distinct PP2A regulatory 
subunits regulate vimentin dephosphorylation, as shown for tau.  
A previous study with fibroblasts suggested that vimentin phosphorylation caused by high (1-2 
µM) but not low (10 nM) concentrations of OA was due to inhibition of protein phosphatase 1 
(PP1), and not PP2A (Eriksson et al., 1992). However, in vivo or in tissue culture, OA has to be 
100-fold more concentrated to cross the membrane at a rate comparable to other PP inhibitors 
such as calyculin A (Favre et al., 1997), whereas in cell extracts, OA inhibits PP2A at about 100-
fold lower concentrations than those effective for PP1 (Cohen et al., 1989). Moreover, various 
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factors such as pH and temperature have an effect on membrane penetration (Namboodiripad 
and Jennings, 1996). Taking this into account, I conclude that with the OA concentrations used 
in my assay I can be sure to have inhibited mainly PP2A and can therefore state that vimentin is 
a substrate of PP2A in vivo. This finding is further supported by immunoprecipitation studies 
demonstrating an association of vimentin with B/PR55 (Turowski et al., 1999). In addition, it 
was shown in vitro that phosphorylation of vimentin was stimulated by PP2A inhibition in a 
dose-dependent manner, using 35-methyl-OA (Yatsunami et al., 1991).  
General PP2A-specific phosphatase activity, as determined with a small artificial phosphopeptide 
as a substrate, was not decreased in L309A brain. This may indicate that elevated levels of 
regulatory subunits other than PR55α and PR61ε were able to counterbalance the L309A-
mediated reduction in PP2A activity. This outcome is in agreement with findings in S. cerevisiae, 
where PP2A activity remained stable after removal or substitution of the carboxy-terminal 
leucine (Evans and Hemmings, 2000). To gain further insight, phosphopeptides would be 
needed that are selectively dephosphorylated by specific PP2A heterotrimers. 
 
In addition to an abnormal dephosphorylation of cytoskeletal proteins in brain, I observed a slit-
eye phenotype in L309A mice that was not caused by motor deficits or eye irritations but was 
rather the consequence of enophthalmos as a result of marked changes in the Harderian gland. 
I showed that PP2A is required for the integrity of the Harderian gland. Specifically I 
demonstrated that L309 of PP2A Cα plays a crucial role in regulating PP2A subunit composition 
and thereby controls cell adhesion in the Harderian gland. 
Our findings were obtained by organ-specific expression of the PP2A Cα mutant L309A. 
Expression of transgenes using the mThy1.2 promoter is mainly but not exclusively confined to 
postmitotic neurons. It has also been reported in immature neuroblast layers of the CNS and in 
several organs and tissues outside the nervous system (Campsall et al., 2002). 
The transgenic gland displayed a delayed and aberrant development. In 11- to 15-month-old 
L309A mice, the Harderian gland was almost completely absent. Nevertheless, the remaining 
glandular structure was intact, with no sign of alterations in cell types. Also, when transgenic 
glandular tissue was pooled, sufficient material was available to perform biochemical 
experiments. Reduced tear production due to a defective lacrimal system may be a reason for 
an opaque cornea occasionally observed in L309A mice. Degeneration of the Harderian gland in 
our L309A mice strikingly resembles that caused by prenatal exposure to 2,4-dichlorophenyl-p-
nitrophenyl ether (nitrofen; NIT) (Gray et al., 1982), where a role of PP2A has been suggested 
(Arufe et al., 1999; Lazzereschi et al., 1997).  
To investigate the nature of PP2A dysfunction responsible for the Harderian gland phenotype, I 
determined the PP2A subunit composition in the gland in more detail. Based on in vitro findings 
that L309A can alter the binding capacity of individual regulatory subunits to the PP2A dimer, I 
assessed the PP2A heterotrimer composition in L309A mutant gland by Western blotting using 
crude protein homogenates. This approach was based on the assumption that regulatory 
subunits, which are not recruited by the AC core dimer are degraded more rapidly and are 
therefore less abundant in vivo, a model proposed earlier in Drosophila Schneider cells (Li et al., 
2002; Silverstein et al., 2002). The notion that the various regulatory subunits may be 
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produced in abundance and compete for binding to the core dimer is supported by our finding 
that PR55α and PR61ε were decreased, whereas in the same tissue PR61γ and PR59 were 
increased. 
Impaired development of the lacrimal system is unlikely caused by defective or reduced 
parasympathetic innervation, as the neuron-specific antibodies NSE and PGP9.5 revealed 
comparable numbers of nerve fibers with similar diameters in both WT and L309A glands.  
The finding that cells in the Harderian gland degenerated whereas those in brain did not, can 
not be explained by relative expression levels of the transgene. Rather, there may be a greater 
redundancy of phosphatases in brain as illustrated by the observation in humans that half of all 
genes were expressed in the brain with many being preferentially expressed in brain compared 
to peripheral tissues (Colantuoni et al., 2000; Consortium, 2004; Sandberg et al., 2000). In 
addition, glandular cells form a tight united cell structure, with cadherin and β-catenin playing 
crucial roles in stabilizing cell-cell contacts, whereas neurons are more loosely organized and 
form contacts via synapses. 
 
Inhibition of PP2A with OA in vitro not only causes demethylation of leucine 309, but 
interestingly also induces hyperphosphorylation of β-catenin and loss of cell-cell contact in 
human epidermal cells (Favre et al., 1997; Serres et al., 2000; Serres et al., 1997). Our group 
has previously shown defective cell adhesion in PP2A Cα-/- embryos (Gotz et al., 2000). There, 
cellular levels of β-catenin and E-cadherin were reduced, and both proteins were translocated to 
the cytoplasm, suggesting a role for PP2A in stabilizing the E-cadherin/β-catenin complex at the 
plasma membrane in blastocysts (Gotz et al., 2000). In the L309A mouse model, reduced 
membrane levels of cadherins and β-catenin may, in part, also be due to altered 
phosphorylation. However, this is difficult to assess as no phosphosite-specific antibodies are 
available for those serine and threonine residues that regulate cell adhesion (Lickert et al., 
2000). For cadherin, adhesion was shown to depend on casein kinase 2 (CK2) and GSK-3β 
mediated phosphorylation (Lickert et al., 2000). Treatment of keratinocytes with OA caused a 
decrease in cadherin phosphorylation, with a shift from the membrane to the cytoplasm and 
preventing cells from forming aggregates (Serres et al., 2000). In L309A Harderian gland, the 
altered localization of cadherin could be due to a reduced phosphorylation by GSK-3β, which is 
negatively regulated by phosphorylation at Ser-9 (Lau et al., 1999). An increased 
phosphorylation was found at this epitope in the L309A gland. Increased Ser-9 phosphorylation 
was not found in L309A brain, suggesting a more sophisticated control mechanism for activities 
of kinases and phosphatases. Also, I did not observe altered β-actin levels in brain, while β-actin 
was reduced to hardly detectable levels in the cytosolic fraction of the Harderian gland. β-actin 
may be destabilized due to an impaired interaction with the cadherin-β-catenin complex through 
α-catenin.  
 
Together, our data show firstly that the carboxy-terminal leucine L309 of the catalytic subunit of 
PP2A determines PP2A heterotrimer composition in vivo. Secondly, I have demonstrated that 
this affects substrate specificity as shown for tau and vimentin. Thirdly, our findings indicate 
that PP2A in general and its heterotrimer composition in particular play a crucial role in cell 
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adhesion in vivo, as demonstrated for the Harderian gland where PP2A stabilizes β-catenin and 
cadherin in the plasma membrane. Reduced recruitment of specific regulatory subunits into the 
PP2A complex was shown to be associated with increased recruitment of other subunits. 
Establishing a role for distinct regulatory subunits, however, awaits further studies. Also, 
because of the observed interference of subunit assembly, B subunit-specific knock-out strains 
may not necessarily assist in this elucidation. 
 
 
9.3.1 PP2A deficits in the thalamus of L309A mice may prevent the 
development of the Harderian gland through thyroid hormones 
 
The metabolic maintenance and functions of Harderian and submandibular glands are regulated 
by hormones (Hoffman, 1971; Kumegawa et al., 1977). The Harderian gland is a large, orbital, 
lacrimal-type gland. Although it has been found to produce lubrication, pheromones, and 
immunoglobulins, its physiological role is not clear (Hoffman, 1971). The observation that 
L309A transgenic mice were significantly smaller in body mass (Figure 18), together with the 
undersized Harderian gland, causes us to speculate that the PP2A composition in brain could 
play a role in the production of thyroid hormones. The weight difference though does not 
translate into body size measured from the nose to the anus (data not shown), indicating that 
L309A mice have no altered level of growth hormones but rather of thyroid hormones, which 
have an impact on metabolic pathways. Also, mediated by altered thyroid hormone levels, PP2A 
could indirectly affect the development of the Harderian gland. In addition PP2A deficits in the 
thalamus as revealed by hyperphosphorylated tau in thalamic neurons of L309A mice (Figure 
16E) could have effects on the brain-pituary-thyroid axis. This hypothesis states that the effects 
mediated through the L309A mutation are not directly linked to the Harderian gland through 
expression in the gland itself (Figure 14), but rather through a pathway involving the thalamus, 
the pineal gland, the thyroid gland and finally thyroid hormone and thyroxine levels (see Figure 
29). 
 
 
 
Figure 28: Body weight or L309A mice compared to WT littermates. Male (left) and female (right) mice show an age 
dependent increase in body weight. This increase is much less pronounced in L309A male mice. In both transgenic males 
and females, there is a significant overall reduction in body weight for mice older than 9 months. Body weight or mass is 
not to be confounded with body size which remains equal for both groups (data not shown). 
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The thyroid gland, which is located in the lower part of the neck, produces and releases two 
hormones, tetraiodothyronine (thyroxine, T4) and triiodothyronine (T3) (LoPresti and Singer, 
1997). The gland has two lobes containing follicles filled with a colloid known as thyroglobulin in 
which the thyroid hormones are stored. The thyroid gland is predominantly a T4-producing 
organ. Only about 20% of T3 is synthesized and released from the thyroid; the remainder is 
produced by peripheral conversion of T4 into T3 by enzymes called deiondinase in the liver and 
kidney (LoPresti and Singer, 1997; Reed and Pangaro, 1995). Thyroid hormone production is 
regulated by serum T4 and T3 levels, as well as through the hypothalamic–pituitary axis. The 
hypothalamus stimulates the release of thyrotropin-releasing hormone (TRH). TRH stimulates 
the pituitary gland to release thyroid-stimulating hormone (thyrotropin, TSH) which, in turn, 
stimulates the thyroid to increase hormone synthesis. A rise in the thyroid hormone level 
inhibits the release of TRH and TSH by a negative feedback mechanism. 
 
 
 
 
 
 
Figure 29: Schematic representation of the brain–
pituitary–thyroid axis. TRH neurons in the paraventricular 
nucleus project their neuroterminals to the external zone of 
the median eminence. This occurs bilaterally, although only a 
unilateral projection is shown. TRH travels through the portal 
vasculature to cause the synthesis and release of TSH from 
thyrotropes. This molecule acts at the thyroid gland to cause 
the biosynthesis and release of the thyroid hormones, T3 and 
T4. These are released into the general circulation to affect 
metabolism and feedback in a negative manner at the 
thyrotropes of the pituitary and the TRH neurons of the PVN. 
PVN, paraventricular nucleus; TRH, thyrotropin-releasing 
hormone; ME, median eminence; iii, third ventricle; TSH, 
thyroid-stimulating hormone; T3, triiodothyronine; T4, 
thyroxine. 
 
 
Chemical destruction of the Harderian gland can be achieved in mice by prenatal exposure to 
the herbicide 2,4-dichlorophenyl-p-nitrophenyl ether (nitrofen; NIT), a human carcinogen no 
longer manufactured or sold (Gray et al., 1982). The effects on experimental mice by NIT are 
striking in regard to resemblance to our L309A mice (Gray et al., 1982). Studies on the toxicity 
of NIT suggest an altered thyroid function (Ambrose et al., 1971), and lowered serum thyroxine 
levels (Gray and Kavlock, 1983). Earlier reports have revealed that growth of the Harderian 
glands is correlated with an increase in thyroxine secretion (Dohler et al., 1979), that thyroxine 
accelerates the development of the gland (Wetterberg et al., 1970), and regression of the 
Harderian gland was reported in thyroidectomized adult rats (Boas and Scow, 1954). In addition 
it has been shown that PP2A plays an important role in thyroid cell growth and in the 
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thyrotropin pathway (Lazzereschi et al., 1997), and observations on sheep thyroid cells indicate 
that PP2A and PP1 could be important mediators of thyroid hormone production (Arufe et al., 
1999).  
With this evidence bringing together PP2A and the Harderian gland, I propose that an altered 
PP2A composition in L309A mice may cause a deterioration of the Harderian glands by lowering 
thyroxine levels during development and/or throughout life. 
Interestingly, the most striking feature of Graves disease, a human diseases involving excessive 
thyroid hormone (hyperthyroidism), is ophthalmopathy, with the eye changes including 
abnormal protrusion of the eyeballs from the orbits (Burman, 1995; Ladenson, 1996; O'Donnell 
and Spaulding, 1997; Streetman and Khanderia, 2003). This exopthalmia (bulging eyes) 
involving 1 or both eyes is the result of a local accumulation of hydrophilic mucopolysaccharides 
leading to edema. This in turn is caused by abnormal antibodies that attach to TSH receptor 
sites on the thyroid gland and cause long-term activation of it. In severe cases, exophthalmia 
can damage the optic nerve (Burch and Wartofsky, 1993; Streetman and Khanderia, 2003; 
Weetman, 1992; Weetman, 2003). In a patient with high rates of T3, T4 and TSH, physical 
examination showed bilateral and symmetrical exophtalmia, together with lid lag, increased 
thyroid volume with irregular surface and hardened consistence (Werneck et al., 2003). The 
Harderian gland as a direct cause for exopthalmia has been described after tumor formation in 
mice, where the bulging of the eyes was due to Halderian gland hyperplasia (Radany et al., 
1997; Sinn et al., 1987). 
Exopthalmia is exactly the opposite of what I observe in the L309A mice, namely enophthalmos. 
Therefore, as expected, L309A mice did not show any hyperthyroidism, which can be quite 
easily diagnosed by physical examination. In hyperthyroidism, the thyroid gland is enlarged, 
soft, and without nodules. This was leaving us with the more probable version of thyroid 
hormone insufficiency (hypothyroidism). In humans, hypothyroidism can cause severe problems 
such as sleep apnea, hypothermia, hypoventilation, neuropsychiatric syndromes, peripheral 
neuropathy, cerebellar ataxia, and coma. A test series of blood sera to answer the question of 
whether L309A mice have altered T3, T4, TSH, and TRH levels is currently being analyzed. 
 
 
9.4 Targeting of PP2A PR55/B isoforms 
 
In a collaboration with K. Schmidt and B. Hemmings from the Friedrich Miescher institute (FMI) 
in Basel, our aim was to produce knock-out mice by targeting the PP2A PR55/B isoforms α, β, 
and γ. The targeting constructs for γ, as outlined in Figure 30, was cloned by A.S. at the Division 
of Psychiatry Research, Zurich, while the constructs for α and β were produced at the FMI in 
Basel. The two constructs, α and γ were transformed into embryonic stem (ES) cells at the 
Institute for lab animal research in Zurich, while the targeting of β and as a repetition also α 
took place at the FMI. For all isoforms, control constructs with an enlarged short arm were 
designed and cloned in a way that the PCR to control for positive targeting could be optimized in 
advance by electroporating the control construct into ES cells. More than 1000 neomycine 
resistance positive ES cell clones were picked per isoform, lysed and analyzed by PCR. For many 
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clones, additional restriction enzyme digests and subsequent Southern blots were performed 
and analyzed. However, only unspecific integration events and some false positives, but no 
targeting by homologous recombination, were detected for all three constructs. This is 
particularly striking, since the constructs were designed to target different exon-intron regions 
and were in part performed at different institutes with diverging methods. How can three 
independent genes be impossible to target with the techniques applied. It seams as if the 
extremely high homology of PR55 isoforms in the range of 90% (see page 45, (Schmidt et al., 
2002)) makes these target sequences to behave in the same way. Since they belong to different 
chromosomes and chromosomal regions, it must be the sequence itself rather than the region 
that makes them inaccessible. The sequence might for example cause the DNA to be particularly 
packed and therefore not accessible for recombination enzymes. Another possibility is that the 
high number of PR55 pseudogenes throughout the genome increases the risk for a random 
recombination. Therefore the number of false positive neomycin resistant clones may have been 
too high to find the needle, namely the homologous recombinant, in the haystack. 
 
 
 
 
 
Figure 30:  
Targeting strategies for the 
three PR55/B isoforms α (A), β 
(B), γ (C). The dotted boxes with 
numbers represent the 
corresponding exons. Important 
restriction enzyme sites are 
indicated and the final targeting 
plasmids are noted, namely pBS, 
pMCS5, and pCR-XL-TOPO. Inserts 
contained the Neomycin resistance 
gene (NEO). IRES; internal 
ribosome entry site to enhance 
translation. lacZ; lacZ reporter gene 
encoding ß-galactosidase. TK; 
thymidine kinase promoter. 
 
 
 
Knockout approaches in general can have three potential outcomes, either (1) an embryonic or 
postnatal lethal phenotype (as has been shown for the PP2A Cα knockout (Gotz et al., 1998)), 
(2) no detectable phenotype due to compensatory mechanisms, or (3) a obvious but not life-
threatening phenotype that may be either expected from known functions of the targeted gene 
or may not be expected at all. Lethality can be overcome by more sophisticated gene targeting 
approaches using either tissue-specific or inducible promoters. Redundancies, on the other 
hand, can be overcome by creating multiple knockouts, or by analyzing the mice even more 
carefully to detect subtle phenotypic alterations. 
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9.5 Conclusion and Perspectives 
 
The dominant negative mutant approach that makes use of Cα mutants is based on the 
screening of yeast mutants (Evans and Hemmings, 2000; Evans et al., 1999). In general, it is 
difficult to predict whether a particular dominant negative mutant phenotype in yeast may also 
be achieved in multiple-tissue organisms, such as mice. Additionally, in the presence of the 
endogenous catalytic subunit, PP2A inhibition is never 100%. This difficulty could be 
circumvented by crossing onto a null background, if the homozygous Cα mutants were viable. 
Nonetheless, analysis of Cα dominant negative mutant mice provided significant insight into the 
role of PP2A in the pathogenesis of tau (Kins et al., 2001) and in the regulation of ERK and JNK 
kinases (Kins et al., 2003). To complement these results, I have shown that a reduced PP2A 
activity in the mouse brain causes modest learning deficits in Morris water maze tasks. In 
addition our data reveal that the carboxy-terminal leucine L309 of the catalytic subunit of PP2A 
determines heterotrimer composition in vivo. This affects substrate specificity as shown for tau 
and vimentin. I have also shown that PP2A in general and its heterotrimer composition in 
particular play a crucial role in development and cell adhesion. Increased recruitment of specific 
regulatory subunits into the PP2A complex was shown to be associated with decreased 
recruitment of others; however, establishing a role for distinct regulatory subunits awaits 
further studies. Also, because of the observed interference of subunit assembly, B subunit-
specific knockout strains may not necessarily assist in this elucidation. 
Overexpression of regulatory PP2A subunits on the other hand may be complicated by the fact 
that total levels of PP2A are tightly regulated (Baharians and Schonthal, 1998; Wera et al., 
1995). As this imposes a limitation to the number of regulatory subunits that can be recruited 
into the functional PP2A holoenzyme complex, this, in essence, implies that overexpression of 
one (transgenic) subunit titrates additional, endogenous regulatory subunits. Therefore, the 
observed phenotype may not be due to an overexpression of a distinct regulatory subunit, but 
may rather be caused by a lower concentration of holoenzymes containing the other 
endogenous subunits. This requires a careful monitoring of the many regulatory subunits, a task 
that is not easy, as it is likely that not all PP2A regulatory subunits have been identified as yet, 
and because specific antibodies are not available for all of them. Nonetheless, transgenic 
overexpression of PP2A regulatory subunits provides a rapid, first insight into tissue-specific 
functions of PP2A. 
 
9.5.1 Relevance for the pathology of AD and FTD 
 
With the two PP2A transgenic mouse lines, L199P and P309A, we could demonstrate that point 
mutations in important functional sites of the catalytic subunit are sufficient to cause abnormal 
phosphorylation of the PP2A substrate tau in the brain. As in L199P mice, PP2A deficits also 
caused discrepancies in learning and memory, whereas these did not seem to be related to tau 
pathology but rather to regulatory mechanisms of PP2A on long term depression that need to be 
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further investigated in electrophysiological studies. Considering the putative role of PP2A in the 
pathogenesis of human diseases, the development of transgenic models of PP2A may provide 
insight into the regulation of PP2A accelerating pathogenesis. A more detailed understanding of 
how regulatory subunits of PP2A are recruited into the core dimer shall help us to discover 
means to control the activity of PP2A in tauopathies like AD and FTD. However, it is unlikey that 
unspecific inhibitors of PP2A like OA, or activators that need yet to be discovered, would be of 
any value in the treatment of these diseases. Understanding the regulatory mechanisms of PP2A 
is therefore crucial in controlling PP2A in a way that specific subunits and consequently 
substrates will be affected without disturbing the general activity of PP2A. Our P309A mice 
provide evidence in vivo that methylation at the well conserved carboxy-terminus of the 
catalytic subunit is important for binding regulatory subunits to the PP2A core dimer. The 
dominant negative mutant PP2AC in these mice demonstrated that PP2A activity towards 
particular substrates, as shown for tau and vimentin, can be regulated without changing its 
general activity, as revealed in a non specific phosphatase assay. Since this meets the 
requirements of a potentially successful therapy for tauopathies, our mouse model may 
eventually lead to the discovery of therapeutic agents that can specifically counteract PP2A 
dysfunction. Considering the laborious task of producing and analyzing transgenic and knockout 
mice, future research in this field should take advantage of recent advents in RNA interference 
techniques. These approaches for efficient down-regulation of transcription is likely to help in 
the transgene design, and in the prediction of the expected phenotyp. 
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10 METHODS 
 
10.1 DNA and bacteria work: Engineering, mutagenesis, 
cloning, extraction, purification, and analysis 
 
10.1.1 Culturing and storage of Escherichia coli (E. coli) 
 
E. coli were grown in Luria Bertani (LB) medium. After transformation, bacteria were plated on LB agar 
plates (LB medium containing 15 g/l Bacto agar) supplemented with the appropriate antibiotics for the 
selection of successfully transformed clones. For long-term storage of transformed E. coli, 200 µl of sterile 
glycerol (100%) were added to 800 µl of o/n bacterial cultures and were kept at -80°C. 
•  LB medium: 10 g/l Bacto tryptone, 5 g/l Bacto yeast extract, 10 g/l NaCl, pH 7.0. 
10.1.2 Preparation and transformation of competent E. coli 
10.1.2.1 Chemically competent E. coli 
 
Chemically competent cells were used for the transformation with large plasmids. To be able to transform 
E. coli, they have to go through a state of competence during which DNA can enter the cells. Such 
competence is achieved by treating E. coli with Ca2+, which destabilizes the cell membrane. The addition of 
DNA to the competent cells then leads to the formation of DNA/Ca2+ complexes, and subsequent heating of 
the cell/DNA suspension causes the DNA to enter the cells.  
To produce competent cells, cultures of DH5α or XL-10 cells grown in LB-medium o/n at 37°C were diluted 
to an OD600 of 0.01. The bacteria were then incubated until they reached an OD600 of 0.4. Cells were pelleted 
by centrifugation at 4,000 g at 4°C for 15 min, resuspended in 10 ml of a 0.1 M CaCl2 solution and kept on 
ice for 1 h. Cells were collected by centrifugation at 4,000 g at 4°C, resuspended in 0.1 M CaCl2, 0.02 M 
MgCl2, 15% (v/v) glycerol. Aliquots of competent cells were immediately frozen in liquid nitrogen and stored 
at -80°C. 
To transform chemically competent cells, diluted circular plasmid DNA or an aliquot of a ligation reaction 
were added to 50 µl E. coli, which have been thawed on ice. This mixture was incubated on ice for 30 min, 
followed by a heat shock at 42°C for 45 s. Cells were chilled on ice for 2 min to be rescued. After addition of 
900 µl LB-medium, prewarmed to 42°C, cells were incubated on a shaker at 225 rpm and 37°C for 1 h. 
Transformed bacteria were plated onto agarose plates containing the appropriate antibiotic for selection and 
were incubated at 37°C. The transformation of ligated and digested pSuper vectors (see 10.1.19) gave rise 
to 300-450 colonies compared to 40 colonies on negative control plates. 
10.1.2.2 Electro-competent E. coli 
 
To prepare electro-competent E. coli, cells were extensively washed with distilled water to remove ions from 
the solution and thereby weakening cell membranes by osmotic stress: An o/n-culture of DH5α cells was 
diluted 1:100 in fresh medium and incubated until an OD600 of 0.5 was reached. The culture was chilled on 
ice for 15 min and harvested by centrifugation at 4,000 g for 15 min at 4°C. The pellet was resuspended in 
ice-cold water and the suspension was centrifuged at 4,000 g for 15 min at 4°C. This step was repeated 
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once. The cells were then resuspended in 10% (v/v) cold glycerol, centrifuged as above and again 
resuspended in glycerol, the cell concentration being about 1-3 x 1010 cells/ml. Aliquots of electro-
competent cells were snap-frozen in liquid nitrogen and stored at -80°C. 
For the transformation, electro-competent cells were exposed to an electric field that temporarily 
destabilizes regions of the cell membrane. In that way small pores are formed through which DNA can enter 
the bacteria. 50 µl of electro-competent cells were gently thawed on ice and mixed with the plasmid solution 
(≤100 ng DNA in H2O or 1-2 µl ligation mixture) and transferred to a chilled electroporation cuvette 
(0.1 mm). Cells were electroporated in the Gene pulser machine at 25 µF, 1.8 kV and pulse controller at 
200 Ω. This produced an electric pulse with a time constant of 4 to 5 msec and field strength of 12.5 kV/cm. 
Immediately 500 µl LB-medium were added to the cells and they were incubated on a shaker at 225 rpm 
and 37°C for 30 min. E.coli were then plated on agarose plates containing the appropriate antibiotics for the 
selection of transformed cells. 
10.1.3 Preparation of plasmid DNA 
 
To extract plasmids from E. coli, Qiagen or Sigma plasmid purification protocols were used. The principle of 
these kits is based on selective alkaline denaturation, alkaline lysis of the cells in combination with the 
anionic detergent SDS (Birnboim and Doly, 1979): Cell walls are cracked, and proteins as well as high 
molecular weight genomic DNA are denatured. In contrast, covalently closed circular DNA remains double-
stranded, stays in solution and can be recovered from the supernatant by binding to an anion-exchange 
resin.  
Plasmid DNA was isolated from small scale (1-2 ml), intermediate scale (20-50 ml) and large scale (250 ml) 
bacterial cultures following the manufacturer’s protocols. To determine the yield of a plasmid DNA 
preparation, the optical density (OD) was measured at 260 nm. Pure DNA shows a ratio of the absorbtion at 
260 nm (A260; protein) to the absorbtion at 280 nm (A280; DNA, RNA) of 1.8 to 2.0, the absrobtion at 310 nm 
being approximately zero. 
10.1.4 Phenol-chloroform extraction of DNA 
 
A mixture of phenol:chloroform:isoamylalcohol (25:24:1) is used to remove proteins from nucleic acid 
solutions. The DNA is recovered from the aqueous phase by precipitation while denatured proteins stay in 
the organic phase and interphase. 
The desired amount of DNA was diluted to 200-300 µl in water, and an equal volume of 
phenol:chloroform:isoamylalcohol (25:24:1) was added. The combination was mixed well on a vortex, and 
after centrifugation at 20,000 g for 5 min, the aqueous phase containing the DNA was transferred to a fresh 
tube. This procedure could be repeated to increase the purity of the DNA preparation. Finally, the DNA in 
the aqueous phase was precipitated and concentrated using one of the following methods. 
10.1.5 Precipitation of DNA by ethanol or isopropanol 
 
To isolate DNA from solution it can be precipitated with ethanol under high-salt condition. The addition of 
ethanol depletes the hydration shell of the negative charged phosphate groups in the backbone of the DNA. 
Positively charged ions bind to these groups so that a precipitate can form. 
DNA was precipitated from solution by adding 1/10 volume of 3 M NaAc (pH 5.2) and 2.5 volumes of cold 
100% ethanol, incubation at -20°C for 30 min and centrifugation at 20,000 g for 20 min at 4°C. After two 
washes with cold 70% ethanol, the DNA pellet was dried for 5-10 min at RT and resuspended in 10 mM Tris 
(pH 8.0) or water. 
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Precipitation of DNA by isopropanol follows the same principle as precipitation by ethanol, nevertheless 
there are two major differences in the outcome, namely small DNA fragments are not well precipitated but 
the precipitated DNA is cleaner. 
DNA was precipitated from solution by adding 1/10 volume of 3 M NaAc (pH 5.2) and 0.7 volumes of 100 % 
Isopropanol and centrifugation at 20,000 g for 20 min at RT. The DNA pellet was dried for 5-10 min at RT 
and resuspended in 10 mM Tris (pH 8.0) or water. 
10.1.6 Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction is a fast method to amplify DNA-sequences of interest (Mullis, 1986). To 
produce multiple copies of DNA, two specific primers are used that are complementary to one of the two 
strands and define the sequence to be amplified. 
The DNA is denatured at 95°C to separates the two strands. A subsequent decrease in temperature allows 
the two primers to anneal to their complementary sequences on the template DNA. The optimal annealing 
temperature for a primer pair is in the range of its melting temperature. In a next step, the heat stable DNA 
polymerase catalyzes the replication of the DNA at 72°C (elongation temperature). By repeating this 
temperature cycle, the DNA sequence of interest is amplified in an exponential manner. 
1 ng of plasmid DNA or 5 ng cDNA were used as a template for the PCR. For the reaction on a Perkin Elmer 
9700 PCR machine, 10 pmol forward primer, 10 pmol reverse primer, 10 mM dNTPs, 2.5 mM MgCl2 and 1 U 
of polymerase were used. The reaction was started by denaturing the DNA and activating the DNA 
polymerase for 5-10 min at 95°C followed by 25-40 cycles; Denaturation for 30 sec to 1 min, annealing of 
primers at 50-65°C for 45 sec to 1.5 min, and elongation at 72°C for 1 to 3 min. The repeated cycles were 
followed by a final elongation step at 72°C for 7 min. The conditions used depended much on the 
polymerase, the melting temperature of the primers and the sequence to be amplified. When PCR fragments 
were used for cloning, a polymerase with proofreading activity was used (eg. Expand High Fidelity PCR 
System, Roche). More frequently however, AmpliTaq Gold DNA poymerase (Applied Biosystems) and 
RedTaq genomic DNA polymerase (Sigma) were used. 
10.1.7 Site-directed mutagenesis 
 
Site-directed mutagenesis allows us to create point mutations, to switch amino acids, and to delete or insert 
single or multiple amino acids without the need of subcloning.  To produce mutations of 1 to 3 amino acids, 
mismatch primers were used to amplify both plasmid strands.  
The L309A amino acid substitution in PP2A Cα was introduced into the cDNA using the QuickChange site-
directed mutagenesis kit (Stratagene) following the manufacturer's protocol. The primers sequences were as 
follows: sense: 5’-GTCGTACCCCAGACTACTTCGCGTAAGGATCCGGTACCG-3’; antisense: 5’-CGGTACCGGATCC 
TTACGCGAAGTAGTCTGGGGTACGAC-3’. The construct was sequenced to confirm the absence of randomly 
introduced mutations (see 10.1.20).  
10.1.8 Colony PCR 
 
Colony PCR is a method that allows the screening of a large number of transformed E. coli clones for 
positives directly off the plate, instead of having to isolate plasmids from small scale cultures of these cells. 
DNA polymerase, dNTPs, primers, MgCl2 and buffer were mixed in a reaction tube as described in the 
section PCR above. For colony PCR, RedTaq genomic DNA polymerase (Sigma) and 35 cycles were used. 
The two primers added to the reaction were specific for the transformed plasmid. Colonies were picked with 
a sterile pipette tip and dipped into the reaction mixture. To break the cell walls and release plasmid DNA, 
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the mixture was boiled at 95°C for 5 min prior to the PCR. PCR products were analyzed on an agarose gel to 
determine which clone contained the plasmid of interest. 
To grow positive clones in culture for the preparation of plasmid DNA, the corresponding pipette tip was 
incubated in LB-medium containing the appropriate antibiotic for selection on a shaker at 37°C o/n. 
10.1.9 Colony hybridization 
 
Colony hybridization was used for a rapid colony screening after the transfection of E. coli with ligation 
mixtures including empty vectors and therefore conferring antibiotic resistance to many negative clones. 
The procedure, in which bacteria are lysed and DNA is fixed to membranes, makes simply use of a 
microwave oven (Foster et al., 1997). 
A transfected ligation reaction was plated on two separate agar plates and colonies grown o/n. Turbo-lifts 
were prepared on pure nitrocellulose transfer membrane filters (0.45 µm, BioTrace). Filters were laid in 
contact with bacteria, keyed with three syringe pinholes, and removed to be placed colony side up on 
Whatman no. 1 filters soaked in 2 x SSC plus 5% SDS for about 2 min. The filters were placed in a 
microwave oven and treated on a rotating turntable for 2.5 min at full setting. Immediately after 
microwaving, the filters were prehybridized at 65°C with 3 x SSC 0.1% SDS, 10 x Denhardt's solution and 
250 µg/m1 denatured salmon sperm DNA for 30 min. The DNA probe with homology to the gene of interest 
was [α-32P]dCTP labeled with the Rediprime II Random Prime Labeling System (Amersham) and 
subsequently purified with the nucleotide removal kit (Quiagen). The [α-32P]dCTP labeled probe was then 
hybridized for about 4 h at 65°C in the prehybridization solution. Washes were at 65°C using 0.1 x SSC. 
0.1% SDS. Kodak Bio-Max films were exposed to the membrane for 1 to 3 days. The Bacterial colonies, 
which are diminished by the lifting onto the filters, were regrown by incubation at 37°C so that they were 
ready for picking when identified as positive. 
10.1.10 Cutting DNA with restriction endonucleases 
 
For DNA cloning tasks or for the analysis of plasmid or genomic DNA, restriction endonucleases of type II 
were used, which recognize and cut DNA at palindrome sequences. 
Cutting 0.2 - 1.0 µg DNA with restriction endonucleases were usually performed for 1 to 4 h with 1 U of 
restriction enzyme under buffer and temperature conditions as recommended by the manufacturers. If 
necessary double digests were performed sequentially, with purification steps in between. Cleavage 
efficiency was observed by agarose gel electrophoresis, with 200 ng of plasmid DNA for analytical purposes 
and 1 µg for preparative gels. 
10.1.11 Forming blunt ends by fill-in and removal of overhangs 
 
To ligate sticky DNA ends of different origin, blunt ends need to be formed before ligation can take place. 
Klenow fragment, a large fragment of DNA polymerase I that retains polymerization and 3'→ 5' exonuclease 
activity of the holoenzyme without degrading 5' termini, was used to fill–in 5' overhangs and remove 
3' overhangs to form blunt ends. 
The reaction to form blunt ends was performed for 15 min at RT in EcoPol buffer (New England Biolabs), 
supplemented with 1 mM DTT and 1 mM dNTPs (each) and 1 U of Klenow fragment per µg of DNA. 
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10.1.12 Hybridization of DNA oligonucleotides 
 
Introduction of short DNA sequences (tags) to gene sequences or additional restriction sites into plasmids 
can be achieved by one cloning step with cassette cloning. These cassettes are short double-stranded 
oligonucleotides sequences with sticky ends to be introduced into the target sequence.  
The DNA oligonucleotides were mixed in equi-molar concentrations in 10 mM Tris (pH 8.0) or water. After 
denaturation for 5 min at 95°C a slow temperature decrease allowed the hybridization of the 
complementary oligonucleotide strands. 
10.1.13 Purification of DNA fragments 
 
PCR products, oligonucleotides and fragments of any enzymatic DNA digestion were either purified by 
recovering the DNA from agarose gels (see 10.1.15) or by using the so called PCR purification kit (Qiagen or 
Sigma) following the manufacturer’s instructions. 
10.1.14 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to determine the size of DNA fragments or to isolate the fragment of 
interest from a DNA mixture. Because of the negatively charged phosphate groups in the backbone of 
nucleic acids, DNA and RNA migrate towards the positive anode when exposed to an electric field. The 
migration rate of DNA is proportional to the inverse log10 number of base pairs (Helling et al., 1974) and 
depends to some extent on the conformation of the DNA. DNA was visualized either by ethidium bromide 
(Sigma) or the more sensitive CYBR green I nucleic acid gel stain (Molecular Probes) for analysis under UV-
light, or by crystal violet (Sigma), which is visible in daylight and was preferred for isolating DNA fragments 
without harming them with UV-light (Dutt, 1980). The length of the observed DNA fragments can be 
determined by comparison with a DNA ladder as marker. Depending on the size range of linear DNA to be 
resolved, 0.4 to 2.0% (w/v) agarose was dissolved in 1x TAE buffer by heating: 
 
% agarose  DNA size range (bp) 
0.40    2000 – 30,000 
0.75    1000 – 15,000 
1.00    500 – 10,000 
1.25    300 – 5000 
1.50    200 – 4000 
2.00    100 – 2500 
 
When cooled down to 50°C, the gel was complemented with 1 µg/ml ethidium bromide. All samples were 
loaded with 1x DNA loading buffer. 
•  TAE (Tris-acetate) buffer: 40 mM Tris-acetate (pH 7.6), 1 mM Na2EDTA. 
•  DNA loading buffer 6x: 0.25% (w/v) bromphenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol.  
10.1.15 Recovery of DNA fragments from agarose gels 
 
After having resolved DNA fragments by electrophoresis the band containing the DNA of interest was cut out 
from the gel using a scalpel. Crystal violet was preferred over ethidium bromide to visualize DNA for the 
recovery; Bands are visible as they separate and can be cut out as soon as they are sufficiently resolved, 
and more importantly the DNA is not exposed to the damaging effects of UV light. Nevertheless if ethidium 
bromide had to be used because crystal violet was too week, the gel was cut on a table with UV-light at 
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302 nm. If sensitive enzymatic reactions followed the DNA recovery, TAE buffer with only 0.1 mM Na2EDTA 
was used to avoid interference of high EDTA concentrations with enzyme activity. Finally, to recover DNA 
from the agarose gel, the gel extraction kit by Qiagen was used according to manufacturer’s instructions.  
10.1.16 Dephosphorylation of plasmid DNA 
 
Digested plasmid DNA containing complementary cohesive ends or blunt ends tend to self-ligate producing 
empty vectors. In order to suppress such self-ligation and therefore decrease the vector background in 
cloning strategies, alkaline phosphatase, either shrimp (SAP, Roche) or calf intestinal (CIP, New England 
Biolabs), were used to remove terminal 5’ phosphate groups from DNA. 
For the hydrolysis of 5’-phosphate groups 1 µg DNA and 1-3 U of SAP or CIP were incubated at 37°C for 1 h 
in the appropriate buffer according to the manufacturers.  
Before ligation, vectors were purified with the GenElute PCR clean up kit (Sigma) and eluted in 50 µl H2O. 
10.1.17 Annealing of oligonucleotides 
 
Oligonucleotides of 64 bases used for the expression of siRNA constructs (Elbashir et al., 2001; Elbashir et 
al., 2001) (see section 11.2.4 p. 103) were annealed by mixing sense and antisense single stranded DNA, 
heating to 95°C and slowly cooling down to 4°C. In detail, 100 pmol of each oligonucleotide (sense and 
antisense) in 120 µl H2O were incubated at 95°C for 5 min, followed by 20 min at 70°C. The mixture was 
then cooled down to 4°C as slowly as possible in a water bath. 
10.1.18 Phosphorylation of DNA at 5’ ends 
 
Annealed oligonucleotides have to be phosphorylated at the 5' hydroxy termini to allow  subsequent ligation. 
40 pmol annealed oligonucleotides (49 µl) were incubated with 50 units of T4 polynucleotide kinase (5 µl) in 
1x T4 ligation buffer (containing ATP, New England Biolabs) at 37°C for 40 min. Enzymes were heat 
inactivated at 65°C for 20 min, then samples were put back on ice. Annealed phosphorylated oligos were at 
0.7 pmol/ul. 
10.1.19 Ligation of DNA fragments 
 
PCR products, double stranded oligonucleotides or other DNA fragments can be ligated to linearized plasmid 
DNA in an ATP consuming enzymatic process. The E. coli T4 DNA ligase catalyzes the ligation of two DNA 
strands at the 5’ phosphate and the 3’ hydroxy groups. 
Depending on the size of the vector and insert, the molar ratio between vector and insert was varied. In the 
case of the pSUPER-GFP vector, approximately 0.3 pmol (300 ng) were mixed with 3 pmol of inserts. This 
mixture was incubated with 400 units of T4 DNA ligase in 1 x T4 ligation buffer (New England Biolabs) at 
4°C overnight. 
In the case of pSUPER, the inserts were designed such that the restriction site BglII was destroyed upon 
correct ligation. This gave the option to digest the ligation mix with BglII to better select positive clones 
after the ligation. 
10.1.20 DNA sequencing 
 
To confirm DNA sequences after cloning or site-directed mutagenesis, constructs were sequenced using DNA 
cycle sequencing based on the chain-terminator method (dideoxy method) (Sanger et al., 1977). In this 
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technique, the DNA to be sequenced is incubated with the Klenow fragment of DNA polymerase I, a suitable 
primer, and a small amount of all four 2’,3’-dideoxynucleoside triphosphates (ddNTPs) labeled with different 
dyes together with an excess of unlabeled deoxynucleoside triphosphates (dNTPs) of the four bases. When 
the dideoxy analog is incorporated in the growing polynucleotide, chain growth is terminated because of the 
absence of a 3’-OH group. The products, a series of truncated chains, are electrophoretically separated in a 
capillary according to molecular weight and are detected by exciting the different dyes coupled to ddNTPs at 
the corresponding wavelengths with a laser.  
The Big Dye terminator v1.1 Cycle Sequencing kit provides buffer, nucleotides and the polymerase. 
1 µg plasmid DNA, 10 pmol primer and 4 µl reaction Ready Mix were mixed in a total reaction volume of 
10 µl. The DNA amplification reaction was carried out using the following parameters on the GeneAmp PCR 
System 9700 (Applied Biosystems): 25 cycles of 15 s at 96°C, 30 s at 96°C, 30 s at 50°C, and 4 min at 
60°C. The samples were then kept at 4°C, DNA was precipitated with ethanol and washed with 70% (v/v) 
ethanol. The DNA pellet was resuspended in 20 µl HPLC-grade water and was analyzed with the ABI Prism 
310 Genetic Analyzer and ABI Prism 7700 Sequence Detector (Applied Biosystems). Sequence readouts of 
200-400 bp by the Sequence detection software 1.9.1 (Applied Biosystems) were transformed to and 
computationally analyzed with the programs SeqMan II and MegAlign 4.00 (DNASTAR). 
10.1.21 Southern blotting of genomic DNA 
 
Southern blotting after restriction digestion of genomic DNA was used to screen ES-cells for the event of 
homologous recombination of the targeting knockout construct. 
10 µg of genomic DNA were digested by the appropriate restriction endonucleases for 12 h. The digest was 
separated on a 0.5% agarose gel using TAE or TBE buffers, whereas TBE gave less background. The gel was 
run slowly for 12 h. Transfer of DNA to a nitrocellulose membrane was as follows: a Hybond N+ membrane 
(Amersham Biosciences) was presoaked in 0.4 M NaOH and the transfer was performed in 0.4 M NaOH 
using capillary blot technique. After 12 h of transfer, the membrane was treated with 2x SSC, let dry and 
was crosslinked with UV-light. To label a DNA probe with [α-32P]dCTP, the Rediprime II Random Prime 
Labelling System (Amersham) and QIAGEN nucleotide removal kit were used. The membrane was 
prehybridized in hybridization buffer containing 0.5 M NaP (pH 7.2), 1% BSA, 0.25 mM EDTA, 15% 
deionized formamide, and 7% SDS for 1 h at 65°C in a roller tube and hybridized with the labeled probe for 
3 h at the same conditions. The membrane was washed with 2x SSC, 1% SDS for 30 min, then twice with 
0.2x SSC, 1% SDS for 15 min at 65°C. The α-32P-labeled and hybridized probes were then detected by a 
Phosphor-Imager screen and read with the STORM 860 Phosphor-Imager (Molecular Dynamics), or by X-ray 
films for several days at -80°C. 
 
 
 
10.2 RNA work: Extraction, purification, and analysis 
 
Since RNA is much more prone to degradation than DNA, special care had to be taken to avoid break down 
of RNA by RNases. All solutions were treated with Diethylpyrocarbonate (DEPC) and autoclaved or sterile 
filtered. The working area and pipettes were treated with RNase away (Catalys). 
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10.2.1 Total RNA extraction from eukaryotic cells 
10.2.1.1 Trizol method 
 
Total RNA was extracted from eukaryotic cells by using a technique described by Chomczynski 
(Chomczynski, 1993). A monophasic chaotropic lysis reagent is used to lyse eukaryotic cells. Addition of 
chloroform to the lysate generates an organic phase to which DNA and proteins are extracted, while RNA 
stays in the aqueous supernatant. The RNA is precipitated from the supernatant with isopropanol, 
resuspended in DEPC treated water and stored in aliquots at -80°C. 
Total RNA was extracted from eukaryotic cells by mechanical shearing in Trizol reagent (Invitrogen) directly 
on the culture dish, passing the lysate several times through a 26G needle. RNA was then purified from 
proteins and DNA by chloroform extraction and isopropanol precipitation. This procedure does not require 
any DNase treatment. 
10.2.1.2 RNeasy kit with optional DNase treatment 
 
The procedure of the RNeasy kit (Qiagen) for purest RNA longer than 200 nucleotides combines lysis of the 
cells with highly denaturing guanidine isothiocyanate buffer and a silica gel based membrane.  
A maximum of 10 x 106 mammalian cells were lysed in the denaturing RLT buffer (Qiagen). The lysate was 
then filtered through a QiaShredder for proper homogenization. After 1:1 dilution with 100% ethanol, the 
cell-homogenate was loaded onto a silica membrane. If necessary, any residual DNA could be degraded with 
a compatible RNase free DNAse kit (Qiagen) after the first washing step In general, the kits were used as 
described in the supplier’s protocols.  
RNA concentration was determined by measuring the absorbance at 260 nm in a capillary 
spectrophotometer (Eppendorf), where an absorbance of 1 unit at 260 nm corresponds to 40 µg RNA per 
ml. The purity of RNA can be estimated by dividing the absorbance at 260 nm through the one at 280 nm 
(A260/A280). Pure RNA has an A260/A280 ratio of 1.9 – 2.1 
10.2.2 Quality assessment of total RNA 
 
The purity, integrity and size distribution of total RNA can be checked by agarose gel electrophoresis (or the 
Agilent 2100 Bioanalyzer). The 18S and 28S ribosomal RNA from eukaryotic sources should appear as sharp 
bands whereas the 28S ribosomal RNA band should be approximately twice as intense as that of the 18S 
RNA band.  
2 µg total RNA were resuspended in RNA sample buffer, heated to 95°C for 5 min and chilled on ice, before 
it was loaded on a 1% agarose gel, together with 2 µl (0.5 µg) RNA 6000 ladder (Ambion), and run in TAE 
buffer at 20 V overnight. The gel was then put in an ethidium bromide bath for 30 min and washed well in 
H2O. The gel was examined on a UV transilluminator to visualize the RNA whereas 28S RNA corresponds to 
4.7 kb and 18S RNA to 1.9 kb. 
•  2x RNA sample buffer (NEB): 2x TBE (pH 8.3), 13% ficoll (w/v), 0.01% bromophenol blue and 7 M urea.  
10.2.3 Quantitative real-time PCR (qRT-PCR) 
 
The method of relative quantification of mRNA in quantitative real-time PCR (qRT-PCR) is based on direct 
monitoring of PCR products by measuring the increase in fluorescence caused by the binding of SYBR Green 
to double stranded (ds) cDNA. The template is the cDNA generated from a reverse transcription reaction. 
Total RNA from cells was isolated (section 10.2.1), RNA concentration was measured in a photometer and 
4 µg were used for reverse transcription. The cDNA was generated using the SuperScript First-Strand 
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Synthesis System for RT-PCR and random hexamers as primers (Invitrogen) following manufacturer’s 
instructions. Specific reverse transcription of mRNA was achieved by using oligo(dT) primers, which bind 
specifically to the poly(A) tails of eukaryotic mRNA. The cDNA was diluted 1:20 in H2O for the qRT-PCR. 
For the detection of mRNA during  qRT-PCR, the following gene specific HPLC-purified primers (Metabion) 
were designed to amplify 70-90 bp at the 5' end of the open reading frame (ORF) using the primer design 
software Primer Express 1.5 (Applied Biosystems): 
 
PR55α [forward: 5’-GTTCAGGAAGCGGAGACCC-3’, reverse: 5’-TCCAGCTCCTGCCATGTTG-3’],  
PR55β [forward: 5’-CCCGCAAAATCAA-CAACAGTT-3’ and 5’-GCAGCCTCGCAGAACCC-3’,  
 reverse: 5’-CCGTGTG-GTTGAATTCTACCG-3’ and 5’-CCATGGTCCGAGCCTGAG-3’],  
PR55γ [forward: 5’-GCTGACATCATCTCTACCGTTGAG-3’, reverse: 5’-GCCGCCCT-TGTCACCTG-3’],  
PR55δ [forward: 5’-GCTTCTCGCAGGTCAAGGG-3’ and 5’-GACGAGGACGTGGCCG-3’,  
  rev.: 5’-AAACTCAACGGTGGAAATGATGT-3’ and 5’-TGTTGCAAGAAGATCTCCAGAGTAA-3’]. 
 
The cDNA was amplified on an ABI Prism 7700 Sequence Detector System using SYBR Green PCR core 
reagents (Applied Biosystems). 
The amplification reaction in a total of 25 µl included the following: 
 
10 x SYBR Green PCR buffer 2.5   µl  1 x 
25 mM MgCl2 3.0   µl  3 mM 
dNTPs 2.5   µl  1.25 mM 
Amp.Erase 0.25 µl  0.25 U 
Ampli Taq Gold 0.15 µl   0.75 U 
primers, 5 µM each 4.0   µl  0.8 µM 
H2O 2.6   µl 
template DNA (1:20) 10    µl  approx. 0.8 ng/µl 
 
For signal detection, the ABI Prism 7700 Sequence Detector System was programmed with an initial 
sterilization step of 2 min at 50°C, followed by 10 min denaturation and polymerase activation at 95°C and 
40 temperature cycles for 15 s at 95°C and 1 min at 60°C. To normalize for fluorescence fluctuations, the 
passive reference dye ROX is used. 
The Sequence Detection Software 1.9.1 (Applied Biosystems) was used for the analysis of raw data and ∆Ct 
values (cycle threshold values) were determined using the standard curve method according to the 
manufacturer’s guidelines (Applied Biosystems). ∆Ct values of the mRNAs of interest were put in relation to 
∆Ct values of one or several of the following stable human reference genes as internal controls (Chen et al., 
2004; Hoerndli et al., 2004): 
GAPD  [forward: 5’-TGGGCTACACTGAGCACCAG-3’, reverse: 5’-CAGCGTCAAAGGTGGAGGAG-3’]  
POLR2F  [forward: 5’-CCCGAAAGATCCCCATCAT-3’, reverse: 5’-CACCCCCCAGTCTTCATAGC-3’]  
PGK  [forward: 5’-TGAAGGACTGTGTAGGCCCAG-3’, reverse: 5’-TTCTTCCTCCACATGAAAGCG-3’]  
 
P-values were calculated with the Mann-Whitney nonparametric test. The specificity of the PCR amplification 
was confirmed on an agarose gel. 
10.2.4 Short interfering RNA (siRNA) 
10.2.4.1 Stable expression of siRNA by pSUPER vector 
 
Post transcriptional gene silencing or RNA interference can be used in mammalian cells and even mice to 
study gene function (Elbashir et al., 2001) Long double-stranded RNA (dsRNA) is processed by a specific 
ribonuclease, called dicer, to a short dsRNA containing 3’ overhangs of 2 nucleotides and a 5’ phosphate 
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(Ketting et al., 2001). This short interfering RNA (siRNA) associates with the RNA-induced silencing complex 
(RISC) that guides siRNA to its corresponding target mRNA (Hammond et al., 2001). Once the siRNA is 
associated with its mRNA target, nucleases within RISC cleave and inactivate the mRNA (Tuschl et al., 
1999; Zamore et al., 2000). 
Apropriate target sequences for silencing were designed following the siRNA user guide (Oct. 2002) by 
Tuschl and coworkers (www.rockefeller.edu/labheads/tuschl/sirna) and recommendations by Ambion 
(www.ambion.com/techlib/tb/tb_506). 19 nucleotide target sequences, which should be flanked in the 
mRNA with AA at the 5’ and TT at the 3’ end were chosen 100 bp from start and termination of translation. 
To verify sequence specificity of a siRNA towards its target, a database search was performed at 
www.ncbi.nlm.nih.gov/BLAST. For the stable expression and production of siRNA in mammalian cells, DNA 
constructs were designed and cloned into the expression vector pSUPER (OligoEngine), such that a hairpin-
loop RNA is formed that can be processed into a functional siRNA. For that, two oligonucleotides were 
designed, which when annealed form a  HindIII and a mutated BglII site and contain the target sequence in 
sense and anti-sense orientation, separated by a 9 bp spacer (loop). Such oligonucleotides (Microsynth) 
were annealed and cloned into pSUPER, which has been modified to express GFP for positive selection. 
pSUPER was then stably transfected into HEK-293 and SH-SY5Y cells (see 10.4.2).  
10.2.4.2 In vitro generated siRNA for transient transfection 
 
For transient transfection of mammalian cells with siRNA constructs, 29-mer oligonucleotides were designed 
such that transcribing them in vitro gave rise to double-stranded functional siRNA. For the in vitro 
transcription, the Silencer siRNA construction kit (Ambion) was used and oligonucleotides were designed 
following the manufacturer’s instructions. siRNA was quantified by diluting it 1:25 in 10 mM Tris-HCl, pH 
8.0, 1 mM EDTA, followed by measuring the absorbance at 260 nm in the spectrophotometer (Eppendorf). 
A260 = siRNA in ng/ml. This number divided by 14 corresponds to siRNA concentration in nM. Transfection 
into mammalian cells was performed as described in chapter 10.4.2.  
 
 
 
10.3 Protein work: Extraction, fractionation, immunoprecipitation 
and analysis 
 
10.3.1 Protein extraction from mouse tissue 
 
For immunoblotting, extracts were prepared with a acetat homogenizer in a buffer containing 70 mM Tris, 
150 mM NaCl, pH 8, and 1% (v/v) Triton X-100 in the presence of protease inhibitors (CompleteTM with 
EDTA, Roche). Brains and other mouse tissues were quickly removed from the sacrificed mouse and 
immediately put in chilled lysis buffer on ice. Homogenates were centrifuged for 5 min at 5,000 g, the 
supernatant was rotated overhead at 4°C for 30 min followed by centrifugation for 30 min at 20,000 g and 
4°C. Supernatants were kept at -20°C.  
As a faster technique used for expression analysis in mouse brains, the tissue was homogenized by passage 
through a 16G and 26G needle on ice in 1.5 ml of extraction buffer per brain. The samples were incubated 
on ice for 30 min followed by a centrifugation for 10 min at full speed. 
For purer protein preparations, supernatants were dialyzed overnight at 4°C on a membrane in contact with 
an appropriate dialysis buffer. 
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10.3.2 Cell fractionation  
 
For cell fractionation, a buffer containing 20 mM Tris-HCl, pH 7.4, 250 mM sucrose, 1 mM DTT and protease 
inhibitors was used. Lysates were centrifuged for 45 min at 100,000 g to separate the cytosolic fraction. The 
pellet was resuspended with 0.5% Triton X-100 and 5 mM EGTA in lysis buffer and centrifuged for 30 min at 
100,000 g. The supernatant was taken as membrane fraction. 
10.3.3 Measurement of protein concentration 
 
Protein concentrations of cell or tissue extracts were measured as described by Lowry et al. (Lowry et al., 
1951) using the DC protein assay (BioRad). Proteins react with an alkaline copper tartrate solution and 
reduce folin reagent. The reduced folin species have a characteristic blue color with an absorption maximum 
at 750 nm. Following the instruction manual, protein concentrations were calculated based on the 
absorptions of a standard curve. The standard curve was recorded with different dilutions of a protein 
standard (BSA) from 0.25 mg/ml to about 1.5 mg/ml in the corresponding solution. 
10.3.4 Immunoblotting of proteins 
 
Immunoblotting is a method to identify a protein of interest and determine its size in a protein extract. 
Proteins are separated by SDS-PAGE and electrophoratically transferred from the gel to a nitrocellulose 
membrane where they are immobilized and can be detected by specific antibodies. 
10.3.4.1 SDS polyacrylamide gel electrophoresis (PAGE) 
 
Separation of proteins was carried out by SDS PAGE (Laemmli, 1970) on NuPAGE Novex Bis-Tris gels 
(Invitrogen). Proteins were dissociated into their polypeptide subunits using the anionic detergent SDS in 
combination with β-mercaptoethanol as a reducing agent of disulfide bonds and heat. SDS with its high 
negative charge and hydrophobic tail that interacts strongly with hydrophobic regions of polypeptide chains 
binds quantitatively to proteins, giving them linearity and uniform charge, so that they can be separated 
solely on the basis if their size. Within a homogenous electric field, the migration speed of an SDS covered 
polypeptide is inversely proportional to the logarithm of its molecular mass. 
Depending on the task, 10% or 4-12% gels were used and usually run at RT and 90 V for 2-3 h. 
• 4x Sample buffer: 100 mM Tris-Base, 100mM Tris-HCl, 8 % (w/v) LDS, 4% (v/v) ß-mercaptoethanol, 40% (v/v) glycerol, 
0.08 % (w/v) serva blueG250, 0.025 phenol red, 0.6‰ EDTA, 1.92 M glycine. 
• 20x NuPage running buffer: 1M MOPS, 1M Tris-Base, 69.3 mM SDS, 20.5mM EDTA. 
10.3.4.2 Transfer of proteins 
 
Following SDS-PAGE the stacking gel was removed and the resolving gel was equilibrated in transfer buffer 
for 3 min on a shaker platform. Whatman papers and nitrocellulose membranes were cut to the size of the 
gel and soaked in transfer buffer. The gel and the membrane were sandwiched between soaked pieces of a 
sponge, Whatman paper and perforated plastic plates. Blotting was carried out in a blotting tank (Novex) for 
2 h at 300 mA at 4°C or overnight at 20 mA at 4°C. 
• Transfer buffer: 1 x MOPS NuPage, 20 % (v/v) methanol 
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10.3.4.3 Ponceau S staining of immobilized proteins 
 
Proteins that are immobilized on a membrane can be reversibly stained using Ponceau S dye. This method 
can serve as a tool to evaluate the efficiency of protein transfer to the membrane, to estimate the amount 
of proteins loaded or even to directly determine the size of proteins. 
Nitrocellulose membranes were washed well in water before they were incubated in Ponceau S for a few 
min. Membranes were then destained by washing them well in water.  
• Ponceau S solution: 0.2% (w/v) Ponceau S red, 3% (w/v) sulfonic acid, 0.1% (v/v) glacial acid. 
10.3.4.4 Coomassie brilliant blue staining of immobilized proteins 
 
Coomassie brilliant blue is a dye that is used to detect unlabeled proteins that are separated by SDS-PAGE. 
Proteins are visualized as discreet blue bands by nonspecific binding of the dye to the positively charged 
amino groups of polypeptides. 
The gel was stained for 1 h on a shaking platform and de-stained until discrete blue bands were visible. 
• staining solution:  0.16% (w/v) Coomassie Brilliant Blue R250, 40% (v/v) methanol, 10% (v/v) acetic acid)  
• destaining solution: 45% (v/v) methanol, 10% (v/v) glacial acetic acid 
10.3.4.5 Western blotting 
 
After the transfer of proteins from the SDS gel to the nitrocellulose membrane, the membrane was blocked 
for at least 1 h in TBST/10% (w/v) milk to prevent unspecific binding of antibodies. The primary antibody 
was diluted in TBST to an appropriate concentration (see section 10.8 p. 100) and the blot was incubated at 
RT for 2 h or overnight at 4°C. To remove all traces of unspecifically bound primary antibodies the 
membrane was washed 3 x for 5 min in TBST. Incubation of the blot with the secondary antibody 
conjugated to horseradish peroxidase was carried out for 1 h at RT. After the addition of ECL reagent 
(Amersham) or SuperSignal West femto (Pierce) as a chemifluorescent substrate for the peroxidase 
enzyme, bands were visualized by using X-omat LS films and the Kodak X-OMAT 2000 Processor. Density 
values were calculated with the ImageJ software (Wayne Rasband, NIH, USA). 
• 10 x TBST: 0.2 M Tris, 2.5 M NaCl, 1% (v/v) Tween 20 
10.3.5 Immunoprecipitation 
 
Immunoprecipitation is a technique to separate, enrich and purify a specific protein and its interaction 
partners from a mixture of various proteins. Immunoprecipitated proteins can subsequently be analyzed by 
Immunoblotting. 
As described by (Lin et al., 1998), the monoclonal antibody 5H4 directed against the Aα subunit of PP2A 
immunoprecipitates free A subunit and the core enzyme, but not holoenzymes, whereas the monoclonal 
antibody 6F9 directed against Aα immunoprecipitates all three species. Using these two antibodies, we 
isolated PP2A heterotrimers. Goat anti-rat IgM (µ chain specific, 1:15) was bound to protein G sepharose 
(1:3) (Amersham Biosciences) in 20 mM sodium phosphate, pH 7.0, before the antibody 5H4 (rat IgM, 1:10) 
could be linked. 5H4 binds repeat 1 near the amino-terminus of A and only precipitates core dimers and A 
monomers. The flowthrough was added to a Sepharose G-6F9 complex. 6F9 recognizes the amino-terminal 
eleven amino acids of A and precipitates the remaining PP2A heterotrimers (Lin et al., 1998). For microcystin 
(MC) precipitation, 50 µl of 50% MC-agarose (Upstate, Lake Placid, NY) was incubated with 3 mg protein 
extract at 4°C overnight.The flowthrough was then brought together with the antibody 6F9 (rat IgG2a, 1:10) 
bound to Sepharose G. 6F9 recognizes the amino-terminal 11 amino acids of A and therefore precipitates the 
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remaining PP2A heterotrimers. All other proteins should have been removed with the flowthrough. The protein 
G-sepharose slurry with antibodies was incubated overnight at 4°C on a head-over-end shaker and all wash 
steps were repeated 3 times with exess sodium phosphate, 20 mM, pH 7.0. Proteins bound to the sepharose 
were eluted from the beads by incubation with SDS gel sample buffer and incubation at 90°C for 5 min. The 
eluted trimers were run on an SDS polyacrylamide gel and blotted to a nitrocellulose membrane for detection 
of PP2A subunits. 
10.3.6 Protein phosphatase assays 
 
One µg of recombinant vimentin (Cytoskeleton, Denver, CO) was labeled with 50 pmol γ-P32-ATP and 0.8 U 
PKA in a buffer containing 0.1 mM dATP, 8 mM MgCl2, 20 mM Tris-HCl pH 7.5, 1 mM benzamidine, 3 mM 
DTT, 10 mM NaF, 2 mM vanadate, and CompleteTM without EDTA at 30°C for 3.5 h. Labeled vimentin was 
purified on SigmaSpin columns (Sigma-Aldrich). Total brain extracts were prepared in TBS in the presence 
of protease inhibitors. Then, 40 ng of labeled vimentin was added to 300 µg brain extract in 50 mM 
imidazole (pH 7.2), 0.2 mM EGTA, 0.02% β-mercaptoethanol, and 0.1 mg/ml BSA. Reactions were stopped 
with β-mercaptoethanol-containing sample buffer and boiling for 5 min followed by SDS-PAGE. General 
phosphatase activity was measured with a Ser/Thr phosphatase assay according to the manufacturer’s 
recommendations (Promega, Madison, WI). Brain homogenates were also incubated with OA (Calbiochem). 
 
 
 
10.4 Mammalian cells in culture 
 
10.4.1 Cultivation and storage of cell lines  
 
The following neuronal and non-neuronal mammalian cell lines have been used; Human embryonic kidney 
HEK-293 cells (DSMZ # ACC 305), and human neuroblastoma SH-SY5Y cells (DSMZ # ACC 209). 
10.4.1.1 HEK-293 cells 
 
HEK-293 cells were cultivated at 37°C/ 5% CO2/ 95% humidity in the following medium: 
•  Cultivation Medium: Dulbecco’s Modified Eagle Medium (DMEM), 10 % (v/v) Foetal Bovine Serum (FCS), Penicillin-
Streptomycin 
• Freezing Medium: 90 % (v/v) FCS, 10 % DMSO 
 
Confluent layers of cells were washed with PBS, released from the dish by incubation with trypsin/EDTA for 
3 min, and split to new plates at ratios of 1:20 to 1:5, depending on the purpose.  
For storage of HEK-293 cells, they were trypsinised and resuspended in culture medium, pelleted by 
centrifugation at 1,000 g for 5 min and resuspended in freezing medium. Cell aliquots were immediately 
chilled on ice and frozen at -80°C in a cetatem box. After one day at -80°C the aliquots were transferred 
to liquid nitrogen and kept for long time storage. 
To recultivate frozen cells, cell aliquots were thawed quickly in a water-bath at 37°C, and before the 
thawing process was complete, cells were resuspended in excess of medium in order to dilute the DMSO. 
Cells were pelleted by centrifugation, resuspended, and plated on dishes at a seeding density corresponding 
to approximately 30% confluency.  
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10.4.1.2 SH-SY5Y cells 
 
SH-SY5Y cells were cultivated at 37°C/ 5% CO2/ 95% humidity in the following cultivation medium:  
•  Cultivation medium:  DMEM/ Nutrient Mixture F-12 (DMEM/F-12) 1:1 mixture, supplemented with 15% (v/v) FCS, and 
2 mM L-glutamine. 
 
Confluent layers of cells were washed with PBS, released from the dish by incubation with trypsin/EDTA for 
3 min, and split to new plates at a ratio of less than 1:5.  
SH-SY5Y cells be triggered to differentiate to a neuronal-like phenotype (Encinas et al., 2000). For 
differentiation, SH-SY5Y cells were seeded on collagen type I coated dishes at a density of 0.3 – 2.0 x 104 
cells/cm2. To induce neuronal differentiation, cells were incubated in medium containing retinoic acid (RA) 
for five days, followed by an additional five days in serum free medium supplemented with brain-derived 
neurotrophic factor (BDNF). 
•  Differentiation medium I (days 1-5): DMEM/F-12, 2 % FCS, 2 mM L-glutamine, 20 µM all-trans retinoic acid (RA). 
•  Differentiation medium II (days 5-10): DMEM/F-12, 2 mM L-glutamine, 50 ng/ml BDNF. 
 
Long time storage of SH-SY5Y cells was achieved as follows: Cells were trypsinised and resuspended in 
culture medium, pelleted by centrifugation at 1,000 g for 5 min and resuspended in freezing medium. Cell 
aliquots were immediately chilled on ice and frozen at -80°C in a polystyrene box. After one day at -80°C 
the aliquots were transferred to liquid nitrogen and kept for long time storage. 
To recultivate frozen cells, cell aliquots were thawed quickly in a water-bath at 37°C, and cells were 
immediately resuspended in cultivation medium and pelleted by centrifugation. After resuspension, cells 
were plated on dishes at a seeding density corresponding to more than 50% confluency.  
• Freezing medium: 90% (v/v) cultivation medium, 10% (v/v) dimethylsulfoxide (DMSO). 
10.4.2 Transient and stable transfection of cultured mammalian cells 
 
Eukaryotic cells can be transiently or stably transfected with circular DNA. Transient transfection is used to 
obtain temporary high levels of expression in a cell line. The DNA is not necessarily integrated into the 
chromosome and consequently no selection marker is used. Cells are harvested and analyzed two days after 
transfection. In contrast, in stable transfection the DNA is integrated in the host genome and non-
transfected cells are eliminated by selection with antibiotics such as geneticin (G418) or hygromycin.  
For the transfection of cultured mammalian cells, a technique was applied that makes use of the fact that 
cationic lipids can create artificial membrane vesicles (liposomes) which can then serve as a DNA carrier. 
The DNA/lipid complex adheres and fuses with the cell membrane and the DNA is released into the 
cytoplasm. 
Cells were grown to 70 – 80% confluency at the day of transfection. 30 min before adding the transfection 
reagent cells were washed with PBS and fresh medium without penicillin/streptomycin was added. For a 60-
mm dish, 10 µg of DNA were diluted into 0.5 ml OPTI-MEM I. 30 µl of lipofectamine 2000 (LF2000) reagent 
were diluted in 0.5 ml OPTI-MEM I and incubated at RT for 5 min. The diluted LF2000 reagent and DNA were 
combined and incubated at RT for 20 min, allowing DNA/LF2000 complexes to from. The complexes were 
then added to the cultured cells. 6 to 12 h later, the medium containing transfection reagent was replaced 
by fresh culture medium. Experiments with transient expression were started 48 h after transfection.  
A similar procedure was used to transfect DNA for stable expression, but in contrast, cells were passaged at 
a 1:5 to 1:10 dilution into fresh growth medium containing penicillin/streptomycin 24 h after transfection. 
The next day, selective medium (including G418) for the antibiotic resistance gene transfected (neomycin) 
was added and selection pressure was kept-up for at least 10 days.  
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To generate a clonal cell line or to select for GFP expression rather than neomycin expression, cells were 
seeded at extremely low density and let grown for a few days. Positive single clone colonies were manually 
picked under a fluorescence microscope. 
 
 
 
10.5 Transgenic and knock-out mice  
 
10.5.1 DNA constructs and transgenic mice 
 
A 978 bp cDNA fragment encoding human PP2A C was fused to a haemagglutinin epitope located 
immediately downstream of the start codon. The L309A amino acid substitution was introduced into the 
cDNA using the QuickChange site-directed mutagenesis kit (Stratagene). The mutated fragment was 
subcloned into the neuron-specific mThy1.2 expression vector (Luthi et al., 1997). For pronuclear injection, 
vector sequences were removed and the DNA was purified with PrepAGene (Bio-Rad) and Millipore 
Ultrafree-MC 0.22 µm filter units.  
Transgenic mice were produced by microinjection of B6D2F1 x B6D2F1 embryos (Gotz et al., 1995). 
Founders were identified by PCR analysis of tail lysates using oligonucleotides Thy1.2 (5’-AAGTCACC 
CAGCAGGGAGGTGCTC-3’) and PP2ACα (5’-TCTCGCAGAGGCTCTTGACCTGGGAC-3’), and intercrossed with 
C57BL/6 mice to establish lines.  
10.5.2 Immunohistochemistry 
10.5.2.1 Tissue preparation 
 
In order to preserve the brain tissue from degradation, mice are perfused transcardially under deep 
anesthesia (with an overdose of Rompun (Bayer)/Etaminol10 (Veterinaria)) using a peristaltic pump 
connected to two reservoirs containing saline and fixative solution, respectively. A cut along the sternum is 
made in order to expose the end of the sternum, then, with sharp scissors, a cut is made through the skin, 
diaphragm and laterally on both sides upward across the ribs and parallel to the lungs; the cannula is then 
inserted through the left ventricle into the ascending aorta. Immediately, the right auricle must be 
punctured with forceps, to allow the escape of return circulation. Perfusion is performed with phosphate 
buffered saline (PBS, pH 7.4) for 10 min at room temperature, followed by 4% paraformaldehyde in PBS on 
ice. Brains were removed and immersion-fixed in the same fixative overnight at 4°C. Immunohistochemistry 
was performed either on thick (40 µm) vibratome sections or on thin (4 µm) paraffin sections. For 
vibratome sections, the tissue was cut directly in PBS after fixation. In contrast, for paraffin sections, tissue 
was first dehydrated in an ascending series of ethanol and xylol prior to paraffin embedding. 
10.5.2.2 Immunostaining of vibratome sections 
 
40 µm vibratome sections were stained free-floating. They were permeabilized with They were 
permeabilized with methanol at –20 °C for 5 min and were blocked for at least 2 h at RT in a PBS blocking 
solution containing 5% goat serum, 5% BSA, and 0.1% Triton-X100. Primary antibodies were added for an 
overnight incubation at 4°C in the same blocking buffer. After several washing steps, secondary antibodies 
were added and incubated in blocking buffer but without Triton-X100 for 2 h at RT. Washing in PBS at RT 
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consisted of three repetitions for 20 min at RT on a rocking platform. Sections were mounted with Mowiol 
(Hoechst) or were dehydrated and flat-embedded between glass slides and coverslips in Eukitt (Kindler). 
10.5.2.3 Immunostaining of paraffin sections 
 
To allow antibodies to penetrate fixed tissue embedded in paraffin, it has to be dewaxed and rehydrated. To 
detect an antigen, specific primary antibodies and secondary antibodies (conjugated to fluorescent dyes or 
biotin) are used. For immunofluorescence, 4 µm paraffin-sections were dewaxed in xylol and rehydrated in 
graded ethanol. They were washed well in PBS (fluorescence) or TBS (DAB) and permeabilized by either 
pretreating the sections with 15 min of microwave at 95°C in citric acid buffer, pH 5.8, or with methanol at 
–20 °C for 5 min. Depending on the antibodies used, some sections were pretreated with 5 µg/ml 
proteinase K or 0.1% Triton X-100 in TBS (TBST) for 2.5 min at 37°C for signal enhancement. Sections 
were then blocked for 30 min in PBS or TBS containing 10% normal serum and 4% milk. Depending on the 
secondary antibody used, the serum was adjusted or a mix of goat and horse were applied. Sections were 
then incubated with the primary antibody diluted in PBS or TBS containing 5% normal serum and 2% milk 
overnight at 4°C or for 1 h at RT. Sections were washed three times with PBS or TBS, were incubated with 
the secondary antibody for 30 min at RT, and were washed again. The fluorescence stained sections were 
mounted directly with Moviol (Hoechst) while vectastain ABC reagent (Vector Laboratories) was added to 
the DAB labeled sections for 30 min. These sections were washed again and were incubated with peroxidase 
substrate solution (DAB) (Pierce) for 10 min. After washing in TBS, sections can be counterstained with 
Nuclear Fast Red (Fluka), rinsed with water followed by dehydration in graded ethanol and xylene. Sections 
were then embedded with in Eukitt (Kindler). 
10.5.3 TUNEL assay 
 
TUNEL (terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling) staining of 4 µm 
paraffin-sections were performed using the TUNEL kit by Boehringer-Mannheim Biochemica with minor 
modifications (Gavrieli et al., 1992; Gotz et al., 2001). 
10.5.4 Decalcification and haematoxylin/eosin (HE) staining of heads 
 
After perfusion with 4% paraformaldehyde, mouse heads were washed in PBS followed by H2O. Then they 
were decalcified at room temperature for 3-4 days in a solution of 0.15 M EDTA and 70 mM HCl, pH 6.5. 
After washing with H2O, the heads were dehydrated and embedded in paraffin. 4 µm sections were 
incubated in haematoxylin for 15 min, hydrated, differentiated in 0.25% HCl in 50% ethanol, rehydrated, 
and rinsed in 96% ethanol. Sections were incubated in eosin for 5 sec, rinsed in 70% ethanol, dehydrated, 
and mounted in Eukitt (Kindler). 
10.5.5 In situ hybridization  
 
WT mice were anaesthetized with a mixture of 2% Rompun (Xylazinum, Bayer) and 10% Ketaminal 10 
(Vererinaria), transcardially perfused with PBS containing 4% paraformaldehyde, postfixed overnight at 
4 °C, and paraffin embedded. Sections (7 µm) were dried overnight at 42 °C on coated glass slides, 
dewaxed and permeabilized by acid treatment (0.1 m HCl for 10 min), followed by a proteinase K treatment 
(10 µg/mL) for 10 min at 37 °C. After acetylation with 0.1 m triethanolamine and 0.4% acetic anhydride 
(20 min at room temperature), sections were incubated for 1 h at room temperature in hybridization buffer 
(25% deionized formamide, 4× SSC, 5× Denhardt’s reagent, 0.25 mg/mL yeast tRNA, 10% dextransulphate, 
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50 mM DTT, 1 mM EDTA, 0.5 mg/mL salmon sperm DNA in 50 mM phosphate buffer pH 7). The sections 
were hybridized overnight at room temperature in hybridization buffer with DIG-labelled 45 bp antisense 
oligonucleotide probes and the complementary sense probes (see materials, page 103). Approximately 30 
ng of DIG labeled oligonucleotide in 30 µl hybridization buffer were used per section. Three negative 
controls were included: (1) a DIG labeled sense probe, (2) a 1:300 diluted DIG labeled antisense probe in 
unlabeled antisense probe, and (3) prehybridization buffer without probe. All samples were incubated for 20 
hours at 37°C. Sections were then washed at 37°C in solutions of decreasing salt concentrations (2x, 1x, 
0.2x SSC), incubated in buffer 1 (100 mM TrisCl (pH7.5) 150 mM NaCl) for 10 min followed by blocking in 
buffer 1 supplemented with 2% (v/v) normal sheep serum and 0.05% Triton-X100, for 30 minutes. 
Immunostaining was then achieved by incubating the sections with an anti-DIG antibody conjugated to 
alkaline phosphatase (Roche) at 1:200 in buffer 1 (100 mm Tris/HCl pH 7.5, 150 mm NaCl, 0.1% Triton X-
100, and 1% normal sheep serum) for 4 hours at room temperature. Sections were washed twice in buffer 1 
and buffer 2 (100 mM TrisCl (pH9.5), 100 mM NaCl, and 50 mM MgCl2) for 10 minutes each. Alkaline 
phosphatase activity was visualized with staining solution (100 mM Tris/HCl pH 9.5, 100 mM NaCl, 50 mM 
MgCl2, 1 mM levamisol, 0.3% NBT, 0.35% BCIP) for 2-14 h in the dark, until the color developed. The 
reaction was stopped with buffer 3 (10 mM Tris Cl (pH8.1) and 1 mM EDTA). After washing, slides were 
mounted in Mowiol (Hoechst). 
All oligonucleotides were labeled with digoxigenin-dUTP using the DIG Oligonucleotide Tailing kit (Roche 
Molecular Biochemicals) following the manufacturer’s instructions. 100 pmol of each oligonucleotide was 
initially used. The yield for each digoxigenin-dUTP labeled oligonucleotide was approximately 4 pmol/µl 
(about 50 ng/µl), as determined by dot blotting onto a Nylon membrane and detected by anti-digoxigenin-
AP conjugates (Roche Molecular Biochemicals) using the CSPD developing system (Roche Molecular 
Biochemicals). 
10.5.6 Extraction of genomic DNA from mouse tails 
 
Mouse tail was lysed and genomic DNA was isolated by precipitation with isopropanol or with the Dneasy 
(Qiagen) or GenElute mammalian genomic DNA kits (Sigma). Depending on the size of the tail and the 
protocol used, the total yield of genomic DNA ranged between 10 and 30 µg. The kits were used according 
to manufacturer’s protocols. Isolated genomic DNA was stored at 4°C. 
10.5.6.1 Simplified mammalian DNA isolation with isopropanol precipitation 
 
4-8 mm mouse tail was lysed at 55°C overnight in 500 µl lysis buffer containing 100 mM Tris-HCl (pH 8.5), 
5 mM EDTA, 0.2 % (w/v) SDS, 200 mM NaCl, 100 µg proteinase K/ml (Laird et al., 1991). After 
centrifugation for 5 min at 22,800 g, 300 µl of the supernatant were transferred into a clean tube. One 
volume of isopropanol was added and the samples were mixed until the precipitation of the genomic DNA 
was complete. Using a pipette tip the precipitate was recovered from the solution and was washed once with 
300 µl of 70% ethanol. The genomic DNA was dissolved in 200 to 500 µl of TE buffer and stored at 4°C. 
10.5.7 Ganzfeld electroretinography (ERG)  
 
Electroretinograms were obtained according to procedures previously described (Seeliger et al., 2001). In 
summary, mice were dark-adapted overnight and their pupils dilated prior to the experiments. The animals 
were anesthetized by subcutaneous injection of ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg). ERGs 
were binocularly recorded from the corneal surface by means of gold wire ring electrodes, and silver needle 
electrodes served as reference (forehead) and ground (tail). The ERG equipment consisted of a Ganzfeld 
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bowl, a DC amplifier, and a PC-based control and recording unit (Toennies Multiliner Vision, 
Jaeger/Toennies, Höchberg, Germany). Bandpass filter cut-off frequencies were 0.1 and 3000 Hz. Single 
flash recordings were obtained both under dark-adapted (scotopic) and light-adapted (photopic) conditions. 
The light adapted part was performed with a background illumination of 30 cd/m2 that started 10 minutes 
before the first recording. Stimuli were presented with increasing intensities from 10-4 cd*s/m2 to 25 
cd*s/m2, divided into ten steps of 0.5 and 1 log cd*s/m2. Ten responses were averaged with an inter-
stimulus interval (ISI) of 5s or 17s (for 1, 3, 10, 25 cd*s/m2).  
10.5.8 Scanning laser ophthalmoscopy (SLO) 
 
Imaging was performed with a Heidelberg Retina Angiograph (HRA1, Heidelberg Engineering GmbH, 
Dossenheim, Germany), a confocal scanning-laser ophthalmoscope providing two laser wavelengths for 
fundus visualization (Argon green, 514 nm, and infrared, 835 nm), and two laser wavelengths for 
angiography (Argon blue, 488 nm (barrier 500 nm) for fluorescence angiography, and infrared, 795 nm 
(barrier 810 nm) for indocyanine green (ICG) angiography).  
Fluoresceine angiography was performed following a s.c. injection of 1.5 mg fluorescein-Na (University 
pharmacy, University of Tuebingen), and ICG angiography following a s.c. injection of 1 mg ICG (ICG-
Pulsion, Pulsion Medical Systems AG, Munich, Germany). 
 
 
 
10.6 Behavioral tests; learning and locomotor activity 
 
10.6.1 Learning-capacity tests in the water maze 
 
The design of the apparatus followed the description given by Morris (Morris, 1984). It consisted of a white 
Plexiglas circular pool of 150 cm diameter and 50 cm height, filled with water (15 cm deep, 24-26°C) made 
opaque by the addition of milk. Distant visual cues for navigation were provided by numerous black and 
white symbols on the walls. A wire mesh platform (14 × 14 cm) was placed 0.5 cm below the water surface, 
with its centre 35 cm from the side of the pool. Every day, animals were adapted to the test room for at 
least 30 min before testing. To avoid visual orientation prior to release, the mice were transferred from their 
cages to the pool in a white plastic cup from which they glided into the water, with the opening of the plastic 
cup toward the wall of the pool. Mice were released from eight symmetrically placed positions on the pool 
perimeter in a predetermined, but not sequential order. They were left swimming either until they found the 
platform or until 120 s (protocol 1) or 90 s (protocol 2) had elapsed. Finding the platform was defined as 
staying on the grid for at least 3 s. After staying on the platform for about 10 s, the mice were given the 
opportunity to climb on to a wire mesh grid attached to a stick, which was also used to pick up swimming 
animals not having found the target. If mice did cross the platform without stopping (jumping immediately 
into the water), they were left swimming until they met the criteria above. Between trials, the animals were 
placed under infrared lamps and allowed to warm up and dry off. Intertrial times were 10 min (protocol 2) 
and varied from 30 to 60 min (protocol 1). The swim paths of the mice were recorded by means of a video 
camera suspended above the centre of the pool and fed to an electronic imaging system (ASBA Wild & Leitz) 
which extracted and stored X-Y coordinates at a frequency of 4.2 Hz, and with 256 × 256 pixels of spatial 
resolution (Noldus). Swim paths were recorded and could be used to calculate a wide range of parameters, 
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the most important being the time required to find the platform during acquisition and reversal phases, and 
the time spent in quadrants in the probe trial. These were determined as a measure of learning success. 
10.6.1.1 Protocol 1 “The simple” 
 
Animals were trained on four consecutive days with six up to 120 s trials daily to find a platform (acquisition 
phase). The position of the hidden platform remained fixed for the acquisition phase. On the 5th day, the 
platform was removed and the time every mouse stayed in the target and the opposite quadrant were 
measured for one minute (called probe trial). After two days of rest the platform position was changed to 
the opposite quadrant and the mice had to relearn the new platform position during three days with 6 trials 
per day (reversal phase). On day four, the platform was again removed and memory retention was 
examined in a single 60 s trial (Wolfer et al., 2001). 
10.6.1.2 Protocol 2 “The sophisticated” 
 
This water maze test is based on the same principle as protocol 1 with the major difference that once the 
individual mouse has learned the platform position, it will immediately get a new position and therefore will 
have to relearn several times. It was described and used by the group of Richard Morris (Chen et al., 2000) 
and was adapted to our apparatus (Morris, 1984) as described above. 
Since all mice have performed in the water maze protocol 1 before, there was no need for a cued training-
to-criterion. For the learning-capacity test the platform was moved between different locations drawn from a 
set of 20 possible locations. Each mouse swam eight trials per day with a maximal trial duration of 90 s and 
an interval between trials of 10 min. Mice had to search for five different platform positions whereas the 
performance criterion to get a new platform position was three trials in a row with an average escape 
latency of less than 15 s. The maximum number of trials was 40 for location 1, and 32 trials thereafter, 
therefore the maximal duration of the test was 21 days. 
10.6.2 Rotarod test (motor coordination) 
 
Motor coordination was measured using an accelerating rotarod device (Ugo Basile, Italy) which consists of 
a rotating drum with a diameter of 3 cm covered with knurled Perspex to provide an adequate grip, and 
accelerating speed from 4 rpm up to 40 rpm. The performance on the Rotarod was recorded by the time 
spent (in s) and the maximal speed reached (in rpm). Each mouse was accustomed to the task 3 times, 
with a maximal time of 300 s, whereas 40 rpm was reached after 270 s. Mice were left at rest for 2 hours, 
and were then tested twice with the same accerlerating speed, the maximal time being 300 s. 
10.6.3 Fear conditioning 
 
During fear conditioning subjects learn to associate a neutral stimulus (CS) or training situation (context) 
with a coinciding painful stimulus (US). Subsequently, learning performance and fear-related behavior can 
be analyzed in the conditioned subject. Six transgenic L199P mice and six WT littermates were tested for 
their response to a conditioned fear stimulus Both contextual and auditory cued fear conditioning were 
studied with a 4-day test protocol. After two adaptation sessions on day1 (‘neutral context’, i.e. a plastic 
cage, 12 × 20 cm, in a soundproof test box, with dim light and a fan providing background noise), animals 
were trained in an altered context (‘shock context’: 25 × 25 cm cm, grid floor, strong light, peppermint 
smell, fan off) on day 2. Animals received three CS-US pairings in 1-min intervals (CS, 4 kHz, 75 dB for 10 
s; US, 0.7 mA foot shock, delivered during the last second of the CS). A control group (n=3 per genotype) 
_____Methods___________________________________________________________ 
 
100
received the same training stimuli without temporal coincidence. On day 3, tone-specific memory of both 
experimental and control mice was tested in the neutral context. As behavioral indicator of fear, occurrence 
of freezing was determined by the experimenter every 10 s for 2 min without the CS, then for 2 min with 
the CS (twice 30 s duration with 30 s pause). At the same time suppression of locomotor activity was 
measured using an infrared photobeam activity monitoring system (SCANET). On day 4, experimental 
animals were tested for their context-specific memory over a period of 2 min in the shock context in the 
same way. 
 
 
10.7 Microscopy 
 
Visual assessment of cell viability in culture and counting of cell density in solution were performed on an 
upright Nikon TMS F light microscope. Manual clonal picking of single cells and counting of transfection rate 
were performed on a Nikon Eclipse TE300 using corresponding fluorescence filters. Analysis of 
haematoxylin/eosin (HE) and immunohistochemical stainings was performed on the fluorescence 
microscopes Eclipse E800 (Nikon) and the inverted DM IRE2 (Leica). The latter captures pictures with the 
digital unit DFC 480 (Leica) directly into the Photoshop 6.0 software (Adobe) while the two other 
microscopes capture pictures with the TV lens C- 0.6 x (Nikon) and the Kappa ImageBase 2.2-Control 
software (Kappa opto-electronics).  
 
 
10.8 Antibodies 
 
Antibodies used for Western blot (WB) analysis, immunohistochemistry (IH), or immunoprecipitation (IP) 
were: HA (Roche, Basel, Switzerland, IH 1:200, WB 1:1000); antiserum 45 (Dr. B. Hemmings, Basel, 
Switzerland, anti-Cα; directed against the first 20 amino acids of Cα, WB 1:100) (Gotz et al., 1998); PP2A/C 
(Oncogene Research Products, Cambridge, MA, WB 1:100); PP2A/A, 6G3 (Covance, Berkeley, CA, WB 
1:1000); PP2A/A, 6F9 and 5H4 (BabCO, Richmond, CA, IP 1:150); PP2A/Bα (Calbiochem, San Diego, CA, 
WB 1:500); PR61γ and PR61ε (Dr. B. Hemmings, WB 1:300); β-actin (Abcam, Cambridge, MA, WB 1:5000); 
β-catenin (Biodesign International, Saco, ME, IH 1:100, WB 1:500); GAPDH (Biodesign International, WB 
1:1000); NSE (DakoCytomation, Glostrup, Denmark, IH 1:200); PGP9.5 (Abcam, WB 1:2000); Pan cadherin 
(Lab Vision, Fremont, CA, IH 1:100, WB 1:500); GSK-3β (Santa Cruz Biotechnology, Santa Cruz, CA, WB 
1:500); p-GSK-3β (Ser 9) (Santa Cruz Biotechnology, WB 1:500); APP C-terminal (Sigma-Aldrich, St. Louis, 
MO, WB 1:4000). The rabbit anti-PR59 antiserum ∆1-113 (WB: 1:5000) was raised against a fusion protein 
containing a 6xHIS-tag fused to amino acids 114-521 of murine PR59. The following phosphotau-specific 
antibodies were used: CP13 (Dr. P. Davies, Bronx, NY, IH 1:500); AT100 and AT180 (Innogenetics, Gent, 
Belgium, IH 1:100) (Goedert et al., 1994); 12E8 (Dr. P. Seubert, Elan Pharmaceuticals, South San 
Francisco, CA, IH 1:100) (Seubert et al., 1995); AD2 (Dr. C. Mourton-Gilles, Lille, France, IH 1:500) (Buee-
Scherrer et al., 1996); pS422 (Biosource, Camarillo, CA, IH 1:50); and S199P (Dr. A. Delacourte; Lille, 
France, IH 1:1000) (Delacourte et al., 1998; Sergeant et al., 1999). For immunofluorescence, secondary 
antibodies were obtained from Molecular Probes (Alexa-Fluor series, Eugene, OR), and for immunoblotting, 
HRP-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA) were used. For more details on 
secondary antibodies see the Materials section 11.8.2 on page 110. 
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11 Materials 
 
 
11.1 Plasmids 
 
pBluescript II KS+ Stratagene 
pcDNA 3, pcDNA 3.1 Invitrogen 
pCR-XL-TOPO Invitrogen 
pCR-II-TOPO Invitrogen 
pEGFP-N1 BD Biosciences, Clontech 
pEX12    Dr. H. van der Putten (Luthi et al., 1997) 
pSUPER     OligoEngine  
 
 
11.2 DNA oligonucleotides 
11.2.1 Primers for qRT-PCR 
 
Gene Sequence 5’ – 3’, forward Sequence 5’ – 3’, reverse 
PR55α GTTCAGGAAGCGGAGACCC TCCAGCTCCTGCCATGTTG 
PR55β (I) CCCGCAAAATCAACAACAGTT CCGTGTGGTTGAATTCTACCG 
PR55β (II) GCAGCCTCGCAGAACCC CCATGGTCCGAGCCTGAG 
PR55γ GCTGACATCATCTCTACCGTTGAG GCCGCCCTTGTCACCTG 
PR55δ (I) GCTTCTCGCAGGTCAAGGG AAACTCAACGGTGGAAATGATGT 
PR55δ (II) GACGAGGACGTGGCCG TGTTGCAAGAAGATCTCCAGAGTAA 
PP2A Cα TATCAGATCACTTGATCGCCTACA CATCTGGATCTGACCACAGCAA 
PR61ε CCGGTGATATTGACAATAGGAGAGA TGCCAGAGCCACCTTTCG 
PR65/Aα TCTTCTCCCAGCATTGCCC TTTCCTGTCAGACTGCGGC 
GAPD (X01677) TGGGCTACACTGAGCACCAG CAGCGTCAAAGGTGGAGGAG 
POLR2F (Z27113) CCCGAAAGATCCCCATCAT CACCCCCCAGTCTTCATAGC 
PGK TGAAGGACTGTGTAGGCCCAG TTCTTCCTCCACATGAAAGCG 
 
11.2.2 Primers for PCR and sequencing (selection) 
 
Name of 
gene/construct 
Use F; forward 
R; reverse 
Sequence 5’ – 3’ 
F (Thy1.2) AAGTCACCCAGCAGGGAGGTGCTC  Thy1.2-PP2A/Cα genotyping 
R (PP2A/Cα) TCTCGCAGAGGCTCTTGACCTGGGAC 
F CTCACTATAGGGCGAATTGGA pSUPER Sequencing of 
insert R TGTGGAATTGTGAGCGGATA 
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11.2.3 Oligonucleotide templates for siRNA (in situ synthesis) 
 
Gene 
S; sense 
A; antisense 
Sequence 5’ – 3’ 
S AAAGATGACAACTCTACCACCCCTGTCTC 
PR55α (A) 
A AAGGTGGTAGAGTTGTCATCTCCTGTCTC 
S AACCACCTAATTTTATTGATCCCTGTCTC 
PR55α (B) 
A AAGATCAATAAAATTAGGTGGCCTGTCTC 
S AAATGACCTGTTACTGGGATCCCTGTCTC 
PR55α (C) 
A AAGATCCCAGTAACAGGTCATCCTGTCTC 
S AACTAAGCAGGAAGTGGGTTCCCTGTCTC 
PR55α (D) 
A AAGAACCCACTTCCTGCTTAGCCTGTCTC 
S AATATTACAACCCGACCCCCCCCTGTCTC 
PR55β (A) 
A AAGGGGGGTCGGGTTGTAATACCTGTCTC 
S AAATGATCTGTTGCTTGGATCCCTGTCTC 
PR55β (C) 
A AAGATCCAAGCAACAGATCATCCTGTCTC 
S AAAAACTTATCTCTTTTCTCCCCTGTCTC 
PR55β (E) 
A AAGGAGAAAAGAGATAAGTTTCCTGTCTC 
S AAGATGACGACCCGGCCGCCCCCTGTCTC 
PR55γ (A) 
A AAGGGCGGCCGGGTCGTCATCCCTGTCTC 
S AACGGTAGAGATGATGTCAGCCCTGTCTC 
PR55γ (F) 
A AAGCTGACATCATCTCTACCGCCTGTCTC 
S AACTTGTCGAAAATGCAGTCGCCTGTCTC 
PR55γ (G) 
A AACGACTGCATTTTCGACAAGCCTGTCTC 
S AAAGGTCATGTCGGGGATGACCCTGTCTC 
PR55γ (X) 
A AAGTCATCCCCGACATGACCTCCTGTCTC 
S AAAATAACAACTCTGCCGCCCCCTGTCTC 
PR55δ (A) 
A AAGGGCGGCAGAGTTGTTATTCCTGTCTC 
S AACGGTGGAAATGATGTCCGCCCTGTCTC 
PR55δ (F) 
A AAGCGGACATCATTTCCACCGCCTGTCTC 
S AAAAATTCGCCGTGGACTCGCCCTGTCTC 
PR55δ (H) 
A AAGCGAGTCCACGGCGAATTTCCTGTCTC 
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11.2.4 Oligonucleotide templates for siRNA (pSUPER expression) 
 
Gene 
S; sense 
A; antisense 
Sequence 5’ – 3’ 
S GATCCCCTCCAGTCTCATAGCAGAGGRRCAAGAGACCTCTGCTATGAGACTG
GATTTTTGGAAA 
PR55α 
A AGCTTTTCCAAAAATCCAGTCTCATAGCAGAGGTCTCTTGAACCTCTGCTATGA
GACTGGAGGG 
S GATCCCCTCAGGTTCATCGTAGGGGTTTCAAGAGAACCCCTACGATGAACCT
GATTTTTGGAAA 
PR55β 
A AGCTTTTCCAAAAATCAGGTTCATCGTAGGGGTTCTCTTGAAACCCCTACGATG
AACCTGAGGG 
S GATCCCCTGCGCCCCACAGCCAGGGCTTCAAGAGAGCCCTGGCTGTGGGGCG
CATTTTTGGAAA 
PR55γ 
A AGCTTTTCCAAAAATGCGCCCCACAGCCAGGGCTCTCTTGAAGCCCTGGCTGT
GGGGCGCAGGG 
S GATCCCCGCGGACATCATTTCCACCGTTCAAGAGACGGTGGAAATGATGTCCG
CTTTTTGGAAA  
PR55δ 
A AGCTTTTCCAAAAAGCGGACATCATTTCCACCGTCTCTTGAACGGTGGAAATGA
TGTCCGCGGG 
 
 
11.2.5 Oligonucleotide templates for in situ hybridization 
 
Gene 
S; sense 
A; antisense 
Sequence 5’ – 3’ 
S (control) CTCAGGTGAAAGGAGCAGTAGATGATGACGTAGCAGAAGCAGATA 
PR55α 
A TATCTGCTTCTGCTACGTCATCATCTACTGCTCCTTTCACCTGAG 
S (control) ATGAAGCCCTTCACAGCTGACATTATCTCTACGGTAGAATTCAAC 
PR55β (I) 
A GTTGAATTCTACCGTAGAGATAATGTCAGCTGTGAAGGGCTTCAT 
S (control) CGGCTCCGGGATCCTGCCACCATCACAACCCTGCGGGTGCCTGTC 
PR55β (II) 
A GACAGGCACCCGCAGGGTTGTGATGGTGGCAGGATCCCGGAGCCG 
S (control) CTGCGGGACCACAGCTATGTGACAGAAGCTGACGTCATCTCCACT 
PR55γ 
A AGTGGAGATGACGTCAGCTTCTGTCACATAGCTGTGGTCCCGCAG 
S (control) AGCTGGAGGCGGCGGCTGCCCGGCGGGCGGCAACGACTTCCAGTG 
PR55δ (I) 
A CACTGGAAGTCGTTGCCGCCCGCCGGGCAGCCGCCGCCTCCAGCT 
S (control) CGACTTCGAGACCCATTTAGAATTACGGCACTACGGGTTCCAATA 
PR55δ (II) 
A TATTGGAACCCGTAGTGCCGTAATTCTAAATGGGTCTCGAAGTCG 
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11.3 Buffers, solutions, media 
 
Designation Composition 
Blocking solution (in situ) 1× Buffer 1 supplemented with 0.1% Triton X-100 and 
2% normal sheep serum 
Buffer 1, 10× (in situ) 100 mM Tris HCl, pH 7.5, 150 mM NaCl:  
Buffer 2 (in situ) 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl2 
Buffer 3, stop solution (in situ) 10 mM Tris-HCl, pH 8.1, 1 mM EDTA 
Coomassie staining solution 0.16% (w/v) Coomassie Brilliant Blue R250, 40% (v/v) 
methanol, 10% (v/v) acetic acid 
Coomassie destaining solution (45% (v/v) methanol, 10% (v/v) glacial acetic acid). 
Dennhard’s solution, 50x Ficoll, polyvinylpyrrolidone, BSA, H2O 
DNA sample buffer 0.25%(w/v) bromphenol blue, 0.25% (w/v) xylene 
cyanol FF, 30% (w/v) glycerol 
Hydrolysis buffer (in situ) 1 M DTT, 1 M NaHCO3, 1 M Na2CO3, H2O 
LB agar LB medium, 15 g/l Bacto Agar 
LB medium 10 g/l Bacto Tryptone, 5 g/l Bacto yeast extract, 10 g/l 
NaCl, pH 7.0 
MOPS buffer, 10x  0.2 M MOPS [3-(N-morpholino)-propanesulfonic acid], 
pH7.2, 0.5 M sodium acetate, 0.01 M EDTA 
Neutralizing buffer (in situ) 1 M DTT (1.52 g in 10 ml H2O), 1 M NaAc (29.4 g in 100 
ml H2O), H2O 
Paraformaldehyd (PFA) 4% in 
PBS 
heat PBS in microwave to 75°C, add 4 g PFA (stirring 
under hood) and NaOH dropwise until clear 
PBS, 10x 1.4 M NaCl, 0.027 M KCL, 0.1 M Na2HPO4 x 2 H20, 
0.018 M KH2PO4 
Ponceau S solution 0.2% (w/v) Poinceau-S red, 3% (w/v) sulfonic acid, 
0.1% (v/v) glacial acid 
Prehybridization and hybridization 
solutions 
500 mg/50 ml formamide (deionised with ion exchanger 
amberlite MB-3), SSC, Denhardt’s, salmon sperm DNA, 
yeast RNA, dextransulfate, DTT, PBS, EDTA (pH 8) 
Protein sample buffer, 2x 450 mM Tris-HCl pH 8.45, 12% (v/v) Glycerol, 4% (w/v) 
SDS, 7.5‰ Coomassie brilliant Blue, 2.5‰ Phenol Red 
RNA sample buffer, 6x 10 mM EDTA, pH 8.0, 0.25% (w/v) bromphenol blue, 
0.25% (w/v) xylenecyanol, 50% (v/v) glycerol 
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Sodium acetate, 3 M, pH 5.2 Sodium acetate × 3 H2O, acetic acid to pH 5.2 
SSC, 20x 3 M NaCl, 300 mM sodiumcitrate (acetate), pH 7.5 
Staining solution (in situ) Buffer 2, NBT (100 mg NBT/ml in 70% 
dimethylformamide), BCIP (50 mg/ml in 100% 
dimethylformamide), 1 M levamisol 
TAE buffer 40 mM Tris-acetate, 1 mM EDTA 
TBS, 10x 0.84 M Tris-HCL, 0.16 M Tris-Base, 1.5 M NaCl 
 
 
11.4 Kits, systems, assays 
 
Name Order nr. Supplier 
Big Dye Terminator v1.1 Cycle Sequencing 4336776 Applied Biosystems 
DC protein assay 500-0113/4/5 BioRad 
CSPD developing system 1 755 633 Roche Molecular Biochemicals 
DIG Oligonucleotide Tailing 1 417 231 Roche Molecular Biochemicals 
ECL Western Blotting Detection Reagents RPN 2106 Amersham Biosciences 
Gene Elute Gel Extraction NA1111 Sigma 
Gene Elute Miniprep PLN-350 Sigma 
Gene Elute PCR Clean-up NA1020 Sigma 
Gene Elute Plasmid Maxiprep PLX-50 Sigma 
QIAGEN Nucleotide Removal  Qiagen 
QIAGEN Plasmid Maxi 12165 Qiagen 
QIAGEN Plasmid Mini 12125 Qiagen 
QIAGEN Rneasy 74104 Qiagen 
QIAquick Gel Extraction 28706 Qiagen 
QIAquick PCR Purification  28106 Qiagen 
QIAshredder 79656 Qiagen 
Quick-change site-directed mutagenesis 200518 Stratagene 
Rediprime II Random Prime Labelling System RPN 1633 Amersham 
Rnase free DNAse 79254 Qiagen 
Ser/Thr phosphatase assay system V2460 Promega 
Silencer siRNA construction 1620 Ambion 
Silencer siRNA labeling 1632 Ambion 
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Superscript first strand synthesis system for 
RT-PCR 
11904-018 Life Technologies 
SuperSignal West Femto Maximum 
Sensitivity Substrate 
34095 Pierce 
SYBR Green PCR Core Reagents 4304886 Applied Biosystems 
TOPO-XL PCR Cloning 45-0008 Invitrogen 
Tunnel stain 1684 817 Roche 
Vectastain ABC (rabbit, mouse, goat) PK-6101/2/5 Vector Laboratories 
 
 
11.5 Chemicals and laboratory commodities 
 
[α-32P]dCTP     Hartmann Analytic 
[γ-32P]dATP     Hartmann Analytic 
Acetic acid, glacial    Merck 
Acetic anhydride     Fluka 
Agarose     Invitrogen 
Amberlite     Merck 
Ampicillin     Sigma 
AmpliTaq Gold polymerase   Applied Biosystems 
β-mercaptoethanol    Sigma  
Bacto agar     Becton Dickinson 
Bacto tryptone     Becton Dickinson 
Bacto yeast     Becton Dickinson 
BDNF      Peprotech 
Biomax MR film     Kodak 
Bovine Serum Albumin (BSA)   Sigma 
Bromo-Chloro-Indolyl Phosphate (BCIP)  Boehringer-Roche 
Bromphenol blue    Sigma 
BSA      Sigma 
BSA, acetylated    Invitrogen 
CaCl2      Sigma 
Chromatography Paper (3MM Chr)  Whatmann 
Cell culture dishes    TTP 
Cell culture media    Invitrogen 
Chloroform     Sigma 
Collagen Type I     Sigma 
Complete protease inhibitor   Roche 
Coomassie Brillant Blue    Merck 
Crystal violet     Sigma 
Culture slides     Falcon 
DAB/Metal Concentrate (10 x)   Pierce 
DAPT      Calbiochem 
DC Protein Assay     BioRAD 
DEPC H20     Ambion 
DEPC      Sigma 
Dextransulfate     Sigma 
DH5α E.coli     Life Technologies 
DMEM/F12     Life Technologies 
DMEM      Life Technologies 
DMSO      Sigma 
DNA ladder 50 bp    Invitrogen 
DNA ladders (100 bp, 1 kb and 2-Log)  New England Biolabs 
DNA Polymerase 1 (Klenow fragment)  New England Biolabs 
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dNTPs      Sigma 
DTT      Sigma 
E. coli tRNA     Sigma 
E.coli T4 DNA ligase    New England Biolabs 
E.coli T4 polynucleotide kinase   New England Biolabs 
EDTA 0.5M solution    Sigma 
EGTA      Fluka 
Ethanol      Merck 
Ethidium bromide    Sigma 
Eukitt      Kindler, Freiburg, Germany 
Fetal calf serum (FCS)    Life Technologies 
Ficoll Typ 400     Sigma 
Formaldehyde     Fluka 
Formamide     Calbiochem, Merck 
Formic acid     Merck 
Gene Pulser cuvette (0.1 cm)   BioRad 
Geneticin G418     Life Technologies  
Glacial acetic acid     Merck 
Glycerol     Sigma 
Glycine      Merck 
Goat Serum     Vector Laboratories 
HCl      Riedel-de Haën 
HEK-293 cells Deutsche Sammlung von Mikroorganismen und   
Zellkulturen #305 
HEPES      Sigma 
Horse Serum     Vector Laboratories 
HPLC-grade H20    Aldrich 
Isoamylalcohol     Merk 
Isopropanol     Sigma 
Kanamycin     Sigma 
KCl      Sigma 
Ketaminal     Vererinaria, Zürich, Switzerland 
KH2PO4      Sigma 
KOAc      Sigma 
KOH      Sigma 
Levamisol      Fluka 
Lipofectamine (LF2000)   Life Technologies 
L-Glutamine     Life Technologies 
LiCl      Merck 
MES Hydrate     Sigma 
MES sodium salt    Sigma 
Methanol     Merck 
MgCl2      Merck 
MgOAc      Sigma 
Microscope slides “SuperFrost Plus”  Menzel-Gläser, Germany 
Microtome blades S35 type   Feather 
Milk/milk powder    Coop 
Mowiol      Hoechst, Germany 
N2 supplement     Life Technologies 
Na2CO3      Fluka 
Na2HPO4     Merck 
NaAc      Merck 
NaCl 5M     Ambion 
NaCl      Sigma 
NaHCO3     Sigma 
NaOH      Sigma 
needle 26GA 5/8 (sterile)   Becton Dickinson 
NH4Oac      Sigma 
Nitrocellulose-membrane 0.1 µm   Schleicher & Schuell 
Nitrocellulose membrane 0.45 µm  BioRad 
Nitrocellulose membrane Hybond-ECL  Amersham Biosciences 
Nitrocellulose membrane Hybond-N+  Amersham Biosciences 
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Nitroblue-Tetrazolium (NBT)   Boehringer-Roche 
Normal sheep serum    Sigma 
NT3      Juro 
Nuclear Fast Red (Kernechtrot)   Fluka 
Nu Page polyacrylamide gel, 10%   Invitrogen 
Okadaic Acid, Sodium Salt   Calbiochem 
Oligonucleotides    Metabion/Microsynth 
Optical 96 well Reaction plate   Applied Biosystems 
Optical adhesive covers    Applied Biosystems 
Optical caps (8 stripes)    Applied Biosystems 
Opti-MEM I     Life Technologies 
Paraformaldehyde     Electron Micr. Sciences 
Pfu Turbo DNA polymerase   Stratagene 
Phenol      Merck 
Phenolred     Sigma 
Pipes      Sigma 
Ponceau-S     Merck 
Polyornithine     Sigma 
Polyvinylpyrrolidone    Sigma 
Proteinase K      Roche 
Protein A Sepharose    Amersham Pharmacia 
Protein G Sepharose    Amersham Pharmacia 
Protein gel marker    Invitrogen 
RedTaq genomic DNA polymerase  Sigma 
Restricition endonucleases   New England Biolabs 
Retinoic Acid     Sigma 
RNA 6000 ladder    Ambion 
Rnase away     Catalys 
RNAse free Proteinase K   Boehringer-Roche 
Rompun (Xylazinum)    Bayer 
Salmon sperm DNA     Roche 
SDS      Sigma 
SeeBlue Plus2 pre-stained protein standard Invitrogen 
Shrimp alkaline phosphatase   Roche 
SH-SY5Y neuroblastoma cells Deutsche Sammlung von Mikroorganismen und 
Zellkulturen #209 
SigmaSpin post reaction purification columns Sigma   
Simply Blue Safe stain    Life Technologies 
Sodium acetate     Sigma 
Sodium citrate     Merck 
SPARE quartz capillaries   Biochrom 
Sucrose     Sigma 
Sulfuric acid     Merck 
SYBR Green I nucleic acid gel stain  Molecular Probes 
Syringe 1 ml     Becton Dickinson 
Tissue freezing medium   Jung 
Tricine      Sigma 
Triethanolamine    Fluka 
Triton X-100     Sigma 
Trizma acetate     Sigma 
Trizma base     Sigma 
Trizma hydrochloride    Sigma 
Trizol      Life Technologies 
Trypsin/EDTA     Invitrogen 
Tween 20     Sigma 
Ultra pure salmon sperm DNA   Invitrogen 
Uvette disposable cuvettes   Eppendorf 
Vimentin (recombinant Syrian hamster) Cytoskeleton 
X-Omat LS film     Kodak 
Xylenecyanol     Merck 
Yeast extract     Becton Dickinson 
Yeast RNA from Brewers yeast   Boehringer-Roche 
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11.6 Laboratory devices 
 
 
ABI Prism 310 Genetic Analyzer   Applied Biosystems,  
ABI Prism 7700 Sequence Detector   Applied Biosystems 
Agilent 2000 Bioanalyzer    Agilent Technologies 
Bio Photometer      Eppendorf 
Blotting Tank      BioRad 
C25 Incubatorshaker     Fisher Scientific 
Centrifuge 5417C     Eppendorf 
Centrifuge 5417R     Eppendorf 
Centrifuge 5804R     Eppendorf 
Concentrator 5301 speedvac    Eppendorf 
Cryotome Leica CM 1900    Leica 
Electrophoresis powersupply consort E865  Witec AG 
Gene Pulser II Electroporation System   BioRad 
Gene Quant Pro (Photometer)    Amersham Pharmacia 
GeneAmp PCR System 9700    Applied Biosystems 
EasyCast Electrophoresis System    Owl 
Kodak X-OMAT 2000 Processor    Kodak 
Memmert waterbath     Fisher Scientific 
Microtome Leica RM 2135    Leica 
MP 220 pH meter     Mettler Toledo 
Nikon Eclipse E800     Nikon 
Nikon Eclipse TE300     Nikon 
Nikon TMS F      Nikon 
NUAIRE Autoflow CO2 jacked Incubator   Inotech  
Rota-Rod 7650      Ugo Basile, Comerio, Italy 
Rotor GSA      Sorvall 
Rotor SS34      Sorvall 
Scaltec SBC 31 Balance    Vaudaux 
Scaltec SBC 51 Balance    Vaudaux 
SKAN VSE-2000-120 sterilhood    Skan 
Sorvall RC 26 Plus      Kendro  
STORM 860 Phosphor-Imager    Molecular Dynamics 
Thermomixer      Eppendorf 
Universal 32 Hettich centrifuge    Fisher scientific 
UV Stratalinker 1800      Stratagene 
Vacuum Pump OME28 C/H    Alcatel 
Vibratome Leica VT 1000S    Leica 
WTB Cabinincubator     Faust 
 
 
11.7 Software 
 
 
Adobe Illustrater 9.0.1     Adobe 
Adobe Photoshop 6.0     Adobe 
Endnote 8, reference manager    Endnote 
ImageJ quantification software    Wayne Rasband, NIH, USA 
Microsoft Excel, Powerpoint, Word (2002)  Microsoft 
Primer Expresss 1.5     Applied Biosystems 
SeqMan II and MegAlign 4.00     DNASTAR 
Sequence detection software 1.9.1   Applied Biosystems 
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11.8 Antibodies 
 
11.8.1 Primary antibodies 
 
See in the Methods section 10.8 on page 100. 
 
 
11.8.2 Secondary antibodies 
 
Antibody Origin Dilution Order Nr Supplier 
anti-digoxigenin-AP 
conjugates 
mouse 1:500 1 093 274 Roche Molecular 
Biochemicals 
anti-goat HRP donkey 1:5000 705 035 147 Jackson 
anti-mouse Cy3 donkey 1:250 715 165 151 Jackson 
anti-mouse HRP goat 1:2000 1858413 Pierce 
anti-rabbit Cy3 donkey 1:250 711 165 152 Jackson 
anti-rabbit HRP goat 1:2000 1858415 Pierce 
anti-rat Cy3 donkey 1:250 712 165 153 Jackson 
anti-rat HRP goat 1:5000 NA 935 V Amersham 
anti-streptavidin biotinyl. goat  BA-0500 Reactolab 
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12 Abbreviations 
 
 
A  Adenosine 
A260  Absorption 260 nm 
A280  Absorption at 280 nm 
aa  amino acids 
AD  Alzheimer’s disease 
AP  Alkaline phosphatase 
ApoE  Apolipoproteine E 
APP  β-amyloid precursor protein 
APPS-α  soluble β-APP cut by α-sec 
APPS-β  soluble β-APP cut by β-sec 
APPswe  APP double mutation, K595N and M596L 
α-sec  α-secretase 
ATP  Adenosine triphosphate 
Aβ  β-amyloid peptide 
Aβ40  β-amyloid peptide of 40 aa 
Aβ42  β-amyloid peptide of 42 aa 
BACE  β-site APP cleavage enzyme (β-secretase) 
β-APP  APP cut by β-sec 
BDNF  Brain-derived neurotrophic factor 
BLAST  Basic local alignment search tool 
bp  base pairs 
BSA  Bovine serum albumine 
β-sec  β-secretase, BACE 
C  Cytosine 
CA  Calyculin 
CaMKII  Calmodulin-dependent protein kinase II 
cDNA  complemetary desoxyribonucleic acid 
Chr  Chromosome 
CT  Threshold cycle 
C-ter  C-terminal 
CTF  C-terminal fragment 
CTF-α  membrane tethered C-ter fragment generated by α-sec 
CTF-β  membrane tethered C-ter fragment generated by β-sec 
Cdk  cyclin-dependent kinase 
dATP   desoxy ATP 
dCTP   desoxy CTP 
DEPC  Diethylpyrocarbonate 
dGTP   desoxy GTP 
DIG  Digoxigenin 
DMEM  Dulbeccos' modified Eagle Medium 
DMEM/F12 DMEM/Nutrient Mixture F-12 
DMSO  Dimethylsulfoxide 
DNA  Desoxyribonucleic acid 
DNase  Desoxyribonuclease 
dNTP  desoxy nucleotide triphosphate 
ds-cDNA double stranded cDNA 
DSMZ  Deutsches Zentrum für molekularbiologische Sammlungen 
dsRNA  double stranded ribonucleic acid 
DTT  Dithiothreitol 
E. coli  Escherichia coli 
ECL  Enhanced chemiluminescence 
EDTA  Ethylen-diamin-tetraacetic acid 
EGTA  Ethylene-glycol-bis(2-aminoethyl)-tetraacetic acid 
ERG   Ganzfeld electroretinography 
ERK  Extracellular signal-related kinase 
F  Farad constante 
FAD  Familial form of Alzheimer’s disease 
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FCS  Fetal calf serum 
FTD  Frontotemporal dementia 
g  gravitational force 
G  Guanidine 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GFAP   glial fibrillary acidic protein 
GFP  Green fluorescent protein 
γ-sec  γ-secretase (protein complex) 
GSK-3  Glycogen synthase kinase 3 
HA  Haemagglutinin 
HEK-293 Human embryonic kidney cells 
HEPES  N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] 
HPLC  High performance liquid chromatography 
HRP  Horseradish peroxidase 
IP  Immunoprecipitation 
JNK  c-Jun N-terminal kinase 
kb  kilobase 
kDa  kilodalton 
LB  Luria Bertani 
LF2000  Lipofectamine 2000 
M  Molar 
MAP   mitogen-activated protein 
MAPK  mitogen-activated protein kinase 
MC  Microcystin 
MKP  MAP kinase phosphatase 
MOPS  3-N-morpholinpropansulfonic acid 
MT  microtubule 
mRNA  messenger ribonucleic acid 
NF  neurofilament 
NFT  Neurofibrillary tangles 
NGF  Nerve growth factor 
NT3  neurotropic factor Neurotrophin-3 
OA  Okadaic acid 
OD  Optical density 
Oligo  Oligonucleotide 
o/n  overnight 
ORF  Open reading frame 
PBS  Phosphate buffered saline 
PBGD  Porphobilinogen-Deaminase  
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
PGK  Phosphoglycerate kinase 
PHF  Paired helical filaments 
PKA  Protein kinase A 
PKC  Protein kinase C 
POLR2F  polymerase (RNA) II (DNA directed) polypeptide F  
poly-dT  desoxy thymidine polymer 
PP  Protein phosphatase 
PP2A  Protein phosphatase 2A 
PS  Presenilin 
PSEN1  gene encoding Presenilin isoform1 
PSEN2  gene encoding Presenilin isoform 2 
PSP   Progressive supranuclear palsy 
PTB  phosphotyrosine interacting/ binding domain  
qRT-PCR quantitative real-time PCR 
RA  Retinoic acid 
RISC  RNA induced silencing complex 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
rpm  rotations per minute 
RT  Room temperature 
SAD  Sporadic Alzheimer’s Disease 
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SAP  Shrimp alkaline phosphatase 
SD  Standard deviation 
SDS  Sodium dodecyl sulfate 
SEM  standard error of the mean 
SH-SY5Y Human neuroblastoma cell line 
siRNA  short interfering RNA 
SLO   scanning laser ophthalmoscopy 
T  Thymidine 
T3  triiodothyronine 
T4  thyroxine 
TAE  Tris acetate EDTA buffer 
tauP301L Tau protein with the mutation P301L 
TBS  Tris buffered saline 
TEA  Triethanolamine 
TSH  thyroid-stimulating hormone 
TUNEL  terminal deoxyribonucleotidyl transferase (TdT)-mediated  
biotin-16-dUTP nick-end labeling 
U  Unit 
UV  Ultra-violett 
V  Volt 
v/v  volume per volume 
w/v  weight per volume 
WB  Western blotting 
WT  wild-type 
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